WO2022187518A1 - Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions - Google Patents
Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions Download PDFInfo
- Publication number
- WO2022187518A1 WO2022187518A1 PCT/US2022/018745 US2022018745W WO2022187518A1 WO 2022187518 A1 WO2022187518 A1 WO 2022187518A1 US 2022018745 W US2022018745 W US 2022018745W WO 2022187518 A1 WO2022187518 A1 WO 2022187518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- certain embodiments
- alkyl
- haloalkyl
- compound
- occurrence
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 325
- AYTMNOIACXGOST-UHFFFAOYSA-N C(CC1)CCN1N1C2=NC=NC2=CC=C1 Chemical class C(CC1)CCN1N1C2=NC=NC2=CC=C1 AYTMNOIACXGOST-UHFFFAOYSA-N 0.000 title description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 162
- 201000011510 cancer Diseases 0.000 claims abstract description 139
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims abstract description 73
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 claims abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 281
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 279
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 242
- 125000005843 halogen group Chemical group 0.000 claims description 221
- 125000005842 heteroatom Chemical group 0.000 claims description 220
- 229910052760 oxygen Inorganic materials 0.000 claims description 215
- 239000001301 oxygen Chemical group 0.000 claims description 215
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 214
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 209
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 203
- 229910052717 sulfur Chemical group 0.000 claims description 203
- 239000011593 sulfur Chemical group 0.000 claims description 203
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 187
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 143
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 134
- 125000001424 substituent group Chemical group 0.000 claims description 129
- 239000002246 antineoplastic agent Substances 0.000 claims description 121
- -1 -N(R4)(R5) Chemical group 0.000 claims description 116
- 229910052739 hydrogen Chemical group 0.000 claims description 107
- 239000001257 hydrogen Chemical group 0.000 claims description 107
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 94
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 89
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 68
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 67
- 229920006395 saturated elastomer Polymers 0.000 claims description 66
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 60
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 59
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000004432 carbon atom Chemical group C* 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 125000002950 monocyclic group Chemical group 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 47
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 46
- 125000004043 oxo group Chemical group O=* 0.000 claims description 45
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 125000001931 aliphatic group Chemical group 0.000 claims description 41
- 125000004429 atom Chemical group 0.000 claims description 40
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 37
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 33
- 208000035475 disorder Diseases 0.000 claims description 31
- 125000002947 alkylene group Chemical group 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 25
- 206010009944 Colon cancer Diseases 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 21
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 21
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 21
- 201000002528 pancreatic cancer Diseases 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 19
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 150000001721 carbon Chemical group 0.000 claims description 15
- 208000005017 glioblastoma Diseases 0.000 claims description 13
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 8
- 229940124647 MEK inhibitor Drugs 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 3
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 3
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000011682 nervous system cancer Diseases 0.000 claims description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 239000003112 inhibitor Substances 0.000 description 55
- 239000003814 drug Substances 0.000 description 46
- 239000000203 mixture Substances 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- 229910052736 halogen Inorganic materials 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- 125000002619 bicyclic group Chemical group 0.000 description 19
- 208000029974 neurofibrosarcoma Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 239000012453 solvate Substances 0.000 description 18
- 229940124597 therapeutic agent Drugs 0.000 description 18
- 125000003636 chemical group Chemical group 0.000 description 16
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 16
- 150000002367 halogens Chemical class 0.000 description 15
- 150000002430 hydrocarbons Chemical group 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 206010033128 Ovarian cancer Diseases 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 208000000172 Medulloblastoma Diseases 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 206010018338 Glioma Diseases 0.000 description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 description 11
- 229910052796 boron Inorganic materials 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 10
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 125000003386 piperidinyl group Chemical group 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102100030708 GTPase KRas Human genes 0.000 description 9
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 9
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 150000004820 halides Chemical class 0.000 description 9
- 201000008968 osteosarcoma Diseases 0.000 description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 9
- 206010042863 synovial sarcoma Diseases 0.000 description 9
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 9
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 8
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 8
- 201000001342 Fallopian tube cancer Diseases 0.000 description 8
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 8
- 229940124785 KRAS inhibitor Drugs 0.000 description 8
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 8
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 8
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 8
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 8
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 8
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical group OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229960002271 cobimetinib Drugs 0.000 description 8
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 8
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 8
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 8
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 8
- 210000004872 soft tissue Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 8
- 229960004066 trametinib Drugs 0.000 description 8
- 206010003571 Astrocytoma Diseases 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 206010038038 rectal cancer Diseases 0.000 description 7
- 201000001275 rectum cancer Diseases 0.000 description 7
- 208000005243 Chondrosarcoma Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 description 6
- 206010057644 Testis cancer Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 229950003054 binimetinib Drugs 0.000 description 6
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 6
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 6
- 208000006359 hepatoblastoma Diseases 0.000 description 6
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 6
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 229950010746 selumetinib Drugs 0.000 description 6
- 201000003120 testicular cancer Diseases 0.000 description 6
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 5
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 5
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 5
- 208000006168 Ewing Sarcoma Diseases 0.000 description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 5
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 201000010175 gallbladder cancer Diseases 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 229910052723 transition metal Inorganic materials 0.000 description 5
- 150000003624 transition metals Chemical class 0.000 description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DKZYXHCYPUVGAF-UHFFFAOYSA-N 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone Chemical compound CN(C)CC1CCC(CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O DKZYXHCYPUVGAF-UHFFFAOYSA-N 0.000 description 4
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 4
- JHPXULZZZSBIJI-UHFFFAOYSA-N 4-piperidin-1-yl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical class C1CCN(CC1)C2=C3CC(=O)NC3=NC=C2 JHPXULZZZSBIJI-UHFFFAOYSA-N 0.000 description 4
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 4
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 4
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- 208000009798 Craniopharyngioma Diseases 0.000 description 4
- 206010014967 Ependymoma Diseases 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 4
- 206010061934 Salivary gland cancer Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 229940124988 adagrasib Drugs 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001923 cyclic compounds Chemical class 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 239000003207 proteasome inhibitor Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229950008933 refametinib Drugs 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- UFZJUVFSSINETF-UHFFFAOYSA-N 4-fluoro-5-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide Chemical compound OCCONC(=O)C1=CC=2SC=NC=2C(F)=C1NC1=CC=C(I)C=C1F UFZJUVFSSINETF-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000009888 Adrenocortical Adenoma Diseases 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 3
- 208000007860 Anus Neoplasms Diseases 0.000 description 3
- 206010006143 Brain stem glioma Diseases 0.000 description 3
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 3
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 3
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 3
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 3
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 3
- 229940124787 MELK inhibitor Drugs 0.000 description 3
- 108700027650 Mitogen-Activated Protein Kinase 7 Proteins 0.000 description 3
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 3
- SPHYIETWIUYGQU-UHFFFAOYSA-N O=C1NC2=NC=CC(N3CCCCC3)=C2N1 Chemical class O=C1NC2=NC=CC(N3CCCCC3)=C2N1 SPHYIETWIUYGQU-UHFFFAOYSA-N 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 description 3
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000004064 acoustic neuroma Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 3
- 201000003354 adrenal cortical adenoma Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 201000011165 anus cancer Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 229940124302 mTOR inhibitor Drugs 0.000 description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 244000309459 oncolytic virus Species 0.000 description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102200006531 rs121913529 Human genes 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000008410 smoothened signaling pathway Effects 0.000 description 3
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- HEVHTYMYEMEBPX-HZPDHXFCSA-N 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C1=CC(OC[C@H](N)C)=CC=C1C1=CN=C2N1N=C(N[C@H](C)C=1C=C(F)C=CC=1)C=C2 HEVHTYMYEMEBPX-HZPDHXFCSA-N 0.000 description 2
- MTPBUCCXRGSDCR-UHFFFAOYSA-N 4-piperidin-1-ylpyridine Chemical compound C1CCCCN1C1=CC=NC=C1 MTPBUCCXRGSDCR-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010073338 Optic glioma Diseases 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229950010482 alpelisib Drugs 0.000 description 2
- 229940126313 avutometinib Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 229940083476 bosulif Drugs 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960003445 idelalisib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 2
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940071539 mirdametinib Drugs 0.000 description 2
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- 229950011068 niraparib Drugs 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 208000008511 optic nerve glioma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 229950002592 pimasertib Drugs 0.000 description 2
- 201000004123 pineal gland cancer Diseases 0.000 description 2
- 229960004403 pixantrone Drugs 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229960001131 ponatinib Drugs 0.000 description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 229950003687 ribociclib Drugs 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 102200006538 rs121913530 Human genes 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229940073531 sotorasib Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229950001269 taselisib Drugs 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229950011257 veliparib Drugs 0.000 description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 1
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- ZRBPIAWWRPFDPY-IRXDYDNUSA-N 1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound NC1=NC(=C(C(=C1)C)C(F)(F)F)C1=C(Cl)C=C2C(N3CCN(C[C@@H]3C)C(=O)C=C)=NC(=NC2=C1F)OC[C@H]1N(C)CCC1 ZRBPIAWWRPFDPY-IRXDYDNUSA-N 0.000 description 1
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- QTWWJUWXADSYNH-UHFFFAOYSA-N 4-piperidin-1-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCCCN1C1=CC=NC2=C1C=CN2 QTWWJUWXADSYNH-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
- SRBJWIBAMIKCMV-GFCCVEGCSA-N 5-[(8-chloroisoquinolin-3-yl)amino]-3-[(2r)-1-(dimethylamino)propan-2-yl]oxypyrazine-2-carbonitrile Chemical compound N1=C(C#N)C(O[C@@H](CN(C)C)C)=NC(NC=2N=CC3=C(Cl)C=CC=C3C=2)=C1 SRBJWIBAMIKCMV-GFCCVEGCSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 description 1
- SVAGFBGXEWPNJC-SPIKMXEPSA-N 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN SVAGFBGXEWPNJC-SPIKMXEPSA-N 0.000 description 1
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 102100031505 Beta-1,4 N-acetylgalactosaminyltransferase 1 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- SCLLZBIBSFTLIN-IFMUVJFISA-N C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O Chemical compound C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O SCLLZBIBSFTLIN-IFMUVJFISA-N 0.000 description 1
- DKFRWZJCNPETGI-SJORKVTESA-N C1=NC(=C(C(=N1)C1CC1)N1C2=C(C=C(C(C3=C(C=CC=C3N)F)=N2)F)C(N2C[C@@H](C)N(C[C@@H]2C)C(=O)C=C)=NC1=O)C1CC1 Chemical compound C1=NC(=C(C(=N1)C1CC1)N1C2=C(C=C(C(C3=C(C=CC=C3N)F)=N2)F)C(N2C[C@@H](C)N(C[C@@H]2C)C(=O)C=C)=NC1=O)C1CC1 DKFRWZJCNPETGI-SJORKVTESA-N 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940126265 GDC-6036 Drugs 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000729811 Homo sapiens Beta-1,4 N-acetylgalactosaminyltransferase 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001115390 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 229940126204 KRAS G12D inhibitor Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940126203 MRTX1133 Drugs 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 102000046796 Mitogen-Activated Protein Kinase 7 Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 238000010746 Mukaiyama hydration reaction Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 229910004749 OS(O)2 Inorganic materials 0.000 description 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 229940126271 SOS1 inhibitor Drugs 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- 208000001662 Subependymal Glioma Diseases 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010072912 YM753 compound Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 description 1
- FYQZGCBXYVWXSP-LCHZDSEPSA-N [(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate Chemical compound CN[C@H]1[C@@H](O[C@H]2[C@H](OC(=O)c3c(C)ccc4c(C)cc(OC)cc34)C=C3C#C[C@@]4(O[C@@H]4C#C\C=C2/3)[C@@H]2COC(=O)O2)O[C@H](C)[C@H](O)[C@@H]1O FYQZGCBXYVWXSP-LCHZDSEPSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229950009557 adavosertib Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- ZAXCMPAWRCMABN-UHFFFAOYSA-N azane;2-hydroxyacetic acid;platinum Chemical compound N.N.[Pt].OCC(O)=O ZAXCMPAWRCMABN-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229940034568 cometriq Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- KTEIFNKAUNYNJU-LBPRGKRZSA-N ent-crizotinib Chemical compound O([C@@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-LBPRGKRZSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229940014684 erivedge Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GOZRRIWDZQPGMN-UHFFFAOYSA-N ethyl 2-[5-(7h-purin-6-ylsulfanyl)pentanoylamino]acetate Chemical compound CCOC(=O)CNC(=O)CCCCSC1=NC=NC2=C1NC=N2 GOZRRIWDZQPGMN-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229950001546 guadecitabine Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940061301 ibrance Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical group C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 229940126533 immune checkpoint blocker Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940050282 inebilizumab-cdon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229940125399 kras g12c inhibitor Drugs 0.000 description 1
- 229940000764 kyprolis Drugs 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229940083118 mekinist Drugs 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 229940030115 ninlaro Drugs 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229940024847 odomzo Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 1
- 229950003618 pracinostat Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950006743 ricolinostat Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- QLLGKCJUPWYJON-HLTSFMKQSA-N roducitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1C(F)=C(CO)[C@@H](O)[C@H]1O QLLGKCJUPWYJON-HLTSFMKQSA-N 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- XFLBOEMFLGLWFF-HDXRNPEWSA-N spiruchostatin Chemical compound C1SSCC\C=C\[C@H]2OC(=O)C[C@H](O)[C@@H](C(C)C)NC(=O)[C@@H]1NC(=O)[C@@H](C)NC(=O)C2 XFLBOEMFLGLWFF-HDXRNPEWSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000030819 subependymoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 229940074352 taletrectinib Drugs 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940069905 tasigna Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical group CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 description 1
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 description 1
- 229950007907 vosaroxin Drugs 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
- BACKGROUND [0003] Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Solid tumors, including breast cancer, lung cancer, and pancreatic cancer remain prevalent among the world population. Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects. New therapies are needed to address this unmet need in cancer therapy.
- Extracellular-signal-regulated kinase 5 also known as mitogen-activated protein kinase 7 (MAPK7) and Big MAPK1 (BMK1)
- MAPK7 mitogen-activated protein kinase 7
- BMK1 Big MAPK1
- one aspect of the invention provides a collection of substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, such as a compound represented by Formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of substituted 4-piperidinyl- imidazo[4,5-b]pyridines and related compounds are described in the detailed description.
- the compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a method of treating a disorder mediated by ERK5 in a subject.
- the method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to a subject in need thereof to treat the disorder, as further described in the detailed description.
- Another aspect of the invention provides a method of inhibiting ERK5 activity.
- the method comprises contacting ERK5 with an effective amount of a compound described herein, such as a compound of Formula I, to inhibit ERK5 activity, as further described in the detailed description.
- BRIEF DESCRIPTION OF THE DRAWINGS [0009] Figure 1 depicts results of the 3D cancer cell culture assay described in Example 14. [0010]
- Figure 2 depicts results of the mouse xenograft tumor growth assay with a pancreatic cancer cell line, as described in Example 15.
- Figure 3 depicts results of the mouse xenograft tumor growth assay with a lung cancer cell line, as described in Example 15.
- DETAILED DESCRIPTION [0012]
- the invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
- the practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I.
- aliphatic or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule.
- aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms.
- aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
- “cycloaliphatic” refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
- Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system.
- the term includes any permissible ring fusion, such as ortho-fused or spirocyclic.
- heterocyclic is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N- oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc.
- a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
- a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
- a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted.
- Exemplary bicyclic rings include: [0017]
- Exemplary bridged bicyclics include:
- lower alkyl refers to a C 1-4 straight or branched alkyl group.
- exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
- lower haloalkyl refers to a C 1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
- heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
- unsaturated as used herein, means that a moiety has one or more units of unsaturation.
- bivalent C 1-8 (or C 1-6 ) saturated or unsaturated, straight or branched, hydrocarbon chain refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
- alkylene refers to a bivalent alkyl group.
- An “alkylene chain” is a polymethylene group, i.e., –(CH 2 ) n –, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- the term “-(C 0 alkylene)-“ refers to a bond. Accordingly, the term “-(C 0-3 alkylene)-” encompasses a bond (i.e.,C 0 ) and a -( C 1-3 alkylene)- group.
- alkenylene refers to a bivalent alkenyl group.
- a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- halogen means F, Cl, Br, or I.
- aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
- aryl may be used interchangeably with the term “aryl ring.”
- aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
- aryl is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
- phenylene refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it.
- phenylene is a bivalent phenyl group when it has two groups attached to it (e.g., ); “p y trivalent phenyl group when it has three groups attached to it (e.g., ).
- arylene refers to a bivalent aryl group.
- heteroaryl and “heteroar—,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
- Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
- heteroaryl and “heteroar—”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused.
- Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
- a heteroaryl group may be mono– or bicyclic.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
- heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heteroarylene refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it.
- heteroarylene is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it.
- pyridinylene refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it.
- pyridinylene is a bivalent pyridine radical when it has two groups attached to it (e.g., ); py y trivalent pyridine radical when it has three groups attached to it (e.g., ).
- heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5– to 7–membered monocyclic or 7–10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4– dihydro–2H–pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N–substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl.
- heterocycle used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl.
- a heterocyclyl group may be mono- or bicyclic.
- heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- oxo-heterocyclyl refers to a heterocyclyl substituted by an oxo group.
- heterocyclylene refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.
- partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
- partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- compounds of the invention may contain “optionally substituted” moieties.
- substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
- an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- R* is C 1-6 aliphatic
- R* is optionally substituted with halogen, – R ⁇ , -(haloR ⁇ ), -OH, –OR ⁇ , –O(haloR ⁇ ), –CN, –C(O)OH, –C(O)OR ⁇ , –NH 2 , –NHR ⁇ , –NR ⁇ 2, or –NO 2
- each R ⁇ is independently selected from C 1–4 aliphatic, –CH 2 Ph, –O(CH 2 ) 0–1 Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ⁇ is unsubstituted or where preceded by halo is substituted only with one or more halogens.
- An optional substituent on a substitutable nitrogen is independently –R ⁇ , –NR ⁇ 2 , – C(O)R ⁇ , –C(O)OR ⁇ , –C(O)C(O)R ⁇ , –C(O)CH 2 C(O)R ⁇ , -S(O) 2 R ⁇ , -S(O) 2 NR ⁇ 2, –C(S)NR ⁇ 2 , – C(NH)NR ⁇ 2 , or –N(R ⁇ )S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1-6 aliphatic, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R ⁇ , taken together with their intervening atom(s) form an un
- the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pect
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
- Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis.
- diastereomeric salts are formed with an appropriate optically- active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C 1- C 12 alkyl, C 1 -C 10 alkyl, and C 1 -C 6 alkyl, respectively.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3- methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1- butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
- cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C 3 -C 6 cycloalkyl,” derived from a cycloalkane.
- exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl.
- cycloalkylene refers to a bivalent cycloalkyl group.
- haloalkyl refers to an alkyl group that is substituted with at least one halogen.
- exemplary haloalkyl groups include -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CF 3 , -CF 2 CF 3 , and the like.
- haloalkylene refers to a bivalent haloalkyl group.
- hydroxyalkyl refers to an alkyl group that is substituted with at least one hydroxyl.
- Exemplary hydroxyalkyl groups include -CH 2 CH 2 OH, -C(H)(OH)CH 3 , -CH 2 C(H)(OH)CH 2 CH 2 OH, and the like.
- alkenyl and alkynyl are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- the term “carbocyclylene” refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it.
- “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it.
- alkoxyl or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- haloalkoxyl refers to an alkoxyl group that is substituted with at least one halogen.
- Exemplary haloalkoxyl groups include -OCH 2 F, -OCHF 2 , -OCF 3 , -OCH 2 CF 3 , -OCF 2 CF 3 , and the like.
- hydroxyalkoxyl refers to an alkoxyl group that is substituted with at least one hydroxyl.
- Exemplary hydroxyalkoxyl groups include -OCH 2 CH 2 OH, -OCH 2 C(H)(OH)CH 2 CH 2 OH, and the like.
- alkoxylene refers to a bivalent alkoxyl group. [0054]
- a cyclopentane susbsituted with an oxo group is cyclopentanone.
- the symbol “ ” indicates a point of attachment.
- the substituent may be attached at any available position on the ring.
- the chemical structure , and he context of a polycyclic fused ring when a chemical structure containing a polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses multiple rings, the one or more substituent(s) may be independently attached to any of the rings crossed by the bond.
- the chemical structure encompasses, for example, , , [0057]
- any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.
- One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
- “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
- solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- Solvate encompasses both solution-phase and isolatable solvates.
- suitable solvates include ethanolates, methanolates, and the like.
- “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
- Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.
- IC 50 is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target.
- the potency of an inhibitor is usually defined by its IC 50 value. The lower the IC 50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response.
- an inhibitor has an IC 50 and/or binding constant of less than about 100 ⁇ M, less than about 50 ⁇ M, less than about 1 ⁇ M, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
- the terms “inhibitor” or “ERK5 inhibitor” or “ERK5 antagonist” are defined as a compound that binds to and/or inhibits ERK5 with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner.
- the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.
- measurable affinity and “measurably inhibit,” as used herein, means a measurable change or inhibition in ERK5 activity between a sample comprising a compound of the present invention, or composition thereof, and ERK5, and an equivalent sample comprising ERK5, in the absence of said compound, or composition thereof.
- effective amount refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
- treating includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
- treatment can be administered after one or more symptoms have developed.
- treatment can be administered in the absence of symptoms.
- treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
- the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
- the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
- the compositions also can include stabilizers and preservatives.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed.
- Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts.
- Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
- compositions specifying a percentage are by weight unless otherwise specified.
- One aspect of the invention provides a compound represented by Formula I: or a pharmaceutically acceptable salt thereof; wherein: R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, C 1-4 hydroxyalkoxyl, -(C 1-4 alkoxylene)-N(R 4 )(R 5 ), halo, or -N(R 4 )(R 5 ); or two occurrences of R 1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms; or two occurrences of R 1
- variables in Formula I above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula I.
- the compound is a compound of Formula I-A, I-B, or I-C, or a pharmaceutically acceptable salt thereof.
- the compound is a compound of Formula I-A, I-B, or I-C, or a pharmaceutically acceptable salt thereof; wherein each of the variables in Formula I-A, I-B, and I-C is as defined in the corresponding description of Formula I-A, I-B, and I-C, below, and described in embodiments herein, both singly and in combination. [0076] In certain embodiments, the compound is a compound of Formula I-A, I-B, or I-C.
- the compound is a compound of Formula I-A, I-B, or I-C, wherein each of the variables in Formula I-A, I-B, and I-C is as defined in the corresponding description of Formula I-A, I-B, and I-C, below, and described in embodiments herein, both singly and in combination.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, C 1-4 hydroxyalkoxyl, -(C 1-4 alkoxylene)-N(R 4 )(R 5 ), halo, or -N(R 4 )(R 5 ); or two occurrences of R 1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1- 3 alkylene group connecting said carbon atoms; or two occurrences of R 1 attached to adjacent carbon atoms are taken together with said carbon atoms to form a carbon-carbon double bond.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, C 1-4 hydroxyalkoxyl, -(C 1-4 alkoxylene)-N(R 4 )(R 5 ), halo, or -N(R 4 )(R 5 ); or two occurrences of R 1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ); or two occurrences of R 1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, C 1-4 hydroxyalkoxyl, -(C 1-4 alkoxylene)-N(R 4 )(R 5 ), halo, or -N(R 4 )(R 5 ).
- two occurrences of R 1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, C 1-4 hydroxyalkoxyl, or -(C 1-4 alkoxylene)-N(R 4 )(R 5 ). In certain embodiments, R 1 represents independently for each occurrence hydroxyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl.
- R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl. [0084] In certain embodiments, R 1 is hydroxyl. In certain embodiments, R 1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 1 is trifluoromethyl.
- R 1 represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 1 is -CH 2 OH. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 1 is methoxy. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 1 is -OCF 3 . In certain embodiments, R 1 represents independently for each occurrence C 1-4 hydroxyalkoxyl. In certain embodiments, R 1 represents independently for each occurrence -(C 1-4 alkoxylene)-N(R 4 )(R 5 ). In certain embodiments, R 1 represents independently for each occurrence halo.
- R 1 is fluoro. In certain embodiments, R 1 represents independently for each occurrence -N(R 4 )(R 5 ). [0085] In certain embodiments, two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms. In certain embodiments, two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R 1 is hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl.
- two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R 1 is hydroxyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl.
- two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R 1 is hydroxyl.
- R 1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R 1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, or cyano.
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or cyano.
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo or C 1-4 alkyl. In certain embodiments, R 2A represents independently for each occurrence halo or cyano. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl.
- R 2A represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl. [0089] In certain embodiments, R 2A represents independently for each occurrence halo, cyano, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. [0090] In certain embodiments, R 2A represents independently for each occurrence halo. In certain embodiments, R 2A is fluoro. In certain embodiments, one instance of R 2A is fluoro attached at the position vicinal to the bond to the piperidine ring. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 2A is methyl. In certain embodiments, R 2A represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 2A is trifluoromethyl. In certain embodiments, R 2A is cyano.
- R 2A represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 2A is -CH 2 OH. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 2A is methoxy. In certain embodiments, R 2A represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 2A is - OCF 3 . In certain embodiments, R 2A represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 2A is -NH 2 . In certain embodiments, R 2A is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- R 2A is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C 3-6 cycloalkyl, C 1-4 alkyl, C 1-4 haloalkyl, or hydrogen; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), ox
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or C 3-6 cycloalkyl; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, o
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, o
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo. In certain embodiments, R 2B is morpholin-2-yl. In certain embodiments, R 2B is morpholin-3-on-6- yl.
- R 2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is 1-methylpiperidin-4-yl. In certain embodiments, R 2B is piperidin-3-yl. In certain embodiments, R 2B is piperidin-2-on-5-yl. [0099] In certain embodiments, R 2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, - N(R 4 )(R 5 ), and halo.
- R 2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and halo.
- R 2B is tetrahydropyran-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and halo.
- R 2B is tetrahydropyran-4-yl.
- R 2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl,C 3-5 cycloalkyl, and halo.
- R 2B is C 3-6 cycloalkyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is C 3-6 cycloalkyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and halo. In certain embodiments, R 2B is C 3-6 cycloalkyl. In certain embodiments, R 2B is cyclopropyl. [0103] In certain embodiments, R 2B is C 1-4 alkyl, C 1-4 haloalkyl, or hydrogen. In certain embodiments, R 2B is C 1-4 alkyl or C 1-4 haloalkyl. In certain embodiments, R 2B is C 1-4 alkyl or hydrogen. In certain embodiments, R 2B is C 1-4 alkyl.
- R 2B is methyl. In certain embodiments, R 2B is C 1-4 haloalkyl. In certain embodiments, R 2B is trifluoromethyl. In certain embodiments, R 2B is hydrogen. [0104] In certain embodiments, R 2B is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R 2B is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0105] As defined generally above, R 2C represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or C 1-4 alkyl.
- R 2C represents independently for each occurrence C 1-4 alkyl or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or methyl. [0106] In certain embodiments, R 2C is hydrogen. In certain embodiments, R 2C represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 2C is methyl. In certain embodiments, R 2C represents independently for each occurrence C 3-5 cycloalkyl. In certain embodiments, R 2C is cyclopropyl.
- R 2C is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R 2C is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- R 3 is hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl. In certain embodiments, R 3 is hydrogen or C 1-4 alkyl. In certain embodiments, R 3 is C 1-4 alkyl or C 3-5 cycloalkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is C 1-4 alkyl. In certain embodiments, R 3 is methyl.
- R 3 is C 3-5 cycloalkyl. In certain embodiments, R 3 is cyclopropyl. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0108] As defined generally above, R 4 represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 4 represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl.
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl.
- R 4 represents independently for each occurrence C 1-4 alkyl or C 3-5 cycloalkyl.
- R 4 is hydrogen.
- R 4 represents independently for each occurrence C 1-4 alkyl.
- R 4 represents independently for each occurrence C 3-5 cycloalkyl.
- R 4 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- R 4 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- R 5 represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 5 represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl.
- R 5 represents independently for each occurrence C 1-4 alkyl or C 3-5 cycloalkyl.
- R 5 is hydrogen.
- R 5 represents independently for each occurrence C 1-4 alkyl.
- R 5 represents independently for each occurrence C 3-5 cycloalkyl.
- R 5 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- R 5 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- R 4 and R 5 each represent independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 4 and R 5 each represent independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl. In certain embodiments, R 4 and R 5 each represent independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 and R 5 each represent independently for each occurrence C 1-4 alkyl or C 3-5 cycloalkyl. In certain embodiments, R 4 and R 5 are hydrogen. In certain embodiments, R 4 and R 5 each represent independently for each occurrence C 1-4 alkyl. In certain embodiments, R 4 and R 5 each represent independently for each occurrence C 3-5 cycloalkyl.
- R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, cyano, -S-(C 1-6 haloalkyl), -S- (C 1-6 alkyl), -S(O) 2 -(C 1-6 alkyl), -S(O) 2 N(R 4 )(R 5 ), -C(O)N(R 4 )(R 5 ), -N(R 4 )C(O)-(C 1-6 aliphatic), - N(R 4 )C(O)-(C 1-6 alkoxy), -N
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl); or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S(O) 2 -(C 1-6 alkyl), C 3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2,
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, - O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 alkyl, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -O- (C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkoxyl or -N(R 4 )(R 5 ). In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , -O-(cyclopropyl), –NH 2 , –CF 3 , –F, or –Cl. In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , –NH 2 , –CF 3 , fluoro, or chloro.
- R 6 represents independently for each occurrence –OCF 3 or –NH 2 .
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S- (C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)- (C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ), hydroxyl, halo, or cyano.
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ) or halo.
- one occurrence of R 6 is C 1-4 haloalkoxyl, C 1-4 haloalkyl, -S-(C 1-4 haloalkyl), or -O-(C 3- 4 cycloalkyl), and any further occurrences of R 6 are –NH 2 .
- one occurrence of R 6 is –OCF 3 , –CF 3 , –SCF 3 , or -O- (cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- one occurrence of R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 .
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), or hydroxyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ), halo, or cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl) or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 3-6 cycloalkyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 1-6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl or C 1-6 haloalkyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl, C 1-6 haloalkyl, or C 3-6 cycloalkyl.
- R 6 represents independently for each occurrence C 1-6 alkyl or C 3-6 cycloalkyl.
- R 6 represents independently for each occurrence C 3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl. In certain embodiments, R 6 is –OCF 3 .
- R 6 represents independently for each occurrence C 1-6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 1-4 alkylene)-(C 3- 4 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 3- 4 cycloalkyl). In certain embodiments, R 6 is -O-(cyclopropyl). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ).
- R 6 is –NH 2 . In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence C 2-6 alkenyl. In certain embodiments, R 6 represents independently for each occurrence C 2-6 alkynyl. In certain embodiments, R 6 represents independently for each occurrence halo. In certain embodiments, R 6 is fluoro or chloro.
- R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl). In certain embodiments, R 6 is -S-CF 3 . In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 alkyl). In certain embodiments, R 6 represents independently for each occurrence -S(O) 2 -(C 1-6 alkyl). [0128] In certain embodiments, R 6 represents independently for each occurrence - S(O) 2 N(R 4 )(R 5 ).
- R 6 represents independently for each occurrence - C(O)N(R 4 )(R 5 ). In certain embodiments, R 6 represents independently for each occurrence - N(R 4 )C(O)-(C 1-6 aliphatic). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )C(O)-(C 1-6 alkoxy). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )-(C 1-6 hydroxyalkoxyl). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )S(O) 2 -(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 3-6 cycloalkyl. In certain embodiments, R 6 is phenyl. In certain embodiments, R 6 represents independently for each occurrence a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R 6 represents independently for each occurrence a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, C 1-4 haloalkyl, and oxo.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 two occurrences of R 6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C 1-4 alkyl, C 1-4 haloalkyl, and oxo.
- R 6 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- R 6 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- X 1 is -C(O)-, -S(O)-, or -S(O) 2 -. In certain embodiments, X 1 is -C(O)-. In certain embodiments, X 1 is -S(O)- or -S(O) 2 -. In certain embodiments, X 1 is - S(O)-. In certain embodiments, X 1 is -S(O) 2 -. In certain embodiments, X 1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, X 1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- X 2 is -C(O)-N(R 2C )-** or -C(O)- C(R 2C )(R 2C )-**, wherein ** indicates the point of attachment to the pyridine ring.
- X 2 is -C(O)-N(R 2C )-**, wherein ** indicates the point of attachment to the pyridine ring.
- X 2 is -C(O)-C(R 2C )(R 2C )-**, wherein ** indicates the point of attachment to the pyridine ring.
- X 2 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, X 2 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- a 1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl substituted with m occurrences of R 6 .
- a 1 is e 1 nts, A is ertain embodiments, A 1 is .
- a 1 is in embodiments, A 1 is [0141]
- a 1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is .
- a 1 is [0142] In certain embodiments, A 1 is
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R 6 .
- a 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is naphthyl substituted with m occurrences of R 6 .
- a 1 is an 8-10 membered bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- a 1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- n is 1 or 2. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, n is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0148] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1.
- m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, m is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0149] As defined generally above, p is 0, 1, 2, or 3. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3.
- p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, p is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0150] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below.
- q is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
- Another aspect of the invention provides a compound represented by Formula I-A: (I-A) or a pharmaceutically acceptable salt thereof; wherein: R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms; R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ); R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic hetero
- variables in Formula I-A above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula I-A.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms. [0156] In certain embodiments, two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence hydroxyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl.
- R 1 represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl.
- R 1 is hydroxyl. In certain embodiments, R 1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 1 is trifluoromethyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 1 is -CH 2 OH.
- R 1 represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 1 is methoxy. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 1 is -OCF 3 . [0159] In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 1 and 1-A, below.
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). [0161] In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or cyano.
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo or C 1-4 alkyl. In certain embodiments, R 2A represents independently for each occurrence halo or cyano. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl.
- R 2A represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl. [0162] In certain embodiments, R 2A represents independently for each occurrence halo, cyano, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. [0163] In certain embodiments, R 2A represents independently for each occurrence halo. In certain embodiments, R 2A is fluoro. In certain embodiments, R 2A is fluoro. In certain embodiments, one instance of R 2A is fluoro attached at the 6-position of the imidazopyridine ring. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 2A is methyl. In certain embodiments, R 2A represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 2A is trifluoromethyl.
- R 2A is cyano. In certain embodiments, R 2A represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 2A is -CH 2 OH. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 2A is methoxy. In certain embodiments, R 2A represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 2A is -OCF 3 . In certain embodiments, R 2A represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 2A is - NH 2 .
- R 2A is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 2A is selected from the groups depicted in the compounds in Table 1 and 1-A, below.
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ),
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, o
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo. In certain embodiments, R 2B is morpholin-2-yl. In certain embodiments, R 2B is morpholin-3-on-6- yl.
- R 2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, oxo, and halo.
- R 2B is 1-methylpiperidin-4-yl. In certain embodiments, R 2B is piperidin-3-yl. In certain embodiments, R 2B is piperidin-2-on-5-yl. [0170] In certain embodiments, R 2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), oxo, hydroxyl, - N(R 4 )(R 5 ), and halo.
- R 2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and halo.
- R 2B is tetrahydropyran-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and halo.
- R 2B is tetrahydropyran-4-yl.
- R 2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, - C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, -C(O)-(C 1-4 alkyl), -C(O)-(C 1-4 haloalkyl), -C(O)-(C 3-5 cycloalkyl), hydroxyl, -N(R 4 )(R 5 ), and halo.
- R 2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 3-5 cycloalkyl, and halo.
- R 2B is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 2B is selected from the groups depicted in the compounds in Table 1 and 1-A, below.
- R 3 is hydrogen or C 1-4 alkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is C 1-4 alkyl.
- R 3 is methyl. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0175] As defined generally above, R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0176] In certain embodiments, R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 represents independently for each occurrence C 1-4 alkyl.
- R 4 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 4 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0177] As defined generally above, R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0178] In certain embodiments, R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 5 is hydrogen. In certain embodiments, R 5 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 1, below.
- R 5 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0179] In certain embodiments, R 4 and R 5 each represent independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 and R 5 are hydrogen. In certain embodiments, R 4 and R 5 each represent independently for each occurrence C 1-4 alkyl. [0180] In certain embodiments, R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl); or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, - O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 alkyl, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -O- (C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkoxyl or -N(R 4 )(R 5 ). In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , -O-(cyclopropyl), –NH 2 , –CF 3 , –F, or –Cl. In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , –NH 2 , –CF 3 , fluoro, or chloro.
- R 6 represents independently for each occurrence –OCF 3 or –NH 2 .
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S- (C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)- (C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ), hydroxyl, halo, or cyano.
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ) or halo.
- one occurrence of R 6 is C 1-4 haloalkoxyl, C 1-4 haloalkyl, -S-(C 1-4 haloalkyl), or -O-(C 3-4 cycloalkyl), and any further occurrences of R 6 are –NH 2 .
- one occurrence of R 6 is –OCF 3 , –CF 3 , –SCF 3 , or -O- (cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- one occurrence of R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 .
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), or hydroxyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ), halo, or cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl) or -S-(C 1-6 alkyl). In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl or C 1-6 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl. In certain embodiments, R 6 is –OCF 3 . In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 1-4 alkylene)-(C 3- 4 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 3- 4 cycloalkyl).
- R 6 is -O-(cyclopropyl). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 6 is –NH 2 . In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence halo.
- R 6 is fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl). In certain embodiments, R 6 is -S-CF 3 . In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 alkyl).
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 is taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 1 and 1-A, below.
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl substituted with m occurrences of R 6 .
- a 1 is
- a 1 is iments, A 1 is
- a 1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is .
- a 1 is [0198] In certain embodiments, A 1 is
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R 6 .
- a 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, A 1 is selected from the groups depicted in the compounds in Table 1 and 1-A, below.
- m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2.
- m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below. In certain embodiments, m is selected from the values represented in the compounds in Table 1 and 1-A, below. [0203] As defined generally above, p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 1, below.
- p is selected from the values represented in the compounds in Table 1 and 1-A, below.
- q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Table 1, below. In certain embodiments, q is selected from the values represented in the compounds in Table 1 and 1-A, below.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms;
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 );
- R 2C is hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl;
- R 3 is hydrogen or C 1-4 alkyl;
- R 4 and R 5 each represent independently for each occurrence hydrogen
- variables in Formula I-B above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula I-B.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms. [0210] In certain embodiments, two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence hydroxyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl.
- R 1 represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl.
- R 1 is hydroxyl. In certain embodiments, R 1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 1 is trifluoromethyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 1 is -CH 2 OH.
- R 1 represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 1 is methoxy. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 1 is -OCF 3 . [0213] In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 2, below. [0214] As defined generally above, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, or cyano.
- R 2A represents independently for each occurrence halo or C 1-4 alkyl. In certain embodiments, R 2A represents independently for each occurrence halo or cyano. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl. [0216] In certain embodiments, R 2A represents independently for each occurrence halo, cyano, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence halo, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. [0217] In certain embodiments, R 2A represents independently for each occurrence halo. In certain embodiments, R 2A is fluoro. In certain embodiments, one instance of R 2A is fluoro.
- R 2A is fluoro attached at the 6-position of the imidazopyridinone ring.
- R 2A represents independently for each occurrence C 1-4 alkyl.
- R 2A is methyl.
- R 2A represents independently for each occurrence C 1-4 haloalkyl.
- R 2A is trifluoromethyl.
- R 2A is cyano.
- R 2A represents independently for each occurrence C 1-4 hydroxyalkyl.
- R 2A is -CH 2 OH.
- R 2A represents independently for each occurrence C 1-4 alkoxyl.
- R 2A is methoxy.
- R 2A represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 2A is -OCF 3 . In certain embodiments, R 2A represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 2A is -NH 2 . In certain embodiments, R 2A is selected from the groups depicted in the compounds in Table 2, below. [0218] As defined generally above, R 2C is hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl. In certain embodiments, R 2C is hydrogen or C 1-4 alkyl. In certain embodiments, R 2C is C 1-4 alkyl or C 3-5 cycloalkyl.
- R 2C is hydrogen or C 3-5 cycloalkyl. In certain embodiments, R 2C is hydrogen or methyl. [0219] In certain embodiments, R 2C is hydrogen. In certain embodiments, R 2C is C 1-4 alkyl. In certain embodiments, R 2C is methyl. In certain embodiments, R 2C is C 3-5 cycloalkyl. In certain embodiments, R 2C is cyclopropyl. In certain embodiments, R 2C is selected from the groups depicted in the compounds in Table 2, below. [0220] As defined generally above, R 3 is hydrogen or C 1-4 alkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is C 1-4 alkyl.
- R 3 is methyl. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 2, below.
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 4 is selected from the groups depicted in the compounds in Table 2, below.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 5 is hydrogen. In certain embodiments, R 5 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 2, below.
- R 4 and R 5 each represent independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 and R 5 are hydrogen.
- R 4 and R 5 each represent independently for each occurrence C 1-4 alkyl.
- R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl); or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, - O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 alkyl, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -O- (C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkoxyl or -N(R 4 )(R 5 ). In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , -O-(cyclopropyl), –NH 2 , –CF 3 , –F, or –Cl. In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , –NH 2 , –CF 3 , fluoro, or chloro.
- R 6 represents independently for each occurrence –OCF 3 or –NH 2 .
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S- (C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)- (C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ), hydroxyl, halo, or cyano.
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ) or halo.
- one occurrence of R 6 is C 1-4 haloalkoxyl, C 1-4 haloalkyl, -S-(C 1-4 haloalkyl), or -O-(C 3-4 cycloalkyl), and any further occurrences of R 6 are –NH 2 .
- one occurrence of R 6 is –OCF 3 , –CF 3 , –SCF 3 , or -O- (cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- one occurrence of R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), or hydroxyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ), halo, or cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl) or -S-(C 1-6 alkyl). In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl or C 1-6 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl. In certain embodiments, R 6 is –OCF 3 . In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 1-4 alkylene)-(C 3-4 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 3- 4 cycloalkyl).
- R 6 is -O-(cyclopropyl). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 6 is –NH 2 . In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence halo.
- R 6 is fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl). In certain embodiments, R 6 is -S-CF 3 . In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 alkyl).
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 two occurrences of R 6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 is selected from the groups depicted in the compounds in Table 2, below.
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl substituted with m occurrences of R 6 .
- a 1 is . ce ta e bodiments, A 1 is ertain embodiments, A 1 is . nts, A 1 is ain embodiment 1 s, A is [0243] In certain embodiments, A 1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is .
- a 1 is .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R 6 .
- a 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is selected from the groups depicted in the compounds in Table 2, below.
- m is 0, 1, 2, or 3.
- m is 0.
- m is 1.
- m is 2.
- m is 3.
- m is 0 or 1.
- m is 1 or 2.
- m is 2 or 3.
- m is 0, 1, or 2.
- m is 1, 2, or 3.
- m is selected from the values represented in the compounds in Table 2, below.
- p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 2, below. [0250] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Table 2, below. [0251] The description above describes multiple embodiments relating to compounds of Formula I-B. The patent application specifically contemplates all combinations of the embodiments.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms;
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 );
- R 2C represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl;
- R 3 is hydrogen or C 1-4 alkyl;
- R 4 and R 5 each represent independently
- variables in Formula I-C above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- the compound is a compound of Formula I-C.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl; or two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms. [0256] In certain embodiments, two occurrences of R 1 attached to different carbon atoms are taken together to form a C 1-3 alkylene group connecting said carbon atoms.
- R 1 represents independently for each occurrence hydroxyl, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence hydroxyl, C 1-4 alkoxyl, or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl.
- R 1 represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl.
- R 1 is hydroxyl. In certain embodiments, R 1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkyl. In certain embodiments, R 1 is trifluoromethyl. In certain embodiments, R 1 represents independently for each occurrence C 1-4 hydroxyalkyl. In certain embodiments, R 1 is -CH 2 OH.
- R 1 represents independently for each occurrence C 1-4 alkoxyl. In certain embodiments, R 1 is methoxy. In certain embodiments, R 1 represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 1 is -OCF 3 . [0259] In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 3, below. [0260] As defined generally above, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, cyano, C 1-4 hydroxyalkyl, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or cyano. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence halo, C 1-4 alkyl, or cyano.
- R 2A represents independently for each occurrence halo or C 1-4 alkyl. In certain embodiments, R 2A represents independently for each occurrence halo or cyano. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, or C 1-4 hydroxyalkyl. In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkyl or C 1-4 haloalkyl. [0262] In certain embodiments, R 2A represents independently for each occurrence halo, cyano, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ).
- R 2A represents independently for each occurrence halo, C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl, C 1-4 haloalkoxyl, or -N(R 4 )(R 5 ). In certain embodiments, R 2A represents independently for each occurrence C 1-4 alkoxyl or C 1-4 haloalkoxyl. [0263] In certain embodiments, R 2A represents independently for each occurrence halo. In certain embodiments, R 2A is fluoro. In certain embodiments, one instance of R 2A is fluoro.
- R 2A is fluoro attached at the 5-position of the dihydropyrrolopyridinone ring.
- R 2A represents independently for each occurrence C 1-4 alkyl.
- R 2A is methyl.
- R 2A represents independently for each occurrence C 1-4 haloalkyl.
- R 2A is trifluoromethyl.
- R 2A is cyano.
- R 2A represents independently for each occurrence C 1-4 hydroxyalkyl.
- R 2A is -CH 2 OH.
- R 2A represents independently for each occurrence C 1-4 alkoxyl.
- R 2A is methoxy. In certain embodiments, R 2A represents independently for each occurrence C 1-4 haloalkoxyl. In certain embodiments, R 2A is -OCF 3 . In certain embodiments, R 2A represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 2A is -NH 2 . In certain embodiments, R 2A is selected from the groups depicted in the compounds in Table 3, below. [0264] As defined generally above, R 2C represents independently for each occurrence hydrogen, C 1-4 alkyl, or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or C 1-4 alkyl.
- R 2C represents independently for each occurrence C 1-4 alkyl or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or C 3-5 cycloalkyl. In certain embodiments, R 2C represents independently for each occurrence hydrogen or methyl. [0265] In certain embodiments, R 2C is hydrogen. In certain embodiments, R 2C represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 2C is methyl. In certain embodiments, R 2C represents independently for each occurrence C 3-5 cycloalkyl. In certain embodiments, R 2C is cyclopropyl. In certain embodiments, R 2C is selected from the groups depicted in the compounds in Table 3, below.
- R 3 is hydrogen or C 1-4 alkyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is C 1-4 alkyl. In certain embodiments, R 3 is methyl. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 3, below. [0267] As defined generally above, R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0268] In certain embodiments, R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 is hydrogen.
- R 4 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 4 is selected from the groups depicted in the compounds in Table 3, below.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl; or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom.
- R 5 represents independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 5 is hydrogen. In certain embodiments, R 5 represents independently for each occurrence C 1-4 alkyl. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 3, below.
- R 4 and R 5 each represent independently for each occurrence hydrogen or C 1-4 alkyl. In certain embodiments, R 4 and R 5 are hydrogen. In certain embodiments, R 4 and R 5 each represent independently for each occurrence C 1-4 alkyl. [0272] In certain embodiments, R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl); or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, - O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 alkyl, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -O- (C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, -N(R 4 )(R 5 ), C 1-6 haloalkyl, or halo. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkoxyl or -N(R 4 )(R 5 ). In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , -O-(cyclopropyl), –NH 2 , –CF 3 , –F, or –Cl. In certain embodiments, R 6 represents independently for each occurrence –OCF 3 , –NH 2 , –CF 3 , fluoro, or chloro.
- R 6 represents independently for each occurrence –OCF 3 or –NH 2 .
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S- (C 1-6 haloalkyl), or -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)- (C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ), hydroxyl, halo, or cyano.
- one occurrence of R 6 is C 1-6 haloalkoxyl, C 1-6 haloalkyl, -S-(C 1-6 haloalkyl), or -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), and any further occurrences of R 6 represent independently for each occurrence -N(R 4 )(R 5 ) or halo.
- one occurrence of R 6 is C 1-4 haloalkoxyl, C 1-4 haloalkyl, -S-(C 1-4 haloalkyl), or -O-(C 3- 4 cycloalkyl), and any further occurrences of R 6 are –NH 2 .
- one occurrence of R 6 is –OCF 3 , –CF 3 , –SCF 3 , or -O- (cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- one occurrence of R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 , –F, or –Cl.
- R 6 is –OCF 3 , –CF 3 , or -O-(cyclopropyl), and any further occurrences of R 6 are independently –NH 2 .
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl), -N(R 4 )(R 5 ), hydroxyl, halo, cyano, -S-(C 1-6 haloalkyl), or -S-(C 1-6 alkyl).
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl, C 1-6 alkoxyl, -O-(C 0-4 alkylene)-(C 3-6 cycloalkyl), or hydroxyl. In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ), halo, or cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl) or -S-(C 1-6 alkyl). In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl or C 1-6 haloalkyl.
- R 6 represents independently for each occurrence C 1-6 haloalkoxyl. In certain embodiments, R 6 is –OCF 3 . In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkoxyl. In certain embodiments, R 6 is methoxy. In certain embodiments, R 6 represents independently for each occurrence -O-(C 0–4 alkylene)-(C 3-6 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 1-4 alkylene)-(C 3-4 cycloalkyl). In certain embodiments, R 6 represents independently for each occurrence -O-(C 3- 4 cycloalkyl).
- R 6 is -O-(cyclopropyl). In certain embodiments, R 6 represents independently for each occurrence -N(R 4 )(R 5 ). In certain embodiments, R 6 is –NH 2 . In certain embodiments, R 6 is hydroxyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 alkyl. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 haloalkyl. In certain embodiments, R 6 is trifluoromethyl. In certain embodiments, R 6 represents independently for each occurrence C 1-6 hydroxyalkyl. In certain embodiments, R 6 represents independently for each occurrence halo.
- R 6 is fluoro or chloro. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 haloalkyl). In certain embodiments, R 6 is -S-CF 3 . In certain embodiments, R 6 represents independently for each occurrence -S-(C 1-6 alkyl).
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- two occurrences of R 6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 two occurrences of R 6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl.
- R 6 is selected from the groups depicted in the compounds in Table 3, below.
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R 6 .
- a 1 is phenyl substituted with m occurrences of R 6 .
- a 1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R 6 .
- a 1 is .
- a 1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R 6 .
- a 1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R 6 .
- a 1 is selected from the groups depicted in the compounds in Table 3, below.
- m is 0, 1, 2, or 3.
- m is 0.
- m is 1.
- m is 2.
- m is 3.
- m is 0 or 1.
- m is 1 or 2.
- m is 2 or 3.
- m is 0, 1, or 2.
- m is 1, 2, or 3.
- m is selected from the values represented in the compounds in Table 3, below.
- p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 3, below. [0296] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2.
- q is selected from the values represented in the compounds in Table 3, below.
- the compound is a compound in Table 1, 1-A, 2, 3, 4, 5, or 6 below, or a pharmaceutically acceptable salt thereof.
- the compound is a compound in Table 1, 1-A, 2, 3, 4, 5, or 6, below.
- the compound is a compound in Table 1, 2, 3, 4, 5, or 6 below, or a pharmaceutically acceptable salt thereof.
- the compound is a compound in Table 1, 2, 3, 4, 5, or 6, below.
- the compound is a compound in Table 1, 1-A, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, 2, or 3, below. In certain embodiments, the compound is a compound in Table 1, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 2, or 3, below. [0300] In certain embodiments, the compound is a compound in Table 1 or 1-A below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 1-A below. In certain embodiments, the compound is a compound in Table 1 below, or a pharmaceutically acceptable salt thereof.
- the compound is a compound in Table 1 below. In certain embodiments, the compound is a compound in Table 2 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 below. In certain embodiments, the compound is a compound in Table 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 3 below. [0301] In certain embodiments, the compound is a compound in Table 1, 1-A, or 4 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, or 4 below. In certain embodiments, the compound is a compound in Table 1 or 4 below, or a pharmaceutically acceptable salt thereof.
- the compound is a compound in Table 1 or 4 below. In certain embodiments, the compound is a compound in Table 2 or 5 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 or 5 below. In certain embodiments, the compound is a compound in Table 3 or 6 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 3 or 6 below.
- a preferred compound has an IC 50 less than 2 ⁇ M against ERK5. In certain embodiments, a more preferred compound has an IC 50 less than 0.5 ⁇ M against ERK5. In certain embodiments, an even more preferred compound has an IC 50 less than or equal to 0.05 ⁇ M against ERK5.
- Methods for preparing compounds described herein are illustrated in the following synthetic Schemes, and in the Examples below. The Schemes are given for the purpose of illustrating the invention, and are not intended to limit the scope or spirit of the invention.
- the synthetic route illustrated in Scheme 1 is a general method for preparing substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds E.
- LG is a leaving group, such as a halide or sulfonate
- M is a metal, such as a boronic acid or ester, or a trialkylstannane
- PG is a protecting group, such as Boc
- Ring formation with carbonyl compound D (wherein R' is, for example, hydrogen; a leaving group, such as a halide; or a hydroxyl group that can be activated using, for example, an amide coupling reagent, such as HATU) affords 4-piperidinyl-imidazo[4,5- b]pyridine E.
- R' is hydrogen (i.e. the carbonyl compound is an aldehyde)
- the ring formation proceeds, for example, by cyclocondensation (using, for example, heating, such as with microwave irradiation), followed by oxidation (using, for example, an oxidant, such as PhI(OAc) 2 or Na2S2O5).
- R' is a leaving group or hydroxyl group (i.e. the carbonyl compound is a carboxylic acid or activated derivative)
- the ring formation proceeds, for example, by condensation (using, for example, a base, such as DIPEA, optionally in the presence of an activating agent, such as an amide coupling reagent, when R' is hydroxyl), followed by cyclocondensation (using, for example, an activating agent, such as cesium fluoride).
- Transition-metal-mediated coupling of imidazo[4,5-b]pyridine A (wherein LG is a leaving group, such as a halide or sulfonate) with cyclic metal reagent B (wherein M is a metal, such as a boronic acid or ester, or a trialkylstannane; and PG is a protecting group, such as Boc), followed by reduction (using, for example, hydrogen and a transition-metal catalyst, such as Pd on carbon), affords protected 4-piperidinyl-imidazo[4,5-b]pyridine C.
- LG is a leaving group, such as a halide or sulfonate
- M is a metal, such as a boronic acid or ester, or a trialkylstannane
- PG is a protecting group, such as Boc
- Diaminopyridine A (wherein PG is a protecting group, such as Boc) is prepared, for example, by analogy to 4-piperidinyl-pyridine C in Scheme 1. Cyclization of diaminopyridine A (using, for example, a reagent such as CDI, phosgene, or triphosgene) affords protected 7-piperidinyl- 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one B.
- a reagent such as CDI, phosgene, or triphosgene
- the synthetic route illustrated in Scheme 4 is a general method for preparing substituted 4-piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-ones and related compounds F.
- Transition-metal-mediated coupling of pyrrolo[2,3-b]pyridine A (wherein LG is a leaving group, such as a halide or a sulfonate) with cyclic metal reagent B (wherein M is a metal, such as a boronic acid or ester, or a trialkylstannane; and PG is a protecting group, such as Boc), followed by reduction (using, for example, hydrogen and a transition-metal catalyst, such as Pd on carbon), affords protected 4-piperidinyl-pyrrolo[2,3-b]pyridine C., which is further functionalized to prepare protected 4-piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one D.
- Functionalization proceeds, for example, by oxidation to form an ⁇ , ⁇ -dihalolactam (using, for example, NBS) followed by reduction (using, for example, a metal, such as zinc) to afford pyridinone D wherein each R 2C is hydrogen.
- R 2C is hydrogen.
- Introduction of other R 2C groups is accomplished by functional group transformations well known in the art, such as, for example enolate alkylation (using, for example, a base, such as LHMDS, and an electrophile, such as methyl iodide).
- the alkene functional group in the coupling product of pyridine or bicyclic heteroaryl A with cyclic metal reagent B in Schemes 1, 2, and 4 can be oxidized, instead of reduced, to afford, for example, an alcohol (using, for example, Mukaiyama hydration conditions) or a 1,2-diol (using, for example, OsO 4 and a stoichiometric oxidant, such as NMO).
- the resulting alcohol(s) can be further functionalized, for example, by alkylation (using, for example, a base, such as NaH, and an electrophile, such as an alkyl halide).
- one aspect of the invention provides a method of treating a disorder mediated by ERK5 in a subject.
- the method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to a subject in need thereof to treat the disorder.
- the compound is a compound of Formula I, I-A, I-B, or I-C defined by one of the embodiments described above.
- the provided compounds are inhibitors of ERK5 and are therefore useful for treating one or more disorders associated with activity of ERK5.
- the present invention provides a method for treating an ERK5-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present invention, or pharmaceutically acceptable composition thereof.
- the term “ERK5-mediated” disorders, diseases, and/or conditions as used herein means any disease or other deleterious condition in which ERK5, or a variant or mutant thereof, is known to play a role.
- another aspect or embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which ERK5, or a variant or mutant thereof, are known to play a role.
- methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder characterized by or associated with increased ERK5 expression and/or increased ERK5 activity comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of ERK5 activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
- inhibitor compounds described herein are believed to bind to and inhibit ERK5, leading to reduced translocation of ERK5 to the cell’s nucleus and/or reduction of ERK5-mediated gene transcription in the nucleus.
- the mitogen- activated protein kinases are a group of proteins able to translate environmental signals elicited by a plethora of stimuli, including growth factors and stresses, into different biological responses such as survival, apoptosis, proliferation, migration, and differentiation.
- the importance of MAPK is underlined by the abnormal signaling conveyed by members of the MAPK family in several human diseases, including Parkinson’s disease, inflammatory disorders, and cancer (see, for example, Kim, E.K.; Choi, E.J. Biochim. Biophys. Acta (2010), 1802, 396– 405; and Kim, S.C. et al. Blood (1999) 93, 3893–3899).
- Extracellular signal-regulated kinase 5 (ERK5, also known as Big MAPK 1, BMK1) is a member of this family, and consists of an amino-terminal kinase domain, with a relatively large carboxy- terminus of unique structure and function that makes it distinct from other MAPK members (Drew et al. Biochim. Biophys. Acta (2012) 1825(1): 37–48).
- cytosolic ERK5 In unstimulated cells and/or in the absence of oncogenic stimuli, cytosolic ERK5 is believed to be in an unphosphorylated inactive folded form, such that the Nuclear Localization Sequence (NLS) is hidden and nuclear translocation is prevented.
- NLS Nuclear Localization Sequence
- ERK5 After stimulus, ERK5 is thought to be activated through a MEK5-dependent phosphorylation at the Thr-Glu-Tyr (TEY) motif of ERK5. This phosphorylation can initiate the ERK5 kinase activity, which can phosphorylate itself in the C-terminus. Following phosphorylation of the C-terminus, ERK5 is understood to assume an open conformation, exposing the NLS sequence that allows ERK5 nuclear translocation.
- TEY Thr-Glu-Tyr
- ERK5 is reported to enhance gene transcription either by phosphorylating transcription factors or, in a kinase-independent manner, by interacting with transcription factors through the transactivation domain (TAD) domain (Tubita et al.(2020) Int. J. Mol. Sci.21(3), 938).
- TAD transactivation domain
- ERK5 is believed to promote tumor growth by, for example, sustaining proliferative signals and evading growth suppressors.
- the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, an ERK5 inhibitor compound as described herein, or a pharmaceutical salt or composition thereof.
- the cellular proliferative disorder is cancer.
- the cancer is characterized by increased ERK5 expression and/or increased ERK5 activity, i.e., “increased activated ERK5.”
- the cancer is characterized by ERK5 genomic amplification and/or constitutively active ERK5 signaling.
- an increase can be by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3- fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10- fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to a control or baseline amount of a function, or activity, or concentration.
- the terms "increased expression” and/or “increased activity" of a substance, such as ERK5, in a sample or cancer or patient refers to an increase in the amount of the substance, such as ERK5, of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6- fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to the amount of the substance, such as ERK5, in a control sample or control samples, such as an individual or group of individuals who are not suffering from the disease or disorder (e.
- a subject can also be determined to have an "increased expression” or “increased activity” of ERK5 if the expression and/or activity of ERK5 is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more, relative to the mean (average) or median amount of ERK5 in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples.
- control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples.
- a proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990).
- a proliferative disease can be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes, such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis, as in proliferative retinopathy and tumor metastasis.
- proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases)
- the pathological angiogenesis as in proliferative retinopathy and tumor metastasis.
- Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
- the disorder is cancer.
- the cancer or proliferative disorder or tumor to be treated using the compounds and methods and uses described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a colorectal cancer, lung cancer, head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and a vascular cancer.
- a cancer is treated by inhibiting or reducing or decreasing or arresting further growth or spread of the cancer or tumor.
- a cancer is treated by inhibiting or reducing the size (e.g., volume or mass) of the cancer or tumor by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the size of the cancer or tumor prior to treatment.
- a cancer is treated by reducing the quantity of the cancers or tumors in the patient by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the quantity of the cancers or tumors prior to treatment.
- the cancer is selected from non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer.
- NSCLC non-small cell lung cancer
- the cancer is a pancreatic cancer, such as an adenocarcinoma.
- the cancer is colorectal cancer (CRC).
- the cancer is a breast cancer, such as ductal breast carcinoma. In some embodiments, the cancer is an ovarian cancer. In some embodiments, the cancer is a brain cancer, such as glioblastoma. In some embodiments, the cancer is a kidney cancer. [0323] In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a melanoma, carcinoma, or blastoma. In certain embodiments, the cancer is a melanoma. In certain embodiments, the cancer is a carcinoma. In certain embodiments, the cancer is an adenocarcinoma. In certain embodiments, the cancer is a blastoma.
- the cancer is breast cancer, lung cancer, pancreatic cancer, cervical cancer, colorectal cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer.
- the cancer is breast cancer.
- the cancer is lung cancer.
- the cancer is pancreatic cancer.
- the cancer is cervical cancer.
- the cancer is colorectal cancer.
- the cancer is prostate cancer.
- the cancer is gastric cancer.
- the cancer is skin cancer.
- the cancer is liver cancer.
- the cancer is bile duct cancer.
- the cancer is nervous system cancer.
- the cancer is breast adenocarcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, prostate adenocarcinoma, gastric adenocarcinoma, melanoma, lung squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, or neuroblastoma.
- the cancer is breast adenocarcinoma.
- the cancer is lung adenocarcinoma.
- the cancer is pancreatic adenocarcinoma.
- the cancer is cervical adenocarcinoma. In certain embodiments, the cancer is prostate adenocarcinoma. In certain embodiments, the cancer is gastric adenocarcinoma. [0326] In certain embodiments, the cancer is melanoma. [0327] In certain embodiments, the cancer is lung squamous cell carcinoma, hepatocellular carcinoma, or cholangiocarcinoma. In certain embodiments, the cancer is lung squamous cell carcinoma. In certain embodiments, the cancer is hepatocellular carcinoma. In certain embodiments, the cancer is cholangiocarcinoma. [0328] In certain embodiments, the cancer is glioblastoma or neuroblastoma.
- the cancer is glioblastoma. In certain embodiments, the cancer is neuroblastoma. [0329] In certain embodiments, the cancer is lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is non-small cell lung cancer. [0330] In certain embodiments, the cancer has elevated ERK5 activity. In certain embodiments, the cancer overexpresses ERK5. In certain embodiments, the cancer has genomically amplified ERK5. In certain embodiments, the cancer has constitutively active ERK5 signaling.
- the cancer is a KRAS mutant cancer.
- the KRAS mutant cancer harbors the KRAS G12C mutation.
- the KRAS mutant cancer harbors the KRAS G12D mutation.
- the KRAS mutant cancer harbors the KRAS G12V mutation.
- the KRAS mutant cancer harbors the KRAS G13 mutation.
- the KRAS mutant cancer harbors one or more KRAS mutations selected from a KRAS G12C, a KRAS G12D mutation, a KRAS G12V mutation, and a KRAS G13 mutation.
- the cancer is a KRAS mutant lung cancer.
- the cancer is a leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin’s disease or non-Hodgkin’s disease), Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, or a solid tumor such as a sarcoma or carcinoma (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma
- a leukemia
- the cancer is glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma.
- the cancer is acoustic neuroma, astrocytoma (e.g.
- GBM Glioblastoma
- the cancer is a type found more commonly in children than adults, such as brain stem glioma, craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor.
- the cancer is mesothelioma, hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphoc
- the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal/stomach (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Wald
- the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal stromal tumor (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Wald
- the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular carcinoma
- hepatoblastoma colon cancer
- rectal cancer ovarian cancer
- ovarian epithelial cancer
- the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic duct
- the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic duct
- the cancer is renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoblastoma, colorectal carcinoma, colorectal cancer, colon cancer, rectal cancer, anal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular carcinoma
- the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
- HCC hepatocellular carcinoma
- hepatoblastoma colon cancer
- rectal cancer ovarian cancer
- ovarian cancer ovarian epi
- the cancer is hepatocellular carcinoma (HCC). In some embodiments, the cancer is hepatoblastoma. In some embodiments, the cancer is colon cancer. In some embodiments, the cancer is rectal cancer. In some embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian epithelial cancer. In some embodiments, the cancer is fallopian tube cancer. In some embodiments, the cancer is papillary serous cystadenocarcinoma. In some embodiments, the cancer is uterine papillary serous carcinoma (UPSC). In some embodiments, the cancer is hepatocholangiocarcinoma.
- HCC hepatocellular carcinoma
- the cancer is hepatoblastoma. In some embodiments, the cancer is colon cancer. In some embodiments, the cancer is rectal cancer. In some embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian epithelial cancer. In some embodiments,
- the cancer is soft tissue and bone synovial sarcoma. In some embodiments, the cancer is rhabdomyosarcoma. In some embodiments, the cancer is osteosarcoma. In some embodiments, the cancer is anaplastic thyroid cancer. In some embodiments, the cancer is adrenocortical carcinoma. In some embodiments, the cancer is pancreatic cancer, or pancreatic ductal carcinoma. In some embodiments, the cancer is pancreatic adenocarcinoma. In some embodiments, the cancer is glioma. In some embodiments, the cancer is malignant peripheral nerve sheath tumors (MPNST). In some embodiments, the cancer is neurofibromatosis-1 associated MPNST.
- MPNST peripheral nerve sheath tumors
- the cancer is Waldenstrom’s macroglobulinemia. In some embodiments, the cancer is medulloblastoma.
- the subject is a human. In certain embodiments, the subject is an adult human. In certain embodiments, the subject is a pediatric human. In certain embodiments, the subject is a companion animal. In certain embodiments, the subject is a canine, feline, or equine. [0346] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein, such as cancer.
- Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) for treating a medical disorder, such as a medical disorder described herein (for example, cancer).
- a medical disorder such as a medical disorder described herein (for example, cancer).
- the compounds described herein, such as a compound of Formula I, or other compounds in Section I can inhibit ERK5 activity.
- another aspect of the invention provides a method of inhibiting ERK5 activity. The method comprises contacting ERK5 with an effective amount of a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein, such as a compound of Formula I, or other compounds in Section I, to inhibit ERK5 activity.
- the compound is a compound of Formula I, I-A, I-B, or I-C defined by one of the embodiments described above.
- III. Combination Therapy Another aspect of the invention provides for combination therapy.
- Substituted 4- piperidinyl-imidazo[4,5-b]pyridine or related compounds described herein (e.g., a compound of Formula I, or other compounds in Section I) or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as a cancer.
- the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein.
- the method includes co-administering one additional therapeutic agent.
- the method includes co-administering two additional therapeutic agents.
- the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.
- One or more other therapeutic agents may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen.
- one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, or 24 hours from one another. In some embodiments, one or more other therapeutic agent and a compound or composition of the invention are administerd as a multiple dosage regimen more than 24 hours aparts. [0352] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
- a compound of the present invention can be administered with one or more other therapeutic agent(s) simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
- the present invention provides a single unit dosage form comprising a compound of the current invention, one or more other therapeutic agent(s), and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- a pharmaceutically acceptable carrier, adjuvant, or vehicle e.g., a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- a composition of the invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of a compound of the invention can be administered.
- the one or more other therapeutic agent(s) and a compound of the invention can act synergistically. Therefore, the amount of the one or more other therapeutic agent(s) in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent.
- a dosage of between 0.01 - 1,000 g/kg body weight/day of the one or more other therapeutic agent(s) can be administered.
- the amount of one or more other therapeutic agent(s) present in the compositions of this invention is preferably no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
- the amount of one or more other therapeutic agent(s) in the presently disclosed compositions ranges from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
- one or more other therapeutic agent(s) is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent.
- the phrase "normally administered” means the amount an FDA- approved therapeutic agent is approved for dosing per the FDA label insert.
- another aspect of the invention provides a method of treating cancer in a subject. The method comprises administering to a subject in need thereof (i) a therapeutically effective amount of a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein and (ii) a second anti-cancer agent, in order to treat the cancer.
- the second anti-cancer agent is an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin- Dependent Kinase Inhibitor, a DNA-PK Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor plus 2-chloro-deoxyadenosine, an HDAC Inhibitor, a Hedgehog Signaling Pathway Inhibitor, an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a MEK Inhibitor, a MELK Inhibitor, a MELK Inhibitor,
- the second anti-cancer agent is an ALK Inhibitor. In certain embodiments, the second anti-cancer agent is an ALK Inhibitor comprisng ceritinib, crizotinib, or alectinib. In certain embodiments, the second anti-cancer agent is an ALK Inhibitor comprisng ceritinib or crizotinib. [0359] In certain embodiments, the second anti-cancer agent is an ATR Inhibitor. In certain embodiments, the second anti-cancer agent is an ATR Inhibitor comprising AZD6738 or VX- 970. [0360] In certain embodiments, the second anti-cancer agent is an A2A Antagonist.
- the second anti-cancer agent is a Base Excision Repair Inhibitor comprising methoxyamine. In certain embodiments, the second anti-cancer agent is a Base Excision Repair Inhibitor, such as methoxyamine. [0361] In certain embodiments, the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor.
- the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (SPRYCEL®, Bristol Myers Squibb); bosutinib (BOSULIF®, Pfizer); and ponatinib (INCLUSIG®, Ariad Pharmaceuticals).
- the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor comprising dasatinib or nilotinib.
- the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor comprising ibrutinib or AVL-292. In certain embodiments, the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor comprising ibrutinib. Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention, can be found in WO2008/039218 and WO2011/090760, the entirety of which are incorporated herein by reference.
- the second anti-cancer agent is a CDC7 Inhibitor. In certain embodiments, the second anti-cancer agent is a CDC7 Inhibitor comprising RXDX-103 or AS- 141. [0364] In certain embodiments, the second anti-cancer agent is a CHK1 Inhibitor. In certain embodiments, the second anti-cancer agent is a CHK1 Inhibitor comprising MK-8776, ARRY- 575, or SAR-020106. [0365] In certain embodiments, the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor.
- the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor, such as a CDK4/CDK6 inhibitor.
- the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics).
- the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor comprising palbociclib.
- the second anti-cancer agent is a DNA-PK Inhibitor. In certain embodiments, the second anti-cancer agent is a DNA-PK Inhibitor comprising MSC2490484A. In certain embodiments, the second anti-cancer agent is Inhibitor of both DNA- PK and mTOR. In certain embodiments, the second anti-cancer agent comprises CC-115. [0367] In certain embodiments, the second anti-cancer agent is a DNMT1 Inhibitor. In certain embodiments, the second anti-cancer agent is a DNMT1 Inhibitor comprising decitabine, RX-3117, guadecitabine, NUC-8000, or azacytidine.
- the second anti- cancer agent comprises a DNMT1 Inhibitor and 2-chloro-deoxyadenosine. In certain embodiments, the second anti-cancer agent comprises ASTX-727. [0368] In certain embodiments, the second anti-cancer agent is a histone deacetylase (HDAC) Inhibitor.
- HDAC histone deacetylase
- the second anti-cancer agent is a HDAC Inhibitor comprising OBP-801, CHR-3996, etinostate, resminostate, pracinostat, CG-200745, panobinostat, romidepsin, mocetinostat, belinostat, AR-42, ricolinostat, KA-3000, or ACY-241.
- the second anti-cancer agent is a Hedgehog Signaling Pathway Inhibitor.
- the second anti-cancer agent is a Hedgehog Signaling Pathway Inhibitor comprising sonidegib (ODOMZO®, Sun Pharmaceuticals) or vismodegib (ERIVEDGE®, Genentech).
- the second anti-cancer agent is an IDO Inhibitor.
- the second anti-cancer agent is an IDO Inhibitor comprising INCB024360.
- the second anti-cancer agent is a JAK Inhibitor.
- the second anti-cancer agent is a JAK Inhibitor comprising ruxolitinib or tofacitinib.
- the second anti-cancer agent is a mTOR Inhibitor. In certain embodiments, the second anti-cancer agent is a mTOR Inhibitor comprising everolimus or temsirolimus. [0373] In certain embodiments, the second anti-cancer agent is a MEK Inhibitor. In certain embodiments, the second anti-cancer agent is a MEK Inhibitor comprising cobimetinib or trametinib. [0374] In certain embodiments, the second anti-cancer agent is a MELK Inhibitor.
- the second anti-cancer agent is a MELK Inhibitor comprising ARN-7016, APTO- 500, or OTS-167. [0375] In certain embodiments, the second anti-cancer agent is a MTH1 Inhibitor. In certain embodiments, the second anti-cancer agent is a MTH1 Inhibitor comprising (S)-crizotinib, TH 2 87, or TH588. [0376] In certain embodiments, the second anti-cancer agent is a Poly ADP ribose polymerase (PARP) Inhibitor.
- PARP Poly ADP ribose polymerase
- the second anti-cancer agent is a PARP Inhibitor comprising MP-124, olaparib (LYNPARZA®, AstraZeneca), BGB-290 (BeiGene, Inc.), talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin), veliparib (ABT-888, AbbVie), niraparib (ZEJULA®, Tesaro), E7449, rucaparib (RUBRACA®, Clovis Oncology), or ABT-767.
- PARP Inhibitor comprising MP-124, olaparib (LYNPARZA®, AstraZeneca), BGB-290 (BeiGene, Inc.), talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin), veliparib (ABT-888, AbbVie), niraparib (ZEJULA®
- the second anti-cancer agent is a Phosphoinositide 3-Kinase (PI3 Kinase) Inhibitor.
- the second anti-cancer agent is a Phosphoinositide 3-Kinase Inhibitor comprising idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); or TGR1202 (formerly RP5230, TG Therapeutics).
- the second anti-cancer agent is a Phosphoinositide 3- Kinase Inhibitor comprising idelalisib.
- the second anti-cancer agent is an inhibitor of both PARP1 and DHODH (i.e., an agent that inhibits both poly ADP ribose polymerase 1 and dihydroorotate dehydrogenase).
- the second anti-cancer agent is a Proteasome Inhibitor.
- the second anti-cancer agent is a Proteasome Inhibitor comprising bortezomib (VELCADE®, Takeda), carfilzomib (KYPROLIS®, Amgen), or ixazomib (NINLARO®, Takeda).
- the second anti-cancer agent is a Proteasome Inhibitor comprising bortezomib or carfilzomib.
- the second anti-cancer agent is a Topoisomerase-II Inhibitor.
- the second anti-cancer agent is a Topoisomerase-II Inhibitor comprising vosaroxin.
- the second anti-cancer agent is a topoisomerase inhibitor.
- Approved topoisomerase inhibitors useful in the present invention include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals) and topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (PIXUVRI®, CTI Biopharma).
- the second anti-cancer agent is a Tyrosine Kinase Inhibitor.
- the second anti-cancer agent is a Tyrosine Kinase Inhibitor comprising bosutinib (BOSULIF®, Pfizer), cabozantinib (COMETRIQ®, Exelexis), imatinib (GLEEVEC®, Novartis), or ponatinib (INCLUSIG®, Ariad Pharmaceuticals).
- the Tyrosine Kinase Inhibitor is an inhibitor of ROS1 and/or NTRK, such as taletrectinib (DS- 6051b, AB-106, AnHeart Therapeutics Co., Ltd.).
- the second anti-cancer agent is a VEGFR Inhibitor.
- the second anti-cancer agent is a VEGFR Inhibitor comprising regorafenib (STIVARGA®, Bayer). In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor. In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor comprising AZD1775.
- the second anti-cancer agent is a compound targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 32043 2 ; GO 6976; lsis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K
- P13K protein kin
- the second anti-cancer agent is a KRAS inhibitor.
- the second anti-cancer agent is a KRAS inhibitor, such as adagrasib (MRTX849, Mirati Therapeutics) or sotorasib (Amgen).
- the KRAS inhibitor is a KRAS G12C inhibitor, such as adagrasib (MRTX849, Mirati Therapeutics), sotorasib (AMG510, Amgen), D-1553 (InventisBio Inc.), GDC-6036, or JNJ-74699157/ARS-3248 (Janssen Biotech and Wellspring Biosciences).
- the KRAS inhibitor is a KRAS G12D inhibitor, such as MRTX1133 (Mirati Therapeutics), RM-030/031 (Revolution Medicines), STX200 (SyntheX), JAB-22000 (JacoBio).
- the KRAS inhibitor is a KRAS G12V inhibitor, such as JAB-23000 (JacoBio).
- the KRAS inhibitor is a pan-KRAS inhibitor, such as BI-1701963 (Boehringer Ingelheim).
- Non-limiting examples of KRAS inhibitors for use as the second anti-cancer agent in the methods and uses described herein include, but are not limited to, those described in WO2020/097537, WO2020/132597, WO2020/035031, WO2020/243103, WO2020/212895, WO2021/041671, WO2021/081212, WO2021/106231, WO2021/107160, WO2021/108683, WO2021/119343, and WO2021/127404, the contents of each of which are herein incorporated by reference in their entireties.
- the second anti-cancer agent is a SOS1 inhibitor, such as BI- 3406.
- the second anti-cancer agent is an agonist of OX40, CD137, CD40, GITR, CD27, HVEM, TNFRSF 2 5, or ICOS.
- the second anti- cancer agent is an agonist of OX40, CD137, CD40, or GITR.
- the second anti-cancer agent is an agonist of CD27, HVEM, TNFRSF 2 5, or ICOS.
- the second anti-cancer agent is a therapeutic antibody.
- the therapeutic antibody targets one of the following: CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, a mucin, TAG-72, CAIX, PSMA, a folate-binding protein, a ganglioside, Le, VEGF, VEGFR, VEGFR2, integrin ⁇ V ⁇ 3, integrin ⁇ 5 ⁇ 1, EGFR, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, tenascin, CD19, KIR, NKG2A, CD47, CEACAM1, c-MET, VISTA, CD73, CD38, BAFF, interleukin-1 beta, B4GALNT1, interleukin-6, and interleukin-6 receptor.
- the second anti-cancer agent is a therapeutic antibody selected from the group consisting of rituximab, ibritumomab tiuxetan, tositumomab, obinutuzumab, ofatumumab, brentuximab vedotin, gemtuzumab ozogamicin, alemtuzumab, IGN101, adecatumumab, labetuzumab, huA33, pemtumomab, oregovomab, minetumomab, cG250, J591, Mov18, farletuzumab, 3F8, ch14.18, KW-2871, hu3S193, lgN311, bevacizumab, IM-2C 6 , pazopanib, sorafenib, axitinib, CDP791, lenvatinib,
- the second anti-cancer agent is a cytokine.
- the cytokine is IL-12, IL-15, GM-CSF, or G-CSF.
- the second anti-cancer agent is sipuleucel-T, aldesleukin (a human recombinant interleukin-2 product having the chemical name des-alanyl-1, serine-125 human interleukin-2), dabrafenib (a kinase inhibitor having the chemical name N- ⁇ 3-[5-(2- aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl ⁇ -2,6- difluorobenzenesulfonamide), vemurafenib (a kinase inhibitor having the chemical name propane-1-sulfonic acid ⁇ 3-[5-(4-chlorophenyl)-1H-pyrrolo
- the second anti-cancer agent is a placental growth factor, an antibody-drug conjugate, an oncolytic virus, or an anti-cancer vaccine. In certain embodiments, the second anti-cancer agent is a placental growth factor. In certain embodiments, the second anti-cancer agent is a placental growth factor comprising ziv-aflibercept. In certain embodiments, the second anti-cancer agent is an antibody-drug conjugate. In certain embodiments, the second anti-cancer agent is an antibody-drug conjugate selected from the group consisting of brentoxumab vedotin and trastuzumab emtransine.
- the second anti-cancer agent is an oncolytic virus. In certain embodiments, the second anti-cancer agent is the oncolytic virus talimogene laherparepvec. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine selected from the group consistint of a GM-CSF tumor vaccine, a STING/GM-CSF tumor vaccine, and NY-ESO-1. In certain embodiments, the second anti-cancer agent is a cytokine selected from IL-12, IL-15, GM- CSF, and G-CSF.
- the second anti-cancer agent is an immune checkpoint inhibitor (also referred to as immune checkpoint blockers).
- Immune checkpoint inhibitors are a class of therapeutic agents that have the effect of blocking immune checkpoints. See, for example, Pardoll in Nature Reviews Cancer (2012) vol.12, pages 252-264.
- the immune checkpoint inhibitor is an agent that inhibits one or more of (i) cytotoxic T ⁇ lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAB3, (v) B7-H 3 , (vi) B7-H4, and (vii) TIM3.
- CTL4 cytotoxic T ⁇ lymphocyte-associated antigen 4
- PD1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PD1 programmed cell death protein 1
- PDL1 programmed cell death protein 1
- PD1 programmed cell death protein 1
- the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab. In certain embodiments, the immune checkpoint inhibitor is ipilumumab. In certain embodiments, the immune checkpoint inhibitor is pembrolizumab. In certain embodiments, the immune checkpoint inhibitor is nivolumab. [0395] In certain embodiments, the second anti-cancer agent is a monoclonal antibody that targets a non-checkpoint target (e.g., herceptin).
- a non-checkpoint target e.g., herceptin
- the second anti-cancer agent is a non-cytoxic agent (e.g., a tyrosine-kinase inhibitor).
- the second anti-cancer agent is selected from mitomycin, ribomustin, vincristine, tretinoin, etoposide, cladribine, gemcitabine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin
- the second anti-cancer agent is radiation therapy.
- the second anti-cancer agent is a MEK Inhibitor.
- the second anti-cancer agent is binimetinib (MEK162, ARRY-438162, ARRAY BIOPHARMA INC.), cobimetinib (COTELLIC®, Exelexis/Genentech/Roche), refametinib (BAY 86–9766, RDEA119; Bayer AG), selumetinib (AZD6244, ARRY-142886; ASTRAZENECA), trametinib (MEKINIST®, Novartis), mirdametinib (PD-0325901, Spring Works Therapeutics), pimasertib (AS703026, MSC1936369B, Merck KGaA) or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is binimetinib, cobimetinib, selumetinib, trametinib, mirdametinib, pimasertib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is binimetinib, cobimetinib, refametinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is binimetinib, cobimetinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing.
- the second anti-cancer agent is trametinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti- cancer agent is trametinib or a pharmaceutically acceptable solvate thereof.
- the second anti-cancer agent is trametinib dimethylsulfoxide. In certain embodiments, the second anti-cancer agent is trametinib.
- the second anti-cancer agent is binimetinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti- cancer agent is cobimetinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti-cancer agent is refametinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti-cancer agent is selumetinib or a pharmaceutically acceptable salt and/or solvate thereof.
- the second anti-cancer agent is binimetinib. In certain embodiments, the second anti-cancer agent is cobimetinib.
- the second anti-cancer agent is refametinib. In certain embodiments, the second anti-cancer agent is selumetinib. [ In some embodiments, the second anti-cancer agent is selected from: or a pharmaceutically acceptable salt and/or solvate thereof.
- MEK inhibitors for use as a second anti-cancer agent in the methods described herein include, but are not limited to, E6201 (Eisai Co Ltd./Strategia Theraputics), GDC-0623 (RG 7421, Genentech, Inc.), CH5126766 (RO5126766, Chugai Pharmaceutical Co., Roche), HL-085 (Shanghai Kechow Pharma, Inc.), SHR7390 (HENGRUI MEDICINE), TQ-B3234 (CHIATAI TIANQING), CS-3006 (CSTONE Pharmaceuticals), FCN- 159 (Fosun Pharmaceuticals), VS-6766 (Verastem Oncology), and IMM-1-104 (Immuneering Corp.).
- the second anti-cancer agent is WX-554.
- WX-554 is a selective, noncompetitive MEK1/2 inhibitor, which has been tested in dose-escalation phase I/II studies (ClinicalTrials.gov: NCT01859351, NCT01581060).
- the second anti-cancer agent is HL-085 (Shanghai Kechow Pharma, Inc.). HL-085 is an orally active, selective MEK inhibitor, which has been tested in phase I clinical study. [0407] In some embodiments, the second anti-cancer agent is FCN-159 (Fosun Pharmaceuticals). [0408] In some embodiments, the second anti-cancer agent is selected from: or a pharmaceutically acceptable salt and/or solvate thereof. [0409] In certain embodiments, the second anti-cancer agent is a TEAD inhibitor.
- a TEAD inhibitor is selected from those described in WO 2020/243415, the contents of which are herein incorporated by reference in their entirety.
- a TEAD inhibitor is a compound of Formula A , pharmaceutically acceptable salt thereof, wherein L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)----
- a TEAD inhibitor is a compound of Formula A-1: , pharmaceutically acceptable salt thereof, wherein L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, -, -SO-,
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -CH(OR)-, -CH(SR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, - (R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, - (R)NSO 2 -, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)
- L 1 is a covalent bond, or a C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, - N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, - SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(
- L 1 is a covalent bond.
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -CH(OR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, or -N(R)C(O)N(R)-.
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are optionally replaced with -CH(SR)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, - OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-.
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, or -N(R)-. In some embodiments, L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -CH(OR)-, -CH(SR)-, or –CH(N(R) 2 )-.
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(O)O-, - OC(O)-, -SO-, -SO 2 -, -C(S)-, -C(S)O-, or -OC(S)-.
- L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-.
- L 1 is -O-, -CH(OR)-, - CH(SR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, - C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-.
- L 1 is -O- , -CH(OR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, or -N(R)C(O)N(R)-.
- L 1 is -CH(SR)-, -S-, - SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or - (R)NC(S)N(R)-.
- L 1 is -O-, -S-, or -N(R)-.
- L 1 is -O-.
- L 1 is -S-.
- L 1 is -N(R)-.
- L 1 is - NH-. In some embodiments, L 1 is -CH(OR)-, -CH(SR)-, or –CH(N(R) 2 )-. In some embodiments, L 1 is -CH(OR)-. In some embodiments, L 1 is -CH(SR)-. In some embodiments, L 1 is – CH(N(R) 2 )-. [0419] In some embodiments, L 1 is -C(O)-, -C(O)O-, -OC(O)-, -SO-, -SO 2 -, -C(S)-, -C(S)O-, or -OC(S)-.
- L 1 is -C(O)-. In some embodiments, L 1 is -C(O)O-. In some embodiments, L 1 is -OC(O)-. In some embodiments, L 1 is -SO-. In some embodiments, L 1 is - SO 2 -. In some embodiments, L 1 is -C(S)-. In some embodiments, L 1 is -C(S)O-. In some embodiments, L 1 is -OC(S)-.
- L 1 is -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, - N(R)C(O)N(R)-, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-.
- L 1 is -C(O)N(R)-.
- L 1 is -(R)NC(O)-.
- L 1 is -OC(O)N(R)-. In some embodiments, L 1 is -(R)NC(O)O-. In some embodiments, L 1 is -N(R)C(O)N(R)-. In some embodiments, L 1 is -SO 2 N(R)-. In some embodiments, L 1 is -(R)NSO 2 -. In some embodiments, L 1 is -C(S)N(R)-. In some embodiments, L 1 is -(R)NC(S)-. or In some embodiments, L 1 is -(R)NC(S)N(R)-.
- L 1 is –CH 2 -, -CH(CH 3 )-, -NH-CH 2 -, -NH-CH(CH 3 )-, -C(O)- NH-, or –N(CH 3 )-. In some embodiments, L 1 is , [0422] In some embodiments, L 1 is selected from those depicted in Table A, below.
- Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A is optionally substituted 1-2 times by halogen, -CN, –NO 2 , or -C 1-6 aliphatic substituted 0-6 times by halogen, -CN, or –NO 2 .
- Ring A is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8-10 membered bicyclic aromatic ring, or a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A is optionally substituted phenyl. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic aromatic ring.
- Ring A is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0426] In some embodiments, Ring A is optionally substituted phenyl, a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen, or a 10-membered bicyclic heteroaromatic ring having 1-2 nitrogen.
- Ring A is optionally substituted , , [0428] In some embodiments, Ring A is optionally substituted 1-2 times by -halogen, -CN, – NO 2 , -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O-C 1-6 aliphatic is independently substituted 0-6 times by -halogen, -CN, or –NO 2 .
- Ring A is optionally substituted 1-2 times by halogen, -CN, –NO 2 , -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O-C 1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen, -CN, or –NO 2 .
- Ring A is optionally substituted 1- 2 times by halogen, -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O- C 1-6 aliphatic is independently substituted 1, 2, 3, 4, 5, or 6 times by halogen.
- Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is cyclohexyl. In some embodiments, Ring A is phenyl. In some embodiments, Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0430] In some embodiments, Ring A is a 8-10 membered bicyclic aromatic ring.
- Ring A is a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0431] In some embodiments, Ring A is optionally substituted 1-2 times by halogen, -CN, – NO 2 , or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen, -CN, or –NO 2 . In some embodiments, Ring A is optionally substituted 1-2 times by halogen, or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen. [0432] In some embodiments, Ring A is selected from wherein each of R 1 and R 7 is independently as described herein.
- Ring A is [0433]
- R 1 is -H, -halogen, -CN, –NO 2 , -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O-C 1-6 aliphatic is substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 1 is unsubstituted –O-C 1-6 aliphatic.
- R 1 is –OCH 3 .
- R 1 is –O-C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen.
- R 1 is –O-C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R 1 is –O-C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 1 is –OCF 3 . In some embodiments, R 1 is [0434] In some embodiments, R 1 is -H, -halogen, -CN, –NO 2 , or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 . In some embodiments, R 1 is –H. In some embodiments, R 1 is –halogen.
- R 1 is –F. In some embodiments, R 1 is –Cl. In some embodiments, R 1 is –Br. In some embodiments, R 1 is –CN. In some embodiments, R 1 is –NO 2 . In some embodiments, R 1 is unsubstituted -C 1-6 aliphatic. In some embodiments, R 1 is – CH 3 . In some embodiments, R 1 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R 1 is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen.
- R 1 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 1 is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 1 is –CF 3 . In some embodiments, R 1 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –CN. In some embodiments, R 1 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –NO 2 .
- R 7 is -H, -halogen, -CN, –NO 2 , -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O-C 1-6 aliphatic is substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 7 is unsubstituted –O-C 1-6 aliphatic.
- R 7 is –OCH 3 .
- R 7 is –O-C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen.
- R 7 is –O-C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R 7 is –O-C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 7 is –OCF 3 . In some embodiments, R 7 is . [0436] In some embodiments, R 7 is -H, -halogen, -CN, –NO 2 , or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 . In some embodiments, R 7 is –H. In some embodiments, R 7 is –halogen.
- R 7 is –F. In some embodiments, R 7 is –Cl. In some embodiments, R 7 is –Br. In some embodiments, R 7 is –CN. In some embodiments, R 7 is –NO 2 . In some embodiments, R 7 is unsubstituted -C 1-6 aliphatic. In some embodiments, R 1 is – CH 3 . In some embodiments, R 7 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R 7 is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen.
- R 7 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 7 is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 7 is –CF 3 . In some embodiments, R 7 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –CN. In some embodiments, R 7 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –NO 2 . [0437] In some embodiments, Ring A is ,
- Ring A is selected from those depicted in Table A, below.
- Ring B is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8-10 membered bicyclic aromatic ring, a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring B is optionally substituted phenyl. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic aromatic ring.
- Ring B is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0441] In some embodiments, Ring B is optionally substituted phenyl or a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen.
- Ring B is optionally substituted 1-4 times by halogen, - S(O) 2 N(R) 2 , -S(O)N(R) 2 , -C(O)N(R) 2 , -C(O)OR, -C 1-6 aliphatic, or –O-C 1-6 aliphatic, wherein each of -C 1-6 aliphatic and –O-C 1-6 aliphatic is independently substituted 0-6 times by halogen, - CN, or –NO 2 .
- Ring B is optionally substituted 1-4 times by –F, -Cl, -Br-, -S(O) 2 NHCH 3 , -S(O)NHCH 3 , -C(O)N(CH 3 ) 2 , -C(O)NHCH 3 , -C(O)OH, -C(O)OCH 3 , -CH 3 , – OCH 3 , or -C(CH 3 ) 3 .
- Ring B is selected from those depicted in Table A, below.
- R 2 is -H, or an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 2 is –H.
- R 2 is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 2 is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C 1-6 alkyl.
- R 2 is , w described herein.
- R 2 is R is as described herein.
- R 2 is . ments, R 2 is , [0451] In some embodiments, R 2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen.
- R 2 is selected from , , n some embodiments, R 2 is or ments, R 2 is [0452] In some embodiments, R 2 is selected from those depicted in Table A, below. [0453] As defined generally above, in some embodiments, R 3 is –H. [0454] In some embodiments, R 3 is iments, R 3 is , , [0455] In some embodiments, R 3 is selected from those depicted in Table A, below. [0456] As defined generally above, R 4 is -H, halogen, -S(O) 2 N(R) 2 , -S(O)N(R) 2 , or - C(O)N(R) 2 .
- R 4 is -H, halogen, -S(O) 2 N(R) 2 , -S(O)N(R) 2 , -C(O)N(R) 2 , or - C(O)OR. In some embodiments, R 4 is –H. In some embodiments, R 4 is halogen. In some embodiments, R 4 is -F. In some embodiments, R 4 is -Cl. In some embodiments, R 4 is -Br. [0458] In some embodiments, R 4 is -S(O) 2 N(R) 2 , -S(O)N(R) 2 , or -C(O)N(R) 2 .
- R 4 is -S(O) 2 N(R) 2 . In some embodiments, R 4 is -S(O)N(R) 2 . In some embodiments, R 4 is -C(O)N(R) 2 . In some embodiments, R 4 is -S(O) 2 NHCH 3 . In some embodiments, R 4 is -S(O)NHCH 3 , -C(O)N(CH 3 ) 2 , -C(O)NHCH 3 , -C(O)OH, or -C(O)OCH 3 . [0459] In some embodiments, R 4 is .
- R 4 is , , [0460] In some embodiments, R 4 is selected from those depicted in Table A, below. [0461] As defined generally above, R 6 is -H or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 6 is –H, -halogen, -CN, –NO 2 , -C 1-6 aliphatic, -OC 1-6 aliphatic, or a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally substituted 1-3 times by -C 1-6 aliphatic or -OC 1-6 aliphatic, wherein each of -C 1-6 aliphatic and -OC 1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 6 is –H. In some embodiments, R 6 is –F.
- R 6 is –Cl. In some embodiments, R 6 is –Br. In some embodiments, R 6 is –CN. In some embodiments, R 6 is –NO 2 . [0464] In some embodiments, R 6 is -C 1-6 aliphatic, substituted 0, 1, 2, 3, 4, 5, or 6 times by - halogen, -CN, or –NO 2 . In some embodiments, R 6 is unsubstituted -C 1-6 aliphatic. In some embodiments, R 6 is –CH 3 . In some embodiments, R 6 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 6 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -F. In some embodiments, R 6 is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 6 is –CF 3 . [0465] In some embodiments, R 6 is -OC 1-6 aliphatic, substituted 0, 1, 2, 3, 4, 5, or 6 times by - halogen, -CN, or –NO 2 . In some embodiments, R 6 is unsubstituted -OC 1-6 aliphatic. In some embodiments, R 6 is –OCH 3 .
- R 6 is -OC 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 . In some embodiments, R 6 is -OC 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -F. In some embodiments, R 6 is -OC 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R 6 is –OCF 3 .
- R 6 is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally substituted 1-3 times by -C 1-6 aliphatic or -OC 1-6 aliphatic, wherein each of -C 1-6 aliphatic and -OC 1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 6 is a 5-membered ring having 1, 2, 3, or 4 nitrogen optionally substituted 1-3 times by -C 1-6 aliphatic.
- R 6 is .
- R 6 is selected from those depicted in Table A, below.
- R w is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R w is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R w is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C 1-6 alkyl.
- R w is , described herein. In some embodiments, R w is is as described herein. [0471] In some embodiments, R w is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C 1-6 alkyl. In some embodiments, R w is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen. In some embodiments, R w is , [0472] In some embodiments, R w is [0473] In some embodiments, R w is [0474] In some embodiments, R w is selected from those depicted in Table A, below.
- R is independently -H or optionally substituted -C 1-6 aliphatic.
- R is –H.
- R is optionally substituted -C 1- 6 aliphatic.
- R is unsubstituted -C 1-6 aliphatic.
- R is –CH 3 .
- R is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by – F.
- R is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R is –CF 3 . [0477] In some embodiments, R is selected from those depicted in Table A, below. [0478] In some embodiments, a TEAD inhibitor is a compound of Formula A-2: , harmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and L 1 is independently as defined and described in embodiments in Section of TEAD Inhibitors of Formulae A, and A-1 to A-50.
- the present invention provides a compound of Formula A-2, or a pharmaceutically acceptable salt thereof, wherein: (a): L 1 is -O- or -S-; R 1 is -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen; R 2 is an optionally substituted 5-membered aromatic ring having 1, 2, 3, or 4 nitrogen; R 3 is -H; R 4 is -S(O) 2 N(R) 2 ; -S(O)N(R) 2 , or -C(O)N(R) 2 , each R independently is selected -H and optionally substituted -C 1-6 aliphatic; R 6 is -H or -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen; and R 7 is -H; or (b): L 1 is -NH-; R 1 is -C 1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen;
- a TEAD inhibitor is a compound of Formula: A-18 or a pharmaceutically acceptable salt thereof, wherein each of X is independently C or N, and each of Ring A, R w , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and L 1 is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50.
- a TEAD inhibitor is a compound of Formula A, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl, a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen, or a 10-membered bicyclic heteroaromatic ring having 1-2 nitrogen; Ring B is phenyl or a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen; and each of R w and L 1 is as defined above and described in embodiments herein, both singly and in combination.
- a TEAD inhibitor is a compound selected from the following: i.
- L 1 is a C 2-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, R is -C 1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F, and R 2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; v.
- TEAD inhibitor is selected from those listed in Table A, or a pharmaceutically acceptable salt thereof. Table A.
- a TEAD inhibitor is T-A-31, T-A-32, T-A-56, T-A- 57, T-A- 60, T-A-63, T-A-68, T-A-74, T-A-83, T-A-94, T-A-96, or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A-31 or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A-32 or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A-56 or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A- 57 or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A- 60 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T- A-63 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-68 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-74 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-83 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-94 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-96 or a pharmaceutically acceptable salt thereof.
- a TEAD inhibitor is T-A-31, T-A-32, T-A-56, T-A- 57, T-A- 60, T-A-63, T-A-68, T-A-74, T-A-83, T-A-94, or T-A-96.
- a TEAD inhibitor is T-A-31.
- a TEAD inhibitor is T-A-32.
- a TEAD inhibitor is T-A-56.
- a TEAD inhibitor is T-A- 57.
- a TEAD inhibitor is T-A-60.
- a TEAD inhibitor is T-A-63.
- a TEAD inhibitor is T-A-68. In certain embodiments, a TEAD inhibitor is T-A-74. In certain embodiments, a TEAD inhibitor is T-A- 83. In certain embodiments, a TEAD inhibitor is T-A-94. In certain embodiments, a TEAD inhibitor is T-A-96.
- TEAD Inhibitors of Formulae B and B-1 [0486] In certain embodiments, a TEAD inhibitor is selected from those described in WO 2020/243423, the contents of which are herein incorporated by reference in their entirety.
- a TEAD inhibitor is a compound of Formula B: , pharmaceutically acceptable salt thereof, wherein L 1 is a covalent bond, or a C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, - CH(OR)-, -CH(SR)-, –CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, - (R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, - (R)NSO 2 -, -C(S)-, -C(S)-, -
- a TEAD inhibitor is a compound of formula B-1 eutically acceptable salt thereof, wherein L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R) 2 )-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, -, -SO-, -SO
- L 1 is -O-, -CH(OR)-, -CH(SR)-, –CH(N(R) 2 )-, -C(O)-, - C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, - N(R)C(O)N(R)-, -S-, -SO-, -SO 2 -, -SO 2 N(R)-, -(R)NSO 2 -, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)- , -(R)NC(S)-, or -(R)NC(S)N(R)-.
- L 1 is -O-, -S-, or -N(R)-. In some embodiments, L 1 is -O-. In some embodiments, L 1 is -S-. In some embodiments, L 1 is -N(R)-. In some embodiments, L 1 is -NH-. In some embodiments, L 1 is selected from those depicted in Table B, below. [0490] In some embodiments, Ring A is optionally substituted phenyl. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring.
- Ring A is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A is , , , [0493] In some embodiments, Ring A is selected from those depicted in Table B, below. [0494] In some embodiments, Ring B is optionally substituted phenyl. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring B is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0496] In some embodiments, Ring B is selected from those depicted in Table B, below. [0497] In some embodiments, R 2 is –H. In some embodiments, R 2 is a warhead group.
- R 2 is [0498] In some embodiments, R 2 is selected from those depicted in Table B, below. [0499] In some embodiments, R 3 is –H. In some embodiments, R 3 is a warhead group. In some embodiments, R 3 is , [0500] In some embodiments, R 3 is selected from those depicted in Table B, below. [0501] In some embodiments, R 4 is –H. In some embodiments, R 4 is halogen. In some embodiments, R 4 is -F. In some embodiments, R 4 is -Cl. In some embodiments, R 4 is -Br. In some embodiments, R 4 is -S(O) 2 N(R) 2 .
- R 4 is -S(O)N(R) 2 . In some embodiments, R 4 is -C(O)N(R) 2 . In some embodiments, R 4 is -S(O) 2 NHCH 3 . [0502] In some embodiments, R 4 is a warhead group. In some embodiments, R 4 is , [0503] In some embodiments, R 4 is selected from those depicted in Table B, below. [0504] In some embodiments, R 6 is -H. In some embodiments, R 6 is -C 1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO 2 .
- R 6 is selected from those depicted in Table B, below. iments, R w is selected from those depicted in Table B, below. [0506] In some embodiments, R is –H. In some embodiments, R is optionally substituted -C 1- 6 aliphatic. In some embodiments, R is unsubstituted -C 1-6 aliphatic. In some embodiments, R is –CF 3 . In some embodiments, R is –CH 3 , –C(CH 3 ) 3 , –CHF 2 , cyclopropyl, –CF 2 CF 3 , or .
- a “warhead group,” as used herein, is capable of covalently binding to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified) present in the binding pocket of a target protein, for example, TEAD, thereby irreversibly inhibiting the protein.
- a warhead group is as defined and described in embodiments in WO 2020/243423, the content of which is herein incorporated by reference in its entirety.
- a TEAD inhibitor is selected from those listed in Table B, or a pharmaceutically acceptable salt thereof. Table B. Exemplary TEAD Inhibitors
- the second anti-cancer agent is a Poly ADP ribose polymerase (PARP) inhibitor.
- PARP Poly ADP ribose polymerase
- a PARP inhibitor is selected from olaparib (LYNPARZA®, AstraZeneca); rucaparib (RUBRACA®, Clovis Oncology); niraparib (ZEJULA®, Tesaro); talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin); veliparib (ABT-888, AbbVie); and BGB-290 (BeiGene, Inc.).
- the second anti-cancer agent is a histone deacetylase (HDAC) inhibitor.
- HDAC histone deacetylase
- an HDAC inhibitor is selected from vorinostat (ZOLINZA®, Merck); romidepsin (ISTODAX®, Celgene); panobinostat (FARYDAK®, Novartis); belinostat (BELEODAQ®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (EPIDAZA®, HBI-8000, Chipscreen Biosciences, China).
- the second anti-cancer agent is a CDK inhibitor, such as a CDK4/CDK6 inhibitor.
- a CDK 4/6 inhibitor is selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics).
- the second anti-cancer agent is a phosphatidylinositol 3 kinase (PI3K) inhibitor.
- a PI3K inhibitor is selected from idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics).
- the second anti-cancer agent is a platinum-based therapeutic, also referred to as platins.
- a platinum-based therapeutic is selected from cisplatin (PLATINOL®, Bristol Myers Squibb); carboplatin (PARAPLATIN®, Bristol Myers Squibb; also, Teva; Pfizer); oxaliplatin (ELOXITIN® Sanofi-Aventis); nedaplatin (AQUPLA®, Shionogi), picoplatin (Poniard Pharmaceuticals); and satraplatin (JM-216, Agennix).
- the second anti-cancer agent is a taxane compound, which causes disruption of microtubules, which are essential for cell division.
- a taxane compound is selected from paclitaxel (TAXOL®, Bristol Myers Squibb), docetaxel (TAXOTERE®, Sanofi-Aventis; DOCEFREZ®, Sun Pharmaceutical), albumin-bound paclitaxel (ABRAXANE®; Abraxis/Celgene), cabazitaxel (JEVTANA®, Sanofi-Aventis), and SID530 (SK Chemicals, Co.) (NCT00931008).
- the second anti-cancer agent is a nucleoside inhibitor, or a therapeutic agent that interferes with normal DNA synthesis, protein synthesis, cell replication, or will otherwise inhibit rapidly proliferating cells.
- a nucleoside inhibitor is selected from trabectedin (guanidine alkylating agent, YONDELIS®, Janssen Oncology), mechlorethamine (alkylating agent, VALCHLOR®, Aktelion Pharmaceuticals); vincristine (ONCOVIN®, Eli Lilly; VINCASAR®, Teva Pharmaceuticals; MARQIBO®, Talon Therapeutics); temozolomide (prodrug to alkylating agent 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC) TEMODAR®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analog, Pfizer); lomustine (alkylating agent
- the second anti-cancer agent is a kinase inhibitor or VEGF-R antagonist.
- Approved VEGF inhibitors and kinase inhibitors useful in the present invention include: bevacizumab (AVASTIN®, Genentech/Roche) an anti-VEGF monoclonal antibody; ramucirumab (CYRAMZA®, Eli Lilly), an anti-VEGFR-2 antibody and ziv-aflibercept, also known as VEGF Trap (ZALTRAP®; Regeneron/Sanofi).
- VEGFR inhibitors such as regorafenib (STIVARGA®, Bayer); vandetanib (CAPRELSA®, AstraZeneca); axitinib (INLYTA®, Pfizer); and lenvatinib (LENVIMA®, Eisai); Raf inhibitors, such as sorafenib (NEXAVAR®, Bayer AG and Onyx); dabrafenib (TAFINLAR®, Novartis); and vemurafenib (ZELBORAF®, Genentech/Roche); MEK inhibitors, such as cobimetanib (COTELLIC®, Exelexis/Genentech/Roche); trametinib (MEKINIST®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (
- kinase inhibitors and VEGF-R antagonists that are in development and may be used in the present invention include tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer/Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib (Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (SUPECT®, IY5511, Il-Yang Pharmaceuticals, S.
- the second anti-cancer agent is an mTOR inhibitor, which inhibits cell proliferation, angiogenesis and glucose uptake.
- an mTOR inhibitor is everolimus (AFINITOR®, Novartis); temsirolimus (TORISEL®, Pfizer); and sirolimus (RAPAMUNE®, Pfizer).
- the second anti-cancer agent is a proteasome inhibitor.
- Approved proteasome inhibitors useful in the present invention include bortezomib (VELCADE®, Takeda); carfilzomib (KYPROLIS®, Amgen); and ixazomib (NINLARO®, Takeda).
- the second anti-cancer agent is a growth factor antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or epidermal growth factor (EGF) or its receptor (EGFR).
- Approved PDGF antagonists which may be used in the present invention include olaratumab (LARTRUVO®; Eli Lilly).
- Approved EGFR antagonists which may be used in the present invention include cetuximab (ERBITUX®, Eli Lilly); necitumumab (PORTRAZZA®, Eli Lilly), panitumumab (VECTIBIX®, Amgen); and osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca).
- the second anti-cancer agent is an aromatase inhibitor.
- an aromatase inhibitor is selected from exemestane (AROMASIN®, Pfizer); anastazole (ARIMIDEX®, AstraZeneca) and letrozole (FEMARA®, Novartis).
- the second anti-cancer agent is an antagonist of the hedgehog pathway.
- Approved hedgehog pathway inhibitors which may be used in the present invention include sonidegib (ODOMZO®, Sun Pharmaceuticals); and vismodegib (ERIVEDGE®, Genentech), both for treatment of basal cell carcinoma.
- the second anti-cancer agent is a folic acid inhibitor. Approved folic acid inhibitors useful in the present invention include pemetrexed (ALIMTA®, Eli Lilly).
- the second anti-cancer agent is a CC chemokine receptor 4 (CCR4) inhibitor.
- CCR4 inhibitors being studied that may be useful in the present invention include mogamulizumab (POTELIGEO®, Kyowa Hakko Kirin, Japan).
- the second anti-cancer agent is an isocitrate dehydrogenase (IDH) inhibitor.
- IDH inhibitors being studied which may be used in the present invention include AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081); IDH305 (Novartis, NCT02987010).
- the second anti-cancer agent is an arginase inhibitor.
- Arginase inhibitors being studied which may be used in the present invention include AEB1102 (pegylated recombinant arginase, Aeglea Biotherapeutics), which is being studied in Phase 1 clinical trials for acute myeloid leukemia and myelodysplastic syndrome (NCT02732184) and solid tumors (NCT02561234); and CB-1158 (Calithera Biosciences).
- the second anti-cancer agent is a glutaminase inhibitor.
- Glutaminase inhibitors being studied which may be used in the present invention include CB-839 (Calithera Biosciences).
- the second anti-cancer agent is an antibody that binds to tumor antigens, that is, proteins expressed on the cell surface of tumor cells.
- Approved antibodies that bind to tumor antigens which may be used in the present invention include rituximab (RITUXAN®, Genentech/BiogenIdec); ofatumumab (anti-CD20, ARZERRA®, GlaxoSmithKline); obinutuzumab (anti-CD20, GAZYVA®, Genentech), ibritumomab (anti- CD20 and Yttrium-90, ZEVALIN®, Spectrum Pharmaceuticals); daratumumab (anti-CD38, DARZALEX®, Janssen Biotech), dinutuximab (anti-glycolipid GD2, UNITUXIN®, United Therapeutics); trastuzumab (anti-HER2, HERCEPTIN®, Genentech); ado-trastuzumab e
- the second anti-cancer agent is a topoisomerase inhibitor.
- Approved topoisomerase inhibitors useful in the present invention include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals); topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (PIXUVRI®, CTI Biopharma).
- the second anti-cancer agent is an inhibitor of anti-apoptotic proteins, such as BCL-2.
- Approved anti-apoptotics which may be used in the present invention include venetoclax (VENCLEXTA®, AbbVie/Genentech); and blinatumomab (BLINCYTO®, Amgen).
- Other therapeutic agents targeting apoptotic proteins which have undergone clinical testing and may be used in the present invention include navitoclax (ABT-263, Abbott), a BCL-2 inhibitor (NCT02079740).
- the second anti-cancer agent is an androgen receptor inhibitor.
- Approved androgen receptor inhibitors useful in the present invention include enzalutamide (XTANDI®, Astellas/Medivation); approved inhibitors of androgen synthesis include abiraterone (ZYTIGA®, Centocor/Ortho); approved antagonist of gonadotropin-releasing hormone (GnRH) receptor (degaralix, FIRMAGON®, Ferring Pharmaceuticals).
- the second anti-cancer agent is a selective estrogen receptor modulator (SERM), which interferes with the synthesis or activity of estrogens.
- Approved SERMs useful in the present invention include raloxifene (EVISTA®, Eli Lilly).
- the second anti-cancer agent is an inhibitor of bone resorption.
- An approved therapeutic which inhibits bone resorption is Denosumab (XGEVA®, Amgen), an antibody that binds to RANKL, prevents binding to its receptor RANK, found on the surface of osteoclasts, their precursors, and osteoclast-like giant cells, which mediates bone pathology in solid tumors with osseous metastases.
- Other approved therapeutics that inhibit bone resorption include bisphosphonates, such as zoledronic acid (ZOMETA®, Novartis).
- the second anti-cancer agent is an inhibitor of interaction between the two primary p53 suppressor proteins, MDMX and MDM2.
- Inhibitors of p53 suppression proteins being studied which may be used in the present invention include ALRN- 6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the interaction of MDMX and MDM2 with p53.
- ALRN-6924 is currently being evaluated in clinical trials for the treatment of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL) (NCT02909972; NCT02264613).
- the second anti-cancer agent is an inhibitor of transforming growth factor-beta (TGF-beta or TGFß).
- Inhibitors of TGF-beta proteins being studied which may be used in the present invention include NIS793 (Novartis), an anti-TGF-beta antibody being tested in the clinic for treatment of various cancers, including breast, lung, hepatocellular, colorectal, pancreatic, prostate and renal cancer (NCT 02947165).
- the inhibitor of TGF-beta proteins is fresolimumab (GC1008; Sanofi-Genzyme), which is being studied for melanoma (NCT00923169); renal cell carcinoma (NCT00356460); and non-small cell lung cancer (NCT02581787).
- the additional therapeutic agent is a TGF-beta trap, such as described in Connolly et al. (2012) Int’l J. Biological Sciences 8:964-978.
- TGF-beta trap such as described in Connolly et al. (2012) Int’l J. Biological Sciences 8:964-978.
- M7824 Merck KgaA - formerly MSB0011459X
- NCT02699515 a bispecific, anti-PD-L1/TGF- ⁇ trap compound
- NCT02517398 NCT02517398
- M7824 is comprised of a fully human IgG1 antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II, which functions as a TGF- ⁇ “trap.”
- the second anti-cancer agent is selected from glembatumumab vedotin-monomethyl auristatin E (MMAE) (Celldex), an anti-glycoprotein NMB (gpNMB) antibody (CR011) linked to the cytotoxic MMAE.
- gpNMB is a protein overexpressed by multiple tumor types associated with cancer cells’ ability to metastasize.
- the second anti-cancer agents is an antiproliferative compound.
- antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in
- aromatase inhibitor as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.
- the term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole.
- Exemestane is marketed under the trade name AROMASINTM.
- Formestane is marketed under the trade name LENTARONTM. Fadrozole is marketed under the trade name AFEMATM. Anastrozole is marketed under the trade name ARIMIDEXTM. Letrozole is marketed under the trade names FEMARATM or FEMArTM. Aminoglutethimide is marketed under the trade name ORIMETENTM.
- a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.
- the term "antiestrogen” as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
- Tamoxifen is marketed under the trade name NOLVADEXTM.
- Raloxifene hydrochloride is marketed under the trade name EVISTATM.
- Fulvestrant can be administered under the trade name FASLODEXTM.
- a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.
- anti-androgen as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEXTM).
- gonadorelin agonist as used herein includes, but is not limited to abarelix, goserelin, and goserelin acetate. Goserelin can be administered under the trade name ZOLADEXTM.
- topoisomerase I inhibitor includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148.
- Irinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSARTM.
- Topotecan is marketed under the trade name HYCAMPTINTM.
- topoisomerase II inhibitor includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as CAELYXTM), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
- Etoposide is marketed under the trade name ETOPOPHOSTM.
- Teniposide is marketed under the trade name VM 26-Bristol
- Doxorubicin is marketed under the trade name ACRIBLASTINTM or ADRIAMYCINTM.
- microtubule active agent relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof.
- Paclitaxel is marketed under the trade name TAXOLTM. Docetaxel is marketed under the trade name TAXOTERETM. Vinblastine sulfate is marketed under the trade name VINBLASTIN R.PTM. Vincristine sulfate is marketed under the trade name FARMISTINTM.
- alkylating agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name CYCLOSTINTM. Ifosfamide is marketed under the trade name HOLOXANTM.
- histone deacetylase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- antiproliferative activity includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
- Gemcitabine is marketed under the trade name GEMZARTM.
- the term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin.
- Carboplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark CARBOPLATTM.
- Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATINTM.
- the term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds” as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (I
- PI3K inhibitor includes, but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including, but not limited to PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , PI3K-C2 ⁇ , PI3K-C2 ⁇ , PI3K-C2 ⁇ , PI3K- C2 ⁇ , Vps34, p110- ⁇ , p110- ⁇ , p110- ⁇ , p110- ⁇ , p85- ⁇ , p85- ⁇ , p55- ⁇ , p150, p101, and p87.
- PI3K inhibitors useful in this invention include but are not limited to ATU-027, SF- 1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.
- the PI3K inhibitor is alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation).
- Bcl-2 inhibitor includes, but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and analogs thereof), dual Bcl-2/Bcl-xL inhibitors (Infinity Pharmaceuticals/Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see WO2008118802), navitoclax (and analogs thereof, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see WO2004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ.
- Bcl-2 inhibitor as used herein includes, but is not limited to compounds having inhibitory activity against Bruton’s Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib.
- SYK inhibitor includes, but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.
- SYK spleen tyrosine kinase
- Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2008039218 and WO2011090760, the entirety of which are incorporated herein by reference.
- SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2003063794, WO2005007623, and WO2006078846, the entirety of which are incorporated herein by reference.
- PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554, and WO2007044729 the entirety of which are incorporated herein by reference.
- JAK inhibitory compounds and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246, and WO2007070514, the entirety of which are incorporated herein by reference.
- Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition e.g., thalidomide (THALOMIDTM) and TNP-470.
- TAALOMIDTM thalidomide
- proteasome inhibitors useful for use in combination with compounds of the invention include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.
- Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.
- Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, ⁇ - ⁇ - or ⁇ - tocopherol or ⁇ - ⁇ - or ⁇ -tocotrienol.
- the term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox- 2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREXTM), rofecoxib (VIOXXTM), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
- bisphosphonates includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
- Etridonic acid is marketed under the trade name DIDRONELTM.
- Clodronic acid is marketed under the trade name BONEFOSTM.
- Tiludronic acid is marketed under the trade name SkelidTM.
- Pamidronic acid is marketed under the trade name AREDIATM.
- Alendronic acid is marketed under the trade name FOSAMAXTM.
- Ibandronic acid is marketed under the trade name BONDRANATTM.
- Risedronic acid is marketed under the trade name ACTONELTM.
- Zoledronic acid is marketed under the trade name ZOMETATM.
- mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (RAPAMUNE®), everolimus (CERTICANTM), CCI- 779 and ABT578.
- heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88.
- biological response modifier refers to a lymphokine or interferons.
- inhibitor of Ras oncogenic isoforms such as H-Ras, K-Ras, or N-Ras
- inhibitor of Ras oncogenic isoforms refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a “farnesyl transferase inhibitor” such as L-744832, DK8G557 or R115777 (ZARNESTRATM).
- telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin.
- methionine aminopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase.
- compounds which target, decrease or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or a derivative thereof.
- proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
- Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (VELCADETM) and MLN 341.
- matrix metalloproteinase inhibitor or (“MMP” inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211 , MMI270B or AAJ996.
- MMP matrix metalloproteinase inhibitor
- FMS-like tyrosine kinase inhibitors which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1- ⁇ -D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase.
- FMS-like tyrosine kinase receptors are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
- HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway.
- Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
- antiproliferative antibodies includes, but is not limited to, trastuzumab (HERCEPTINTM), Trastuzumab-DM1, erbitux, bevacizumab (AVASTINTM), rituximab (RITUXAN ® ), PRO64553 (anti-CD40) and 2C4 Antibody.
- antibodies is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
- compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
- compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
- HDAC histone deacetylase
- SAHA suberoylanilide hydroxamic acid
- HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N- hydroxy-3-[4-[(2-hydroxyethyl) ⁇ 2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt.
- Somatostatin receptor antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230.
- Tumor cell damaging approaches refer to approaches such as ionizing radiation.
- ionizing radiation means ionizing radiation that occurs as either electromagnetic rays (such as X- rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art.
- EDG binders and ribonucleotide reductase inhibitors.
- EDG binders refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720.
- ribonucleotide reductase inhibitors refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin.
- Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1 ,3-dione derivatives.
- VEGF vascular endothelial growth factor
- compounds, proteins or monoclonal antibodies of VEGF such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; ANGIOSTATINTM; ENDOSTATINTM; anthranilic acid amides; ZD4190; Zd 6 474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab (AVASTINTM).
- VEGF aptamer such as Macugon
- Photodynamic therapy refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as VISUDYNETM and porfimer sodium.
- Angiostatic steroids as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11- ⁇ -epihydrocotisol, cortexolone, 17 ⁇ -hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.
- Implants containing corticosteroids refers to compounds, such as fluocinolone and dexamethasone.
- Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.
- the structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patents International (e.g., IMS World Publications).
- the second anti-cancer agent is an immuno-oncology agent.
- an immuno-oncology agent refers to an agent which is effective to enhance, stimulate, and/or up-regulate immune responses in a subject.
- the administration of an immuno-oncology agent with a compound of the invention has a synergic effect in treating a cancer.
- An immuno-oncology agent can be, for example, a small molecule drug, an antibody, or a biologic or small molecule.
- biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines.
- an antibody is a monoclonal antibody. In some embodiments, a monoclonal antibody is humanized or human.
- an immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses.
- Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF).
- B7 family includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7- H6.
- TNF family of molecules that bind to cognate TNF receptor family members which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT ⁇ R, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin ⁇ /TNF ⁇ , TNFR2, TNF ⁇ , LT ⁇ R, Lymphotoxin ⁇ 1 ⁇ 2, FA
- an immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF- ⁇ , VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.
- a combination of a compound of the invention and an immuno- oncology agent can stimulate T cell responses.
- an immuno-oncology agent is: (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4; or (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
- T cell activation e.g., immune checkpoint inhibitors
- an antagonist of a protein that inhibits T cell activation e.g., immune
- an immuno-oncology agent is an antagonist of inhibitory receptors on NK cells or an agonist of activating receptors on NK cells.
- an immuno-oncology agent is an antagonist of KIR, such as lirilumab.
- an immuno-oncology agent is an agent that inhibits or depletes macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357).
- CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357).
- an immuno-oncology agent is selected from agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell energy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
- block inhibitory receptor engagement e.g., PD-L1/PD-1 interactions
- Tregs e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex
- an immuno-oncology agent is a CTLA-4 antagonist.
- a CTLA-4 antagonist is an antagonistic CTLA-4 antibody.
- an antagonistic CTLA-4 antibody is YERVOY (ipilimumab) or tremelimumab.
- an immuno-oncology agent is a PD-1 antagonist.
- a PD-1 antagonist is administered by infusion.
- an immuno-oncology agent is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.
- a PD-1 antagonist is an antagonistic PD-1 antibody.
- an antagonistic PD-1 antibody is OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI- 0680 (AMP-514; WO2012/145493).
- an immuno-oncology agent may be pidilizumab (CT-011).
- an immuno-oncology agent is a recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224.
- an immuno-oncology agent is a PD-L1 antagonist.
- a PD-L1 antagonist is an antagonistic PD-L1 antibody.
- a PD-L1 antibody is MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS- 936559 (WO2007/005874), and MSB0010718C (WO2013/79174).
- an immuno-oncology agent is a LAG-3 antagonist.
- a LAG-3 antagonist is an antagonistic LAG-3 antibody.
- a LAG3 antibody is BMS-986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO009/44273).
- an immuno-oncology agent is a CD137 (4-1BB) agonist.
- a CD137 (4-1BB) agonist is an agonistic CD137 antibody.
- a CD137 antibody is urelumab or PF-05082566 (WO12/32433).
- an immuno-oncology agent is a GITR agonist.
- a GITR agonist is an agonistic GITR antibody.
- a GITR antibody is BMS-986153, BMS-986156, TRX-518 (WO006/105021, WO009/009116), or MK- 4166 (WO11/028683).
- an immuno-oncology agent is an indoleamine (2,3)- dioxygenase (IDO) antagonist.
- IDO antagonist is selected from epacadostat (INCB024360, Incyte); indoximod (NLG-8189, NewLink Genetics Corporation); capmanitib (INC280, Novartis); GDC-0919 (Genentech/Roche); PF-06840003 (Pfizer); BMS:F001287 (Bristol Myers Squibb); Phy906/KD108 (Phytoceutica); an enzyme that breaks down kynurenine (Kynase, Ikena Oncology, formerly known as Kyn Therapeutics); and NLG- 919 (WO09/73620, WO009/1156652, WO11/56652, WO12/142237).
- an immuno-oncology agent is an OX40 agonist.
- an OX40 agonist is an agonistic OX40 antibody.
- an OX40 antibody is MEDI-6383 or MEDI-6469.
- an immuno-oncology agent is an OX40L antagonist.
- an OX40L antagonist is an antagonistic OX40 antibody.
- an OX40L antagonist is RG-7888 (WO06/029879).
- an immuno-oncology agent is a CD40 agonist.
- a CD40 agonist is an agonistic CD40 antibody.
- an immuno-oncology agent is a CD40 antagonist. In some embodiments, a CD40 antagonist is an antagonistic CD40 antibody. In some embodiments, a CD40 antibody is lucatumumab or dacetuzumab. [0601] In some embodiments, an immuno-oncology agent is a CD27 agonist. In some embodiments, a CD27 agonist is an agonistic CD27 antibody. In some embodiments, a CD27 antibody is varlilumab. [0602] In some embodiments, an immuno-oncology agent is MGA271 (to B7H3) (WO11/109400).
- an immuno-oncology agent is abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolimab, avelumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab,
- an immuno-oncology agent is an immunostimulatory agent.
- antibodies blocking the PD-1 and PD-L1 inhibitory axis can unleash activated tumor-reactive T cells and have been shown in clinical trials to induce durable anti-tumor responses in increasing numbers of tumor histologies, including some tumor types that conventionally have not been considered immunotherapy sensitive. See, e.g., Okazaki, T. et al. (2013) Nat. Immunol. 14, 1212–1218; Zou et al. (2016) Sci. Transl. Med. 8.
- the anti-PD-1 antibody nivolumab (OPDIVO ® , Bristol Myers Squibb, also known as ONO-4538, MDX1106 and BMS-936558), has shown potential to improve the overall survival in patients with RCC who had experienced disease progression during or after prior anti-angiogenic therapy.
- the immunomodulatory therapeutic specifically induces apoptosis of tumor cells.
- Approved immunomodulatory therapeutics which may be used in the present invention include pomalidomide (POMALYST®, Celgene); lenalidomide (REVLIMID®, Celgene); ingenol mebutate (PICATO®, LEO Pharma).
- an immuno-oncology agent is a cancer vaccine.
- the cancer vaccine is selected from sipuleucel-T (PROVENGE®, Dendreon/Valeant Pharmaceuticals), which has been approved for treatment of asymptomatic, or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer; and talimogene laherparepvec (IMLYGIC®, BioVex/Amgen, previously known as T-VEC), a genetically modified oncolytic viral therapy approved for treatment of unresectable cutaneous, subcutaneous and nodal lesions in melanoma.
- sipuleucel-T PROVENGE®, Dendreon/Valeant Pharmaceuticals
- IMLYGIC® BioVex/Amgen, previously known as T-VEC
- an immuno-oncology agent is selected from an oncolytic viral therapy such as pexastimogene devacirepvec (PexaVec/JX-594, SillaJen/formerly Jennerex Biotherapeutics), a thymidine kinase- (TK-) deficient vaccinia virus engineered to express GM-CSF, for hepatocellular carcinoma (NCT02562755) and melanoma (NCT00429312); pelareorep (REOLYSIN®, Oncolytics Biotech), a variant of respiratory enteric orphan virus (reovirus) which does not replicate in cells that are not RAS-activated, in numerous cancers, including colorectal cancer (NCT01622543); prostate cancer (NCT01619813); head and neck squamous cell cancer (NCT01166542); pancreatic adenocarcinoma (NCT00998322); and non-small cell lung cancer (NSCLC) (
- an immuno-oncology agent is selected from JX-929 (SillaJen/formerly Jennerex Biotherapeutics), a TK- and vaccinia growth factor-deficient vaccinia virus engineered to express cytosine deaminase, which is able to convert the prodrug 5- fluorocytosine to the cytotoxic drug 5-fluorouracil; TG01 and TG02 (Targovax/formerly Oncos), peptide-based immunotherapy agents targeted for difficult-to-treat RAS mutations; and TILT- 123 (TILT Biotherapeutics), an engineered adenovirus designated: Ad5/3-E2F-delta24-hTNF ⁇ - IRES-hIL20; and VSV-GP (ViraTherapeutics) a vesicular stomatitis virus (VSV) engineered to express the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), which can be
- an immuno-oncology agent is a T-cell engineered to express a chimeric antigen receptor, or CAR.
- the T-cells engineered to express such chimeric antigen receptor are referred to as a CAR-T cells.
- CARs have been constructed that consist of binding domains, which may be derived from natural ligands, single chain variable fragments (scFv) derived from monoclonal antibodies specific for cell-surface antigens, fused to endodomains that are the functional end of the T-cell receptor (TCR), such as the CD3-zeta signaling domain from TCRs, which is capable of generating an activation signal in T lymphocytes.
- binding domains which may be derived from natural ligands, single chain variable fragments (scFv) derived from monoclonal antibodies specific for cell-surface antigens, fused to endodomains that are the functional end of the T-cell receptor (TCR), such as the CD3-zeta signaling domain from TCRs
- the CAR-T cell is one of those described in U.S. Patent 8,906,682 (June et al.; hereby incorporated by reference in its entirety), which discloses CAR-T cells engineered to comprise an extracellular domain having an antigen binding domain (such as a domain that binds to CD19), fused to an intracellular signaling domain of the T cell antigen receptor complex zeta chain (such as CD3 zeta).
- an antigen binding domain such as a domain that binds to CD19
- CD3 zeta intracellular signaling domain of the T cell antigen receptor complex
- an immunostimulatory agent is an activator of retinoic acid receptor-related orphan receptor ⁇ (ROR ⁇ t).
- ROR ⁇ t is a transcription factor with key roles in the differentiation and maintenance of Type 17 effector subsets of CD4+ (Th17) and CD8+ (Tc17) T cells, as well as the differentiation of IL-17 expressing innate immune cell subpopulations such as NK cells.
- an activator of ROR ⁇ t is LYC-55716 (Lycera), which is currently being evaluated in clinical trials for the treatment of solid tumors (NCT02929862).
- an immunostimulatory agent is an agonist or activator of a toll- like receptor (TLR).
- TLR toll- like receptor
- Suitable activators of TLRs include an agonist or activator of TLR9 such as SD-101 (Dynavax).
- SD-101 is an immunostimulatory CpG which is being studied for B-cell, follicular and other lymphomas (NCT02254772).
- Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCT02124850) and ovarian cancer (NCT02431559).
- immuno-oncology agents that can be used in the present invention include urelumab (BMS-663513, Bristol Myers Squibb), an anti-CD137 monoclonal antibody; varlilumab (CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS- 986178 (Bristol Myers Squibb), an anti-OX40 monoclonal antibody; lirilumab (IPH2102/BMS- 986015, Innate Pharma, Bristol Myers Squibb), an anti-KIR monoclonal antibody; monalizumab (IPH2201, Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab (GS-5745, Gilead Sciences), an anti-MMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR monoclonal antibody.
- BMS-663513 Bristol Myers Squibb
- an immunostimulatory agent is selected from elotuzumab, mifamurtide, an agonist or activator of a toll-like receptor, and an activator of ROR ⁇ t.
- an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-15). rhIL-15 has been tested in the clinic as a therapy for melanoma and renal cell carcinoma (NCT01021059 and NCT01369888) and leukemias (NCT02689453).
- an immunostimulatory agent is recombinant human interleukin 12 (rhIL-12).
- an IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-15, Novartis/Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL15:sIL-15RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck squamous cell carcinoma (NCT02452268).
- a recombinant human interleukin 12 (rhIL-12) is NM-IL-12 (Neumedicines, Inc.), NCT02544724, or NCT02542124.
- an immuno-oncology agent is selected from those described in Jerry L. Adams et al., “Big opportunities for small molecules in immuno-oncology,” Cancer Therapy 2015, Vol.14, pages 603-622, the content of which is incorporated herein by reference in its entirety.
- an immuno-oncology agent is selected from the examples described in Table 1 of Jerry L. Adams et al.
- an immuno-oncology agent is a small molecule targeting an immuno-oncology target selected from those listed in Table 2 of Jerry L. Adams et al.
- an immuno-oncology agent is a small molecule agent selected from those listed in Table 2 of Jerry L. Adams et al.
- an immuno-oncology agent is selected from the small molecule immuno-oncology agents described in Peter L. Toogood, “Small molecule immuno-oncology therapeutic agents,” Bioorganic & Medicinal Chemistry Letters 2018, Vol. 28, pages 319-329, the content of which is incorporated herein by reference in its entirety.
- an immuno-oncology agent is an agent targeting the pathways as described in Peter L. Toogood.
- an immuno-oncology agent is selected from those described in Sandra L.
- an immuno-oncology agent is a bispecific T cell engager (BITE®) antibody construct.
- a bispecific T cell engager (BITE®) antibody construct is a CD19/CD3 bispecific antibody construct.
- a bispecific T cell engager (BITE®) antibody construct is an EGFR/CD3 bispecific antibody construct.
- a bispecific T cell engager (BITE®) antibody construct activates T cells.
- a bispecific T cell engager (BITE®) antibody construct activates T cells, which release cytokines inducing upregulation of intercellular adhesion molecule 1 (ICAM-1) and FAS on bystander cells.
- a bispecific T cell engager (BITE®) antibody construct activates T cells which result in induced bystander cell lysis.
- the bystander cells are in solid tumors.
- the bystander cells being lysed are in proximity to the BITE®-activated T cells.
- the bystander cells comprises tumor-associated antigen (TAA) negative cancer cells.
- the bystander cells comprise EGFR-negative cancer cells.
- an immuno-oncology agent is an antibody which blocks the PD-L1/PD1 axis and/or CTLA4.
- an immuno-oncology agent is an ex vivo expanded tumor-infiltrating T cell.
- an immuno-oncology agent is a bispecific antibody construct or chimeric antigen receptors (CARs) that directly connect T cells with tumor-associated surface antigens (TAAs).
- TAAs tumor-associated surface antigens
- Exemplary Immune Checkpoint Inhibitors [0619]
- an immuno-oncology agent is an immune checkpoint inhibitor as described herein. [0620]
- the terms “immune checkpoint inhibitor” and “checkpoint inhibitor” as used herein relate to agents useful in preventing cancer cells from avoiding the immune system of the patient.
- T-cell exhaustion results from chronic exposure to antigens that has led to up-regulation of inhibitory receptors.
- inhibitory receptors serve as immune checkpoints in order to prevent uncontrolled immune reactions.
- PD-1 and co-inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin domain-3 (Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often referred to as a checkpoint regulators.
- an immune checkpoint inhibitor is an antibody to PD-1.
- PD-1 binds to the programmed cell death 1 receptor (PD-1) to prevent the receptor from binding to the inhibitory ligand PDL-1, thus overriding the ability of tumors to suppress the host anti-tumor immune response.
- the checkpoint inhibitor is a biologic therapeutic or a small molecule.
- the checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
- the checkpoint inhibitor inhibits a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof.
- a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof.
- the checkpoint inhibitor interacts with a ligand of a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof.
- the checkpoint inhibitor is an immunostimulatory agent, a T cell growth factor, an interleukin, an antibody, a vaccine or a combination thereof.
- the interleukin is IL-7 or IL-15.
- the interleukin is glycosylated IL-7.
- the vaccine is a dendritic cell (DC) vaccine.
- DC dendritic cell
- Checkpoint inhibitors include any agent that blocks or inhibits in a statistically significant manner, the inhibitory pathways of the immune system. Such inhibitors can include small molecule inhibitors or can include antibodies, or antigen binding fragments thereof, that bind to and block or inhibit immune checkpoint receptors or antibodies that bind to and block or inhibit immune checkpoint receptor ligands.
- Illustrative checkpoint molecules that can be targeted for blocking or inhibition include, but are not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is expressed on all NK, ⁇ , and memory CD8 + ( ⁇ ) T cells), CD160 (also referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases, A2aR, and various B-7 family ligands.
- CTLA-4 CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is expressed on all NK, ⁇ , and memory CD8 + ( ⁇ ) T cells
- CD160 also referred to as BY55
- B7 family ligands include, but are not limited to, B7- 1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7.
- Checkpoint inhibitors include antibodies, or antigen binding fragments thereof, other binding proteins, biologic therapeutics, or small molecules, that bind to and block or inhibit the activity of one or more of CTLA-4, PDL1, PDL2, PD1, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD 160 and CGEN-15049.
- Illustrative immune checkpoint inhibitors include, but are not limited to, Tremelimumab (CTLA- 4 blocking antibody), anti-OX40, PD-L1 monoclonal Antibody (Anti-B7-Hl; MEDI4736), MK- 3475 (PD-1 blocker), Nivolumab (anti-PD1 antibody), CT-011 (anti-PD1 antibody), BY55 monoclonal antibody, AMP224 (anti-PDL1 antibody), BMS- 936559 (anti-PDL1 antibody), MPLDL3280A (anti-PDL1 antibody), MSB0010718C (anti-PDL1 antibody), and ipilimumab (anti-CTLA-4 checkpoint inhibitor).
- CTLA-4 blocking antibody PD-L1 monoclonal Antibody
- Anti-B7-Hl MEDI4736
- MK- 3475 PD-1 blocker
- Nivolumab anti-PD1 antibody
- CT-011 anti-PD1 antibody
- Checkpoint protein ligands include, but are not limited to PD-L1, PD-L2, B7-H3, B7-H4, CD28, CD86 and TIM-3.
- the immune checkpoint inhibitor is selected from a PD-1 antagonist, a PD-L1 antagonist, and a CTLA-4 antagonist.
- the checkpoint inhibitor is selected from the group consisting of nivolumab (OPDIVO®), ipilimumab (YERVOY®), and pembrolizumab (KEYTRUDA®).
- the checkpoint inhibitor is selected from nivolumab (anti-PD-1 antibody, OPDIVO®, Bristol Myers Squibb); pembrolizumab (anti-PD-1 antibody, KEYTRUDA®, Merck); ipilimumab (anti-CTLA- 4 antibody, YERVOY®, Bristol Myers Squibb); durvalumab (anti-PD-L1 antibody, IMFINZI®, AstraZeneca); and atezolizumab (anti-PD-L1 antibody, TECENTRIQ®, Genentech).
- nivolumab anti-PD-1 antibody, OPDIVO®, Bristol Myers Squibb
- pembrolizumab anti-PD-1 antibody, KEYTRUDA®, Merck
- ipilimumab anti-CTLA- 4 antibody, YERVOY®, Bristol Myers Squibb
- durvalumab anti-PD-L1 antibody, IMFINZI®, Astra
- the checkpoint inhibitor is selected from the group consisting of lambrolizumab (MK-3475), nivolumab (BMS-936558), pidilizumab (CT-011), AMP-224, MDX-1105, MEDI4736, MPDL3280A, BMS-936559, ipilimumab, lirlumab, IPH2101, pembrolizumab (KEYTRUDA®), and tremelimumab.
- MK-3475 lambrolizumab
- BMS-936558 nivolumab
- CT-011 pidilizumab
- AMP-224 pidilizumab
- MDX-1105 MEDI4736
- MPDL3280A MPDL3280A
- BMS-936559 ipilimumab
- lirlumab IPH2101, pembrolizumab (KEYTRUDA®)
- tremelimumab tremelimum
- an immune checkpoint inhibitor is REGN2810 (Regeneron), an anti-PD-1 antibody tested in patients with basal cell carcinoma (NCT03132636); NSCLC (NCT03088540); cutaneous squamous cell carcinoma (NCT02760498); lymphoma (NCT02651662); and melanoma (NCT03002376); pidilizumab (CureTech), also known as CT- 011, an antibody that binds to PD-1, in clinical trials for diffuse large B-cell lymphoma and multiple myeloma; avelumab (BAVENCIO®, Pfizer/Merck KGaA), also known as MSB0010718C), a fully human IgG1 anti-PD-L1 antibody, in clinical trials for non-small cell lung cancer, Merkel cell carcinoma, mesothelioma, solid tumors, renal cancer, ovarian cancer, bladder cancer, head and neck cancer, and gastric cancer; or PDR
- Tremelimumab (CP-675,206; Astrazeneca) is a fully human monoclonal antibody against CTLA-4 that has been in studied in clinical trials for a number of indications, including: mesothelioma, colorectal cancer, kidney cancer, breast cancer, lung cancer and non-small cell lung cancer, pancreatic ductal adenocarcinoma, pancreatic cancer, germ cell cancer, squamous cell cancer of the head and neck, hepatocellular carcinoma, prostate cancer, endometrial cancer, metastatic cancer in the liver, liver cancer, large B-cell lymphoma, ovarian cancer, cervical cancer, metastatic anaplastic thyroid cancer, urothelial cancer, fallopian tube cancer, multiple myeloma, bladder cancer, soft tissue sarcoma, and melanoma.
- AGEN-1884 (Agenus) is an anti-CTLA4 antibody that is being studied in Phase 1 clinical trials for advanced solid tumors (NCT02694822).
- a checkpoint inhibitor is an inhibitor of T-cell immunoglobulin mucin containing protein-3 (TIM-3).
- TIM-3 inhibitors that may be used in the present invention include TSR-022, LY3321367 and MBG453.
- TSR-022 (Tesaro) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT02817633).
- LY3321367 (Eli Lilly) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT03099109).
- a checkpoint inhibitor is an inhibitor of T cell immunoreceptor with Ig and ITIM domains, or TIGIT, an immune receptor on certain T cells and NK cells.
- TIGIT inhibitors that may be used in the present invention include BMS-986207 (Bristol Myers Squibb), an anti-TIGIT monoclonal antibody (NCT02913313); OMP-313M32 (Oncomed); and anti-TIGIT monoclonal antibody (NCT03119428).
- a checkpoint inhibitor is an inhibitor of Lymphocyte Activation Gene-3 (LAG-3).
- LAG-3 inhibitors that may be used in the present invention include BMS- 986016 and REGN3767 and IMP321.
- BMS-986016 (Bristol Myers Squibb), an anti-LAG-3 antibody, is being studied in glioblastoma and gliosarcoma (NCT02658981).
- REGN3767 (Regeneron), is also an anti-LAG-3 antibody, and is being studied in malignancies (NCT03005782).
- IMP321 is an LAG-3-Ig fusion protein, being studied in melanoma (NCT02676869); adenocarcinoma (NCT02614833); and metastatic breast cancer (NCT00349934).
- Checkpoint inhibitors that can be used in the present invention include OX40 agonists.
- OX40 agonists that are being studied in clinical trials include PF-04518600/PF-8600 (Pfizer), an agonistic anti-OX40 antibody, in metastatic kidney cancer (NCT03092856) and advanced cancers and neoplasms (NCT02554812; NCT05082566); GSK3174998 (Merck), an agonistic anti-OX40 antibody, in Phase 1 cancer trials (NCT02528357); MEDI0562 (Medimmune/AstraZeneca), an agonistic anti-OX40 antibody, in advanced solid tumors (NCT02318394 and NCT02705482); MEDI6469, an agonistic anti-OX40 antibody (Medimmune/AstraZeneca), in patients with colorectal cancer (NCT02559024), breast cancer (NCT01862900), head and neck cancer (NCT02274155) and metastatic prostate cancer (NCT01303705); and BMS-986178 (Bristol Myers
- Checkpoint inhibitors that can be used in the present invention include CD137 (also called 4-1BB) agonists.
- CD137 agonists that are being studied in clinical trials include utomilumab (PF-05082566, Pfizer) an agonistic anti-CD137 antibody, in diffuse large B-cell lymphoma (NCT02951156) and in advanced cancers and neoplasms (NCT02554812 and NCT05082566); urelumab (BMS-663513, Bristol Myers Squibb), an agonistic anti-CD137 antibody, in melanoma and skin cancer (NCT02652455) and glioblastoma and gliosarcoma (NCT02658981); and CTX-471 (Compass Therapeutics), an agonistic anti-CD137 antibody in metastatic or locally advanced malignancies (NCT03881488).
- Checkpoint inhibitors that can be used in the present invention include CD27 agonists.
- CD27 agonists that are being studied in clinical trials include varlilumab (CDX-1127, Celldex Therapeutics) an agonistic anti-CD27 antibody, in squamous cell head and neck cancer, ovarian carcinoma, colorectal cancer, renal cell cancer, and glioblastoma (NCT02335918); lymphomas (NCT01460134); and glioma and astrocytoma (NCT02924038).
- Checkpoint inhibitors that can be used in the present invention include glucocorticoid- induced tumor necrosis factor receptor (GITR) agonists.
- GITR glucocorticoid- induced tumor necrosis factor receptor
- GITR agonists that are being studied in clinical trials include TRX518 (Leap Therapeutics), an agonistic anti-GITR antibody, in malignant melanoma and other malignant solid tumors (NCT01239134 and NCT02628574); GWN323 (Novartis), an agonistic anti-GITR antibody, in solid tumors and lymphoma (NCT02740270); INCAGN01876 (Incyte/Agenus), an agonistic anti-GITR antibody, in advanced cancers (NCT02697591 and NCT03126110); MK-4166 (Merck), an agonistic anti- GITR antibody, in solid tumors (NCT02132754) and MEDI1873 (Medimmune/AstraZeneca), an agonistic hexameric GITR-ligand molecule with a human IgG1 Fc domain, in advanced solid tumors (NCT02583165).
- TRX518 Leap Therapeutics
- Checkpoint inhibitors that can be used in the present invention include inducible T- cell co-stimulator (ICOS, also known as CD278) agonists.
- ICOS agonists that are being studied in clinical trials include MEDI-570 (Medimmune), an agonistic anti-ICOS antibody, in lymphomas (NCT02520791); GSK3359609 (Merck), an agonistic anti-ICOS antibody, in Phase 1 (NCT02723955); JTX-2011 (Jounce Therapeutics), an agonistic anti-ICOS antibody, in Phase 1 (NCT02904226).
- Checkpoint inhibitors that can be used in the present invention include killer IgG-like receptor (KIR) inhibitors.
- KIR killer IgG-like receptor
- KIR inhibitors that are being studied in clinical trials include lirilumab (IPH2102/BMS-986015, Innate Pharma/Bristol Myers Squibb), an anti-KIR antibody, in leukemias (NCT01687387, NCT02399917, NCT02481297, NCT02599649), multiple myeloma (NCT02252263), and lymphoma (NCT01592370);IPH2101 (1-7F9, Innate Pharma) in myeloma (NCT01222286 and NCT01217203); and IPH4102 (Innate Pharma), an anti-KIR antibody that binds to three domains of the long cytoplasmic tail (KIR3DL2), in lymphoma (NCT02593045).
- Checkpoint inhibitors that can be used in the present invention include CD47 inhibitors of interaction between CD47 and signal regulatory protein alpha (SIRPa).
- CD47/SIRPa inhibitors that are being studied in clinical trials include ALX-148 (Alexo Therapeutics), an antagonistic variant of (SIRPa) that binds to CD47 and prevents CD47/SIRPa- mediated signaling, in phase 1 (NCT03013218); TTI-621 (SIRPa-Fc, Trillium Therapeutics), a soluble recombinant fusion protein created by linking the N-terminal CD47-binding domain of SIRPa with the Fc domain of human IgG1, acts by binding human CD47, and preventing it from delivering its “do not eat” signal to macrophages, is in clinical trials in Phase 1 (NCT02890368 and NCT02663518); CC-90002 (Celgene), an anti-CD47 antibody, in leukemias (NCT02641002); and Hu
- Checkpoint inhibitors that can be used in the present invention include CD73 inhibitors.
- CD73 inhibitors that are being studied in clinical trials include MEDI9447 (Medimmune), an anti-CD73 antibody, in solid tumors (NCT02503774); and BMS-986179 (Bristol Myers Squibb), an anti-CD73 antibody, in solid tumors (NCT02754141).
- Checkpoint inhibitors that can be used in the present invention include agonists of stimulator of interferon genes protein (STING, also known as transmembrane protein 173, or TMEM173).
- STING stimulator of interferon genes protein
- Agonists of STING that are being studied in clinical trials include MK-1454 (Merck), an agonistic synthetic cyclic dinucleotide, in lymphoma (NCT03010176); and ADU- S100 (MIW815, Aduro Biotech/Novartis), an agonistic synthetic cyclic dinucleotide, in Phase 1 (NCT02675439 and NCT03172936).
- Checkpoint inhibitors that can be used in the present invention include CSF1R inhibitors.
- CSF1R inhibitors that are being studied in clinical trials include pexidartinib (PLX3397, Plexxikon), a CSF1R small molecule inhibitor, in colorectal cancer, pancreatic cancer, metastatic and advanced cancers (NCT02777710) and melanoma, non-small cell lung cancer, squamous cell head and neck cancer, gastrointestinal stromal tumor (GIST) and ovarian cancer (NCT02452424); and IMC-CS4 (LY3022855, Lilly), an anti-CSF-1R antibody, in pancreatic cancer (NCT03153410), melanoma (NCT03101254), and solid tumors (NCT02718911); and BLZ945 (4-[2((1R,2R)-2-hydroxycyclohexylamino)-benzothiazol-6- yloxyl]-pyridine-2-carboxylic acid methylamide, Novartis), an orally available inhibitor of CSF1R, in advanced solid
- Checkpoint inhibitors that can be used in the present invention include NKG2A receptor inhibitors.
- NKG2A receptor inhibitors that are being studied in clinical trials include monalizumab (IPH2201, Innate Pharma), an anti-NKG2A antibody, in head and neck neoplasms (NCT02643550) and chronic lymphocytic leukemia (NCT02557516).
- the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab.
- the method further comprises administering to the subject a third anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fourth anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fifth anti-cancer agent.
- the third anti-cancer agent is one of the second anti-cancer agents described above. In certain embodiments, the fourth anti-cancer agent is one of the second anti-cancer agents described above. In certain embodiments, the fifth anti-cancer agent is one of the second anti-cancer agents described above. [0645]
- the doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician.
- the substituted 4- piperidinyl-imidazo[4,5-b]pyridine or related compound described herein e.g., a compound of Formula I, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti-cancer agent, described above
- the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein e.g., a compound of Formula I, or other compounds in Section I
- the additional therapeutic agent(s) e.g.
- the second, third, or fourth, or fifth anti-cancer agent, described above are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder.
- the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein e.g., a compound of Formula I, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti-cancer agent, described above
- the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein e.g., a compound of Formula I, or other compounds in Section I
- the additional therapeutic agent(s) e.g. the second, third, or fourth, or fifth anti- cancer agent, described above
- a synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy.
- a lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.
- kits comprising a therapeutically effective amount of the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.
- a pharmaceutically acceptable carrier e.g., a compound of Formula I, or other compounds in Section I
- optionally at least one additional therapeutic agent listed above e.g., a compound of Formula I, or other compounds in Section I
- Pharmaceutical Compositions and Dosing Considerations [0648] As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
- compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.
- oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula I, I-A, I-B, or I-C) and a pharmaceutically acceptable carrier.
- a therapeutically effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
- a therapeutically effective amount is an amount sufficient for inhibition of ERK5.
- a therapeutically effective amount is an amount sufficient for treating a proliferative disease, such as cancer.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
- a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention.
- an aforementioned formulation renders orally bioavailable a compound of the present invention.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- lozenges using a flavored basis, usually sucrose and acacia or tragacanth
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin;
- the pharmaceutical compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. [0673] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- the compounds of the present invention When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc.
- parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
- the effective amount may be less than when the agent is used alone.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
- the invention further provides a unit dosage form (such as a tablet or capsule) comprising a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein in a therapeutically effective amount for the treatment of a medical disorder described herein.
- the resulting mixture was stirred overnight at 50 °C under nitrogen atmosphere. The reaction was quenched by the addition of water (100 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 mL). The resulting mixture was washed with 50 mL of brine. The combined organic layers were dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
- reaction mixture was stirred at 25 °C for 30 mins. On completion, the reaction mixture was poured into ice water 150 mL and extracted with EA (3 X 60 mL), the organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude product benzyl 2-([2-amino-4-[1-(tert- butoxycarbonyl)piperidin-4-yl]pyridin-3-yl]carbamoyl)morpholine- 4-carboxylate (4.20 g, 85.34%) as a brown gum and used into the next step directly.
- the crude product was purified by Prep-HPLC with the following conditions Column: Sunfire Prep C18 OBD Column, 50*250 mm, 5 ⁇ m 10nm; Mobile Phase A: Water (20 mmol/L NH 4 HCO 3 ), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 20% B to 55% B in 12 min, 55% B; Wave Length: 220nm; RT1(min): 12.
- EXAMPLE 4 Synthesis of 2-(4-[2-cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine- 1-carbonyl)-5-(trifluoromethoxy) aniline (I-4) Part I – Synthesis of tert-butyl 4-[2-cyclopropyl-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate [0707] A mixture of tert-butyl 4-(2,3-diaminopyridin-4-yl) piperidine-1-carboxylate (2.00 g, 6.840 mmol, 1.00 equiv) and cyclopropanecarbaldehyde (0.48g,6.840mmol,1.00equiv) in MeOH under nitrogen atmosphere.
- the resulting mixture was stirred for 4h at 50 degrees C.
- the resulting mixture was extracted with EtOAc (3 x 100mL).
- the combined organic layers were dried over anhydrous Na 2 SO 4 .
- the resulting mixture was washed with 100 mL of brine. After filtration, the filtrate was concentrated under reduced pressure.
- the crude product was purified by Prep-HPLC with the following conditions (Column, YMC-Actus Triart C18, 30 mm X 150 mm, 5um; mobile phase, Water(10 mmol/L NH4HCO3) and ACN (50% PhaseB up to 65% in 6 min); Detector, uv220nm.This resulted in tert-butyl N-[2-(4-[2- cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carbonyl)-5-(trifluoromethoxy) phenyl] carbamate (117 mg, 18.88%) as a light yellow solid.
- reaction mixture was stirred at - 78 °C for 60 mins.
- dibromotetrafluoroethane 118.53 g, 456.192 mmol, 1.05 equiv
- THF 500 mL
- the resulting mixture was then warmed to room temprature over 2 h.
- the reaction was quenched with sat. NH 4 Cl (500 mL), and extracted with ether (2 x 200 mL).
- reaction mixture was filtered through a Celite pad and concentrated under reduced pressure to give tert-butyl 4-(2,3-diamino-5-fluoropyridin-4- yl)piperidine-1-carboxylate (2.20 g, 79.94%) as a brown solid.
- the rection mixture was stirred at 100 °C for 3 hours. On completion, the reaction mixture was added ice water (50 mL) and extracted with EA (3 x 30 mL). The combined organic layers were washed with bine (50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure.
- EXAMPLE 8 Synthesis of 7-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)- 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (II-3) Part I – Synthesis of tert-Butyl 4- ⁇ 2-oxo-1H,3H-imidazo[4,5-b]pyridin-7-yl ⁇ piperidine-1- carboxylate [0725] A solution of tert-butyl 4-(2,3-diaminopyridin-4-yl)piperidine-1-carboxylate (0.8 g, 2.736 mmol, 1.00 equiv) and CDI (0.89 g, 5.472 mmol, 2 equiv) in dimethylformamide (8 mL, 109.447 mmol, 40.00 equiv) was stirred for 16 h at rt under nitrogen atmosphere.
- the crude product was purified by Prep- HPLC with the following conditions (Column: XBridge Shield RP18 OBD Column, 19*150 mm, 5 ⁇ m; Mobile Phase A: Water (0.05%NH 3 H 2 O), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 58% B in 8 min); Detector, UV220nm). This resulted in 7- (piperidin-4-yl)-1H,3H-imidazo[4,5-b]pyridin-2-one (400 mg) as a white solid.
- EXAMPLE 10 Synthesis of 4-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)- 5-fluoro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (III-1) Part I – Synthesis of 4-chloro-1-(triisopropylsilyl) pyrrolo[2,3-b] pyridine [0729] To a stirred solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine (450.0 g, 2949.0 mmol, 1.0 equiv) in THF (4,500 mL) was added NaH (106.2 g, 4424.0 mmol, 1.5 equiv) in portions at 0 °C under nitrogen atmosphere.
- the reaction was monitored by LCMS.
- the resulting mixture was filtered, the filter cake was washed with EA (3x3 ml).
- the filtrate was concentrated under reduced pressure.
- the resulting mixture was diluted with water (5 ml) and extracted with EA (3x3 ml).
- the combined organic layers were washed with con.NaCl, dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure to used directly.
- EXAMPLE 11 Synthesis of Additional 4-Piperidinyl-1,3-dihydro-2H-pyrrolo[2,3- b]pyridin-2-ones and Related Compounds [0737] The compounds listed in Table 9 below were prepared using experimental procedures described in the Examples and Detailed Description. Table 9 also lists each compound’s 1 H NMR characterization data and mass-to-charge ratio observed by LC/MS. Chemical structures are presented in Table 3 above. TABLE 9.
- EXAMPLE 12 – Biological Assay for Inhibiting Isolated ERK5 [0738] Exemplary compounds were tested for ability to inhibit isolated ERK5 using the LANCE® Ultra time-resolved FRET assay. Assay procedures and results are described below.
- Recombinant human Erk5 catalytic domain (1-398 amino acids of accession number NP_002740.2) was purchased from Carna Biosciences (Product number 04-146, Lot 13CBS- 0805 C). The protein was expressed as an N-terminal GST-fusion protein (73 kDa) in E.coli.
- GST-Erk5 was purified using glutathione Sepharose chromatography and activated using His- tagged MAP2K5. The activated GST-Erk5 was then purified using Ni-NTA chromatography resulting in 53% purity.
- the protein was stored at 515 ⁇ g/mL (7.05 ⁇ M) in storage buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% v/v glycerol, pH 7.5), at -80°C.
- the substrate for the kinase was LANCE® Ultra Europium-anti-phospho-eIF4E- binding protein 1 (Thr37/46) peptide (Perkin Elmer TRF0216-D).
- the sequence motif for the peptide was ST(pT)PGGTLFST(pT)PG, with (pT) denoting the two potential phospo-theronines.
- Test compounds were prepared as 30 mM stock solutions in DMSO, stored under dry nitrogen gas. Solutions were plated into Echo® Qualified 384-well low dead volume microplates (Labcyte LP-0200). Compounds were then dosed into white, low-volume 384-well assay plates (Greiner Bio-One Ltd 784075) using the Labcyte Echo® 650 acoustic dosing platform.
- Test compounds were dosed in a 12-point, 2-fold dilution series at 100 ⁇ M top concentration then backfilled to 1% v/v DMSO. The top concentration was adjusted based on expected compound potency.
- a tool compound (BAY-885) was included in each assay plate as a standard. High controls (1% v/v DMSO) were included in rows A and O, with low controls (10 ⁇ M BAY-885) in rows B and P. Two identical sets of assay plates were prepared and tested in two independent experiments.
- the reaction was initiated by adding 3 ⁇ L of 2-fold concentrated kinase buffer (15 nM Erk5, 10 mM MgCl 2 , 1 mM EGTA, 50 mM HEPES, 1 mM DTT, 0.01% v/v Tween 20, pH 7.5), using an electronic multichannel pipette and mixing the assay volume three times.
- the final reaction composition was 7.5 nM Erk5, 50 nM ULight-eIF4E-binding protein 1 (Thr37/46) peptide, 150 ⁇ M ATP, 10 mM MgCl 2 , 1 mM EGTA, 50 mM HEPES, 1 mM DTT, 0.01% v/v Tween 20, pH 7.5.
- the level of resonance energy transfer was detected using an Envision Xcite plate reader (Perkin Elmer), with excitation at 350 nm and emission at 620 nm and 665 nm. The ratio of signal at 665 nm and 620 nm was taken as the level of phosphorylated substrate.
- the data was normalised to % inhibition by setting 0% as the signal from the high control and 100% as that from the low control. Values were plotted, and IC 50 values were calculated using Dotmatics Studies (Dotmatics Knowledge Solutions). Part II – Results [0745] Experimental results are provided in Table 10 and 10-A, below. The symbol “++++” indicates an IC 50 less than or equal to 0.05 ⁇ M.
- the polyclonal SN12C-MEF2-luc cell line was generated by stably transducing SN12C cells with aMEF2-responsive transcription element upstream of a firefly luciferase gene and a cytomegalovirus (CMV) promoter element upstream of a renilla luciferase gene. Generation of this cell line was carried out at Sygnature Discovery.
- CMV cytomegalovirus
- This cell line was grown in RPMI 1640 media (Gibco #11530406) without phenol red supplemented with 10 % FBS, 1 % L- glutamine, 1 % penicillin/streptomycin, 250 ⁇ g/mL Hygromycin B gold and 1.25 ⁇ g/mL puromycin. Cells were grown at 37 °C in a humidified environment with 5 % CO 2 . [0748] On day 1 cells were seeded in 384-well black-walled plates (Greiner 781091) at a density of 10,000 cells per well in 20 ⁇ L of culture media.
- Luminescence signal was then read on an EnVision Xcite multimode plate reader (Perkin-Elmer). [0749] The firefly signal was then normalised to the renilla signal, and IC 50 values were calculated using Dotmatics Studies (Dotmatics Knowledge Solutions) or GraphPad Prism. Values for cells treated only with DMSO were defined as the minimum control. Values for cells treated only with trametinib (125 nM) were defined as the maximum control. Part II – Results [0750] Experimental results are provided in Table 11 and 11-A, below. The symbol “***” indicates an IC 50 less than or equal to 0.05 ⁇ M. The symbol “**” indicates an IC 50 in the range of 0.5 ⁇ M to greater than 0.05 ⁇ M.
- EXAMPLE 14 Biological Assay for Inhibiting 3D Cancer Cell Cultures with Combination Therapy
- An exemplary compound from the prior published literature having ERK5 inhibitory activity was tested for ability to inhibit 3D cancer cell cultures of pancreatic cancer and lung cancer as part of a combination therapy with a MEK1/2 inhibitor. Assay procedures and results are described below. Part I – Procedures for 3D Cancer Cell Culture Assay [0752] Assays were conducted using KRAS mutant (NCI-H2122 and A549) and KRAS wild- type (NCI-H520) human lung cancer cell lines according to the procedures described in Haagensen, E. J., et al.
- EXAMPLE 15 Biological Assay for Inhibiting Mouse Xenograft Tumor Growth
- An exemplary compound from the prior published literature having ERK5 inhibitory activity was tested, alone or in combination with trametinib, for ability to inhibit tumor growth in patient-derived mouse xenograft models of pancreatic cancer and lung cancer. Assay procedures and results are described below. Part I – Procedures for Patient-Derived Mouse Xenograft (PDX) Tumor Growth Assay
- Balb/c mice (6-8 weeks old) were inoculated subcutaneously in the right flank with a primary human tumor xenograft model tumor fragment (2-3 mm 3 in diameter) for tumor development.
- mice were inoculated with a human lung adenocarcinoma tumor model (MSCLC, ADC model LU6424) that harbors a BRAF mutation (LU6424); in a second study, mice were inoculated with a human pancreatic tumor model (adenosquamous carcinoma model PA6258) with a KRAS G12D mutation (PA6258).
- MSCLC human lung adenocarcinoma tumor model
- PA6258 human pancreatic tumor model
- PA6258 KRAS G12D mutation
- mice were randomly allocated to four treatment groups of 3 mice each. Mice were treated with one of the following: 1. Vehicle control, 2. Exemplary ERK5 inhibitor alone (60 mg/kg, dosed daily by intraperitoneal injection), 3. Trametinib alone (0.3 mg/kg, dosed daily orally), or 4.
- ERK5 inhibitor 60 mg/kg, dosed daily by intraperitoneal injection, and 0.3 mg/kg, dosed daily orally, respectively.
- Tumors were measured twice per week using calipers.
- the exemplary ERK5 inhibitor used in this experiment is a potent and selective tool compound from the prior published literature having an IC 50 in vitro of approximately 35 nM in each of the assays described in Examples 12 and 13, and with high selectivity for ERK5, but with a short half-life and short PD effect.
- Plasma samples were withdrawn at 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24 hours following IV dosing, and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24 hours following PO dosing.
- Blood samples were centrifuged at 4,000 g for 5 minutes at 4 °C to obtain plasma samples.
- Plasma samples were diluted with acetonitrile containing internal standard, vortexed for 30 seconds, then centrifuged at 4,000 rpm for 15 minutes at 4 °C. The supernatant was diluted with water, and compound concentration was determined by HPLC/MS/MS compared to calibration standards of 0.5-1,000 ng/mL. Part II – Results [0761] Experimental results are provided in Table 12, below. Where route is listed as “IV*”, the compound was dosed IV at 1 mg/kg. TABLE 12.
- Exemplary compounds are tested to determine their ability to inhibit cancer cell growth in combination with selected standard-of-care agents in cancer cell lines by CellTiter Glo Luminescent Cell Viability Assay. Assay procedures are described below. Part I – Procedures for Combination Therapy Assay for Inhibiting Cancer Cells [0763] Combinations to be examined with selected cell lines are listed in Table 13. Plates are prepared in matrix fashion, with one axis having a blank row and 8 serial dilutions (3-fold) of a second anti-cancer agent, and the other axis having a blank row and 6 serial dilutions (3-fold) of an exemplary ERK5 inhibitor compound.
- DMSO concentration in the cell cultures is 0.2%.
- Top concentration for most second anti-cancer agents is 3 ⁇ M.
- Top concentration for trametinib and cobimetinib is 1 ⁇ M.
- Top concentration for a TEAD inhibitor, MRTX1133, and a MEK-RAF inhibitor is 10 ⁇ M.
- Top concentration for an exemplary ERK5 inhibitor is 3 ⁇ M or 10 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides substituted 4-pipcridinyl-imidazo[4,5-b]pyridincs and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
Description
Attorney Docket No.396661-027WO (186993) SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of and priority to United States Provisional Patent Application serial number 63/156,281, filed March 3, 2021, the contents of which are hereby incorporated by reference in their entirety. FIELD OF THE INVENTION [0002] The invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer. BACKGROUND [0003] Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Solid tumors, including breast cancer, lung cancer, and pancreatic cancer remain prevalent among the world population. Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects. New therapies are needed to address this unmet need in cancer therapy. [0004] Extracellular-signal-regulated kinase 5 (ERK5), also known as mitogen-activated protein kinase 7 (MAPK7) and Big MAPK1 (BMK1), has been reported to impact cell survival, proliferation, migration, and differentiation. The mechanism of ERK5’s effects are believed to include translocation to the nucleus and enhancing gene transcription, by phosphorylating transcription factors and/or interacting with transcription factors through the transactivation domain. Evidence suggests that ERK5 may be involved in the onset and progression of multiple cancers, and that inhibition of ERK5 activity may provide a therapeutic benefit for cancer. Use of certain ERK5 inhibitor compounds for treating cancer has been described in, for example, international patent application WO 2019/170543, the contents of which are herein incorporated by reference in its entirety.
[0005] New compounds having inhibitory activity toward ERK5 are therefore needed as therapeutic agents for the treatment of medical disorders, such as cancer. The present invention addresses the foregoing needs and provides other related advantages. SUMMARY [0006] The invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer. In particular, one aspect of the invention provides a collection of substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, such as a compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. Further description of additional collections of substituted 4-piperidinyl- imidazo[4,5-b]pyridines and related compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier. [0007] Another aspect of the invention provides a method of treating a disorder mediated by ERK5 in a subject. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to a subject in need thereof to treat the disorder, as further described in the detailed description. [0008] Another aspect of the invention provides a method of inhibiting ERK5 activity. The method comprises contacting ERK5 with an effective amount of a compound described herein,
such as a compound of Formula I, to inhibit ERK5 activity, as further described in the detailed description. BRIEF DESCRIPTION OF THE DRAWINGS [0009] Figure 1 depicts results of the 3D cancer cell culture assay described in Example 14. [0010] Figure 2 depicts results of the mouse xenograft tumor growth assay with a pancreatic cancer cell line, as described in Example 15. [0011] Figure 3 depicts results of the mouse xenograft tumor growth assay with a lung cancer cell line, as described in Example 15. DETAILED DESCRIPTION [0012] The invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D.M. Weir & C.C. Blackwell, eds.); “Current protocols in molecular biology” (F.M. Ausubel et al., eds., 1987, and periodic updates); and “Current protocols in immunology” (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety. [0013] Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls. Definitions [0014] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. These definitions apply regardless
of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “- O-alkyl” etc. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference. [0015] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. [0016] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as ortho-fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N- oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus
(including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:
[0017] Exemplary bridged bicyclics include:
[0018] The term “lower alkyl” refers to a C1-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl. [0019] The term “lower haloalkyl” refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms. [0020] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)). [0021] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation. [0022] As used herein, the term “bivalent C1-8 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein. [0023] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., –(CH2)n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. [0024] The term “-(C0 alkylene)-“ refers to a bond. Accordingly, the term “-(C0-3 alkylene)-” encompasses a bond (i.e.,C0) and a -( C1-3 alkylene)- group. [0025] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more
hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. [0026] The term “halogen” means F, Cl, Br, or I. [0027] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl group when it has two groups attached to it (e.g., ); “p
y trivalent phenyl group when it has three groups attached to it (e.g., ). The
“arylene” refers to a bivalent aryl group. [0028] The terms “heteroaryl” and “heteroar–,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar–”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting
examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono– or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. [0029] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it. The term “pyridinylene” refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it. For example, “pyridinylene” is a bivalent pyridine radical when it has two groups attached to it (e.g., );
py y trivalent pyridine radical when it has three groups attached to it (e.g., ).
[0030] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5– to 7–membered monocyclic or 7–10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0–3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4– dihydro–2H–pyrrolyl), NH (as in pyrrolidinyl), or +NR (as in N–substituted pyrrolidinyl). [0031] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by an oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.
[0032] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0033] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0034] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; –(CH2)0–4R°; –(CH2)0–4OR°; -O(CH2)0–4Ro, –O–(CH2)0– 4C(O)OR°; –(CH2)0–4CH(OR°)2; –(CH2)0–4SR°; –(CH2)0–4Ph, which may be substituted with R°; –(CH2)0–4O(CH2)0-1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0-1-pyridyl which may be substituted with R°; –NO2; –CN; – N3; -(CH2)0–4N(R°)2; –(CH2)0–4N(R°)C(O)R°; –N(R°)C(S)R°; –(CH2)0–4N(R°)C(O)NR°2; -N(R°)C(S)NR°2; –(CH2)0–4N(R°)C(O)OR°; –N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; –(CH2)0–4C(O)R°; –C(S)R°; –(CH2)0–4C(O)OR°; –(CH2)0–4C(O)SR°; -(CH2)0–4C(O)OSiR°3; –(CH2)0–4OC(O)R°; –OC(O)(CH2)0–4SR–, SC(S)SR°; –(CH2)0–4SC(O)R°; –(CH2)0–4C(O)NR°2; –C(S)NR°2; –C(S)SR°; –SC(S)SR°, -(CH2)0–4OC(O)NR°2; -C(O)N(OR°)R°; –C(O)C(O)R°; –C(O)CH2C(O)R°; –C(NOR°)R°; -(CH2)0–4SSR°; –(CH2)0– 4S(O)2R°; –(CH2)0–4S(O)2OR°; –(CH2)0–4OS(O)2R°; –S(O)2NR°2; –S(O)(NR°)R°; – S(O)2N=C(NR°2)2; -(CH2)0–4S(O)R°; -N(R°)S(O)2NR°2; –N(R°)S(O)2R°; –N(OR°)R°; – C(NH)NR°2; –P(O)2R°; -P(O)R°2; -OP(O)R°2; –OP(O)(OR°)2; SiR°3; –(C1-4 straight or branched alkylene)O–N(R°)2; or –(C1-4 straight or branched alkylene)C(O)O–N(R°)2. [0035] Each R° is independently hydrogen, C1-6 aliphatic, –CH2Ph, –O(CH2)0-1Ph, -CH2-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =O and =S; or each R° is optionally substituted with a monovalent substituent independently selected from halogen, –(CH2)0–2R ●, –(haloR ●), –(CH2)0–2OH, –(CH2)0–2OR ●, – (CH2)0–2CH(OR ●)2; -O(haloR ●), –CN, –N3, –(CH2)0–2C(O)R ●, –(CH2)0–2C(O)OH, –(CH2)0– 2C(O)OR ●, –(CH2)0–2SR ●, –(CH2)0–2SH, –(CH2)0–2NH2, –(CH2)0–2NHR ●, –(CH2)0–2NR ● 2, –NO2, –SiR ●3, –OSiR ● 3, -C(O)SR ●, –(C1-4 straight or branched alkylene)C(O)OR ●, or –SSR ●. [0036] Each R ● is independently selected from C1-4 aliphatic, –CH2Ph, –O(CH2)0-1Ph, or a 5– 6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ● is unsubstituted or where
preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, –O(C(R*2))2–3O–, or – S(C(R*2))2–3S–, or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is –O(CR*2)2–3O–, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0037] When R* is C1-6 aliphatic, R* is optionally substituted with halogen, – R ●, -(haloR ●), -OH, –OR ●, –O(haloR ●), –CN, –C(O)OH, –C(O)OR ●, –NH2, –NHR ●, –NR ●2, or –NO2, wherein each R ● is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ● is unsubstituted or where preceded by halo is substituted only with one or more halogens. [0038] An optional substituent on a substitutable nitrogen is independently –R†, –NR† 2, – C(O)R†, –C(O)OR†, –C(O)C(O)R†, –C(O)CH2C(O)R†, -S(O)2R†, -S(O)2NR†2, –C(S)NR† 2, – C(NH)NR† 2, or –N(R†)S(O)2R†; wherein each R† is independently hydrogen, C1-6 aliphatic, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R† is C1-6 aliphatic, R† is optionally substituted with halogen, –R ●, -(haloR ●), -OH, –OR ●, – O(haloR ●), –CN, –C(O)OH, –C(O)OR ●, –NH2, –NHR ●, –NR ● 2, or –NO2, wherein each R ● is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ● is unsubstituted or where preceded by halo is substituted only with one or more halogens. [0039] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and
are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like. [0040] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference. [0041] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and
amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. [0042] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention. [0043] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically- active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers. [0044] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention
can have the S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent a compound described herein may exist as a atropisomer (e.g., substituted biaryls), all forms of such atropisomer are considered part of this invention. [0045] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences. [0046] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate. [0047] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and C1-C6 alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3- methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1- butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc. [0048] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group. [0049] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.
[0050] The term “hydroxyalkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like. [0051] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively. [0052] The term “carbocyclylene” refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it. [0053] The terms “alkoxyl” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like. The term “hydroxyalkoxyl” refers to an alkoxyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkoxyl groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, and the like. The term “alkoxylene” refers to a bivalent alkoxyl group. [0054] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane susbsituted with an oxo group is cyclopentanone. [0055] The symbol “ ” indicates a point of attachment. [0056] When a chemical structure containing a ring is depicted with a substituent having a bond that crosses a ring bond, the substituent may be attached at any available position on the ring. For example, the chemical structure
, and he context of a polycyclic fused ring, when a chemical structure containing a
polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses
multiple rings, the one or more substituent(s) may be independently attached to any of the rings crossed by the bond. To illustrate, the chemical structure
encompasses, for example,
, , [0057] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated. [0058] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O. [0059] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans. [0060] The term “IC50” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target. The potency of an inhibitor is usually defined by its IC50 value. The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and/or binding constant of less than about 100 µM, less
than about 50 µM, less than about 1 µM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM. [0061] As used herein, the terms “inhibitor” or “ERK5 inhibitor” or “ERK5 antagonist” are defined as a compound that binds to and/or inhibits ERK5 with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner. In some embodiments, the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions. [0062] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibition in ERK5 activity between a sample comprising a compound of the present invention, or composition thereof, and ERK5, and an equivalent sample comprising ERK5, in the absence of said compound, or composition thereof. [0063] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route. [0064] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In some embodiments, treatment can be administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
[0065] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo. [0066] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975]. [0067] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. [0068] In addition, when a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. [0069] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps. [0070] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.
I. Substituted 4-Piperidinyl-imidazo[4,5-b]pyridines and Related Compounds [0071] The invention provides substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds. The compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds. [0072] One aspect of the invention provides a compound represented by Formula I:
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, -(C1-4 alkoxylene)-N(R4)(R5), halo, or -N(R4)(R5); or two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; or two occurrences of R1 attached to adjacent carbon atoms are taken together with said carbon atoms to form a carbon-carbon double bond; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C3-6 cycloalkyl, C1-4 alkyl, C1-4 haloalkyl, or hydrogen; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group
consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo; R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R4 and R5 each represent independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-( C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, cyano, -S-(C1-6 haloalkyl), -S-(C1-6 alkyl), -S(O)2-(C1-6 alkyl), - S(O)2N(R4)(R5), -C(O)N(R4)(R5), -N(R4)C(O)-(C1-6 aliphatic), -N(R4)C(O)-(C1-6 alkoxy), - N(R4)-(C1-6 hydroxyalkoxyl), -N(R4)S(O)2-(C1-6 alkyl), C3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo; X1 is -C(O)-, -S(O)-, or -S(O)2-; X2 is -C(R2B)=N-**, -C(O)-N(R2C)-**, or -C(O)-C(R2C)(R2C)-**; wherein ** indicates the point of attachment to the pyridine ring; A1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered
bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; n is 1 or 2; m and p are each independently 0, 1, 2, or 3; and q is 0, 1, or 2. [0073] The definitions of variables in Formula I above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii). [0074] In certain embodiments, the compound is a compound of Formula I. [0075] In certain embodiments, the compound is a compound of Formula I-A, I-B, or I-C, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound of Formula I-A, I-B, or I-C, or a pharmaceutically acceptable salt thereof; wherein each of the variables in Formula I-A, I-B, and I-C is as defined in the corresponding description of Formula I-A, I-B, and I-C, below, and described in embodiments herein, both singly and in combination. [0076] In certain embodiments, the compound is a compound of Formula I-A, I-B, or I-C. In certain embodiments, the compound is a compound of Formula I-A, I-B, or I-C, wherein each of the variables in Formula I-A, I-B, and I-C is as defined in the corresponding description of Formula I-A, I-B, and I-C, below, and described in embodiments herein, both singly and in combination. [0077] As defined generally above, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, -(C1-4 alkoxylene)-N(R4)(R5), halo, or -N(R4)(R5); or two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1- 3 alkylene group connecting said carbon atoms; or two occurrences of R1 attached to adjacent carbon atoms are taken together with said carbon atoms to form a carbon-carbon double bond.
[0078] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0079] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, -(C1-4 alkoxylene)-N(R4)(R5), halo, or -N(R4)(R5); or two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring. [0080] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); or two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring. In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. [0081] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, -(C1-4 alkoxylene)-N(R4)(R5), halo, or -N(R4)(R5). In certain embodiments, two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring. In certain embodiments, two occurrences of R1 attached to adjacent carbon atoms are taken together with said carbon atoms to form a carbon-carbon double bond. [0082] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, or -(C1-4 alkoxylene)-N(R4)(R5). In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. [0083] In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl.
[0084] In certain embodiments, R1 is hydroxyl. In certain embodiments, R1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R1 is methyl. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R1 is trifluoromethyl. In certain embodiments, R1 represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R1 is -CH2OH. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R1 is methoxy. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R1 is -OCF3. In certain embodiments, R1 represents independently for each occurrence C1-4 hydroxyalkoxyl. In certain embodiments, R1 represents independently for each occurrence -(C1-4 alkoxylene)-N(R4)(R5). In certain embodiments, R1 represents independently for each occurrence halo. In certain embodiments, R1 is fluoro. In certain embodiments, R1 represents independently for each occurrence -N(R4)(R5). [0085] In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R1 is hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R1 is hydroxyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R1 is hydroxyl. In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; and any additional occurrence of R1 is C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. [0086] In certain embodiments, R1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
[0087] As defined generally above, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). [0088] In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R2A represents independently for each occurrence halo or cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0089] In certain embodiments, R2A represents independently for each occurrence halo, cyano, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. [0090] In certain embodiments, R2A represents independently for each occurrence halo. In certain embodiments, R2A is fluoro. In certain embodiments, one instance of R2A is fluoro attached at the position vicinal to the bond to the piperidine ring. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl. In certain embodiments, R2A is methyl. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R2A is trifluoromethyl. In certain embodiments, R2A is cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R2A is -CH2OH. In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R2A is methoxy. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R2A is - OCF3. In certain embodiments, R2A represents independently for each occurrence -N(R4)(R5). In certain embodiments, R2A is -NH2. In certain embodiments, R2A is selected from the groups
depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R2A is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0091] As defined generally above, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C3-6 cycloalkyl, C1-4 alkyl, C1-4 haloalkyl, or hydrogen; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0092] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or C3-6 cycloalkyl; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0093] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently
selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0094] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. [0095] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. [0096] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. [0097] In certain embodiments, R2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -
C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is morpholin-2-yl. In certain embodiments, R2B is morpholin-3-on-6- yl. [0098] In certain embodiments, R2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is 1-methylpiperidin-4-yl. In certain embodiments, R2B is piperidin-3-yl. In certain embodiments, R2B is piperidin-2-on-5-yl. [0099] In certain embodiments, R2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, - N(R4)(R5), and halo. In certain embodiments, R2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, and halo. In certain embodiments, R2B is tetrahydropyran-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, and halo. In certain embodiments, R2B is tetrahydropyran-4-yl.
[0100] In certain embodiments, R2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0101] In certain embodiments, R2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl,C3-5 cycloalkyl, and halo. [0102] In certain embodiments, R2B is C3-6 cycloalkyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5),
and halo. In certain embodiments, R2B is C3-6 cycloalkyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, and halo. In certain embodiments, R2B is C3-6 cycloalkyl. In certain embodiments, R2B is cyclopropyl. [0103] In certain embodiments, R2B is C1-4 alkyl, C1-4 haloalkyl, or hydrogen. In certain embodiments, R2B is C1-4 alkyl or C1-4 haloalkyl. In certain embodiments, R2B is C1-4 alkyl or hydrogen. In certain embodiments, R2B is C1-4 alkyl. In certain embodiments, R2B is methyl. In certain embodiments, R2B is C1-4 haloalkyl. In certain embodiments, R2B is trifluoromethyl. In certain embodiments, R2B is hydrogen. [0104] In certain embodiments, R2B is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R2B is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0105] As defined generally above, R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R2C represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or methyl. [0106] In certain embodiments, R2C is hydrogen. In certain embodiments, R2C represents independently for each occurrence C1-4 alkyl. In certain embodiments, R2C is methyl. In certain embodiments, R2C represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R2C is cyclopropyl. In certain embodiments, R2C is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R2C is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0107] As defined generally above, R3 is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R3 is hydrogen or C1-4 alkyl. In certain embodiments, R3 is C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is C1-4 alkyl. In certain embodiments, R3 is methyl. In certain embodiments, R3 is C3-5 cycloalkyl. In certain embodiments, R3 is cyclopropyl. In certain embodiments, R3 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R3 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
[0108] As defined generally above, R4 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R4 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0109] In certain embodiments, R4 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R4 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R4 is hydrogen. In certain embodiments, R4 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R4 represents independently for each occurrence C3-5 cycloalkyl. [0110] In certain embodiments, R4 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R4 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0111] As defined generally above, R5 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R5 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0112] In certain embodiments, R5 represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R5 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R5 represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R5 is hydrogen. In certain embodiments, R5 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R5 represents independently for each occurrence C3-5 cycloalkyl. [0113] In certain embodiments, R5 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R5 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
[0114] In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0115] In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 and R5 each represent independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R4 and R5 are hydrogen. In certain embodiments, R4 and R5 each represent independently for each occurrence C1-4 alkyl. In certain embodiments, R4 and R5 each represent independently for each occurrence C3-5 cycloalkyl. [0116] In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom. [0117] As defined generally above, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, cyano, -S-(C1-6 haloalkyl), -S- (C1-6 alkyl), -S(O)2-(C1-6 alkyl), -S(O)2N(R4)(R5), -C(O)N(R4)(R5), -N(R4)C(O)-(C1-6 aliphatic), - N(R4)C(O)-(C1-6 alkoxy), -N(R4)-(C1-6 hydroxyalkoxyl), -N(R4)S(O)2-(C1-6 alkyl), C3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo. [0118] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two
occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0119] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S(O)2-(C1-6 alkyl), C3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo. [0120] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0121] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, - O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 alkyl, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -O- (C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl
or -N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence –OCF3, -O-(cyclopropyl), –NH2, –CF3, –F, or –Cl. In certain embodiments, R6 represents independently for each occurrence –OCF3, –NH2, –CF3, fluoro, or chloro. In certain embodiments, R6 represents independently for each occurrence –OCF3 or –NH2. [0122] In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S- (C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)- (C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0-4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5), hydroxyl, halo, or cyano. In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5) or halo. In certain embodiments, one occurrence of R6 is C1-4 haloalkoxyl, C1-4 haloalkyl, -S-(C1-4 haloalkyl), or -O-(C3-4 cycloalkyl), and any further occurrences of R6 are –NH2. [0123] In certain embodiments, one occurrence of R6 is –OCF3, –CF3, –SCF3, or -O- (cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2. [0124] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), or hydroxyl. In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5), halo, or cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl) or -S-(C1-6 alkyl).
[0125] In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 haloalkyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl or C3-6 cycloalkyl. [0126] In certain embodiments, R6 represents independently for each occurrence C3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. [0127] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6 is –OCF3. In certain embodiments, R6 represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6 is methoxy. In certain embodiments, R6 represents independently for each occurrence -O-(C0–4 alkylene)-(C3-6 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C1-4 alkylene)-(C3-4 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C3-4 cycloalkyl). In certain embodiments, R6 is -O-(cyclopropyl). In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5). In certain embodiments, R6 is –NH2. In certain embodiments, R6 is hydroxyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6 is methyl. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6 is trifluoromethyl. In certain embodiments, R6 represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6 represents independently for each occurrence C2-6 alkenyl. In certain embodiments, R6 represents independently for each occurrence C2-6 alkynyl. In certain embodiments, R6 represents independently for each occurrence halo. In certain embodiments, R6 is fluoro or chloro. In certain embodiments, R6 is fluoro. In certain embodiments, R6 is chloro. In certain embodiments, R6 is cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl). In certain embodiments, R6 is -S-CF3. In certain embodiments,
R6 represents independently for each occurrence -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence -S(O)2-(C1-6 alkyl). [0128] In certain embodiments, R6 represents independently for each occurrence - S(O)2N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence - C(O)N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence - N(R4)C(O)-(C1-6 aliphatic). In certain embodiments, R6 represents independently for each occurrence -N(R4)C(O)-(C1-6 alkoxy). In certain embodiments, R6 represents independently for each occurrence -N(R4)-(C1-6 hydroxyalkoxyl). In certain embodiments, R6 represents independently for each occurrence -N(R4)S(O)2-(C1-6 alkyl). [0129] In certain embodiments, R6 represents independently for each occurrence C3-6 cycloalkyl. In certain embodiments, R6 is phenyl. In certain embodiments, R6 represents independently for each occurrence a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R6 represents independently for each occurrence a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. [0130] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo. In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0131] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. In certain embodiments, two occurrences of R6 are taken together with
the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo. [0132] In certain embodiments, R6 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, R6 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0133] As defined generally above, X1 is -C(O)-, -S(O)-, or -S(O)2-. In certain embodiments, X1 is -C(O)-. In certain embodiments, X1 is -S(O)- or -S(O)2-. In certain embodiments, X1 is - S(O)-. In certain embodiments, X1 is -S(O)2-. In certain embodiments, X1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, X1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0134] As defined generally above, X2 is -C(R2B)=N-**, -C(O)-N(R2C)-**, or -C(O)- C(R2C)(R2C)-**; wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is -C(R2B)=N-** or -C(O)-N(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is -C(O)-N(R2C)-** or -C(O)- C(R2C)(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is -C(R2B)=N-**, wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is -C(O)-N(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is -C(O)-C(R2C)(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring. In certain embodiments, X2 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, X2 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0135] As defined generally above, A1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen,
and sulfur; or an 8-10 membered bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0136] In certain embodiments, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0137] In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6.
[0138] In certain embodiments, A1 is phenyl substituted with m occurrences of R6. In certain
[0140] In certain embodiments, A1 is e 1
nts, A is ertain embodiments, A1 is . ts, A1 is
in embodiments, A1 is
[0141] In certain embodiments, A1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is . In ce
embodiments, A1 is
[0142] In certain embodiments, A1 is
[0144] In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R6. In certain embodiments, A1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6.
[0145] In certain embodiments, A1 is naphthyl substituted with m occurrences of R6. In certain embodiments, A1 is an 8-10 membered bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. [0146] In certain embodiments, A1 is selected from the groups depicted in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, A1 is selected from the groups depicted in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0147] As defined generally above, n is 1 or 2. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, n is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0148] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, m is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0149] As defined generally above, p is 0, 1, 2, or 3. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is 2 or 3. In certain embodiments, p is 0, 1, or 2. In certain embodiments, p is 1, 2, or 3. In certain embodiments, p is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, p is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below. [0150] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Tables 1, 2, 3, 4, 5, and 6, below. In certain embodiments, q is selected from the values represented in the compounds in Tables 1, 1-A, 2, 3, 4, 5, and 6, below.
[0151] The description above describes multiple embodiments relating to compounds of Formula I. The patent application specifically contemplates all combinations of the embodiments. [0152] Another aspect of the invention provides a compound represented by Formula I-A:
(I-A) or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)- (C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo; R3 is hydrogen or C1-4 alkyl;
R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2. [0153] The definitions of variables in Formula I-A above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii). [0154] In certain embodiments, the compound is a compound of Formula I-A. [0155] As defined generally above, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms.
[0156] In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0157] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0158] In certain embodiments, R1 is hydroxyl. In certain embodiments, R1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R1 is methyl. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R1 is trifluoromethyl. In certain embodiments, R1 represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R1 is -CH2OH. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R1 is methoxy. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R1 is -OCF3. [0159] In certain embodiments, R1 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R1 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0160] As defined generally above, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). [0161] In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R2A represents independently for each
occurrence halo or cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0162] In certain embodiments, R2A represents independently for each occurrence halo, cyano, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. [0163] In certain embodiments, R2A represents independently for each occurrence halo. In certain embodiments, R2A is fluoro. In certain embodiments, R2A is fluoro. In certain embodiments, one instance of R2A is fluoro attached at the 6-position of the imidazopyridine ring. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl. In certain embodiments, R2A is methyl. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R2A is trifluoromethyl. In certain embodiments, R2A is cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R2A is -CH2OH. In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R2A is methoxy. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R2A is -OCF3. In certain embodiments, R2A represents independently for each occurrence -N(R4)(R5). In certain embodiments, R2A is - NH2. In certain embodiments, R2A is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R2A is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0164] As defined generally above, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5),
and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0165] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- 6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. [0166] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. [0167] In certain embodiments, R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo.
[0168] In certain embodiments, R2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is morpholinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is morpholin-2-yl. In certain embodiments, R2B is morpholin-3-on-6- yl. [0169] In certain embodiments, R2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is piperidinyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is piperidin-4-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is piperidin-3-yl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo. In certain embodiments, R2B is 1-methylpiperidin-4-yl. In certain embodiments, R2B is piperidin-3-yl. In certain embodiments, R2B is piperidin-2-on-5-yl. [0170] In certain embodiments, R2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, - N(R4)(R5), and halo. In certain embodiments, R2B is tetrahydropyranyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, and halo. In certain embodiments, R2B is tetrahydropyran-4-yl substituted with 0, 1, or 2 substituents
independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, and halo. In certain embodiments, R2B is tetrahydropyran-4-yl. [0171] In certain embodiments, R2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, - C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. In certain embodiments, R2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo. [0172] In certain embodiments, R2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is pyrazolyl substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo. In certain embodiments, R2B is a 6-membered monocyclic heteroaryl having 1, 2, or 3 nitrogen atoms, wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, and halo.
[0173] In certain embodiments, R2B is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R2B is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0174] As defined generally above, R3 is hydrogen or C1-4 alkyl. In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is C1-4 alkyl. In certain embodiments, R3 is methyl. In certain embodiments, R3 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R3 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0175] As defined generally above, R4 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0176] In certain embodiments, R4 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 is hydrogen. In certain embodiments, R4 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R4 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R4 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0177] As defined generally above, R5 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0178] In certain embodiments, R5 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R5 is hydrogen. In certain embodiments, R5 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R5 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R5 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0179] In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 and R5 are hydrogen. In certain embodiments, R4 and R5 each represent independently for each occurrence C1-4 alkyl. [0180] In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain
embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom. [0181] As defined generally above, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0182] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0183] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, - O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 alkyl, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -O- (C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl or -N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence –OCF3, -O-(cyclopropyl), –NH2, –CF3, –F, or –Cl. In certain embodiments, R6 represents independently for each occurrence –OCF3, –NH2, –CF3, fluoro, or chloro. In certain embodiments, R6 represents independently for each occurrence –OCF3 or –NH2.
[0184] In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S- (C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)- (C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5), hydroxyl, halo, or cyano. In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5) or halo. In certain embodiments, one occurrence of R6 is C1-4 haloalkoxyl, C1-4 haloalkyl, -S-(C1-4 haloalkyl), or -O-(C3-4 cycloalkyl), and any further occurrences of R6 are –NH2. [0185] In certain embodiments, one occurrence of R6 is –OCF3, –CF3, –SCF3, or -O- (cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2. [0186] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), or hydroxyl. In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5), halo, or cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl) or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl. [0187] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6 is –OCF3. In certain embodiments, R6 represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6 is methoxy. In certain embodiments, R6 represents independently for each occurrence -O-(C0-4 alkylene)-(C3-6
cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C1-4 alkylene)-(C3-4 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C3-4 cycloalkyl). In certain embodiments, R6 is -O-(cyclopropyl). In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5). In certain embodiments, R6 is –NH2. In certain embodiments, R6 is hydroxyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6 is methyl. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6 is trifluoromethyl. In certain embodiments, R6 represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6 represents independently for each occurrence halo. In certain embodiments, R6 is fluoro or chloro. In certain embodiments, R6 is fluoro. In certain embodiments, R6 is chloro. In certain embodiments, R6 is cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl). In certain embodiments, R6 is -S-CF3. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 alkyl). [0188] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0189] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl.
[0190] In certain embodiments, R6 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R6 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0191] As defined generally above, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0192] In certain embodiments, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0193] In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0194] In certain embodiments, A1 is phenyl substituted with m occurrences of R6. In certain embodiments, A1 is
[0197] In certain embodiments, A1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is . In c
embodiments, A1 is
[0198] In certain embodiments, A1 is
[0200] In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R6. In certain embodiments, A1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6.
[0201] In certain embodiments, A1 is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, A1 is selected from the groups depicted in the compounds in Table 1 and 1-A, below. [0202] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 1, below. In certain embodiments, m is selected from the values represented in the compounds in Table 1 and 1-A, below. [0203] As defined generally above, p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 1, below. In certain embodiments, p is selected from the values represented in the compounds in Table 1 and 1-A, below. [0204] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Table 1, below. In certain embodiments, q is selected from the values represented in the compounds in Table 1 and 1-A, below. [0205] The description above describes multiple embodiments relating to compounds of Formula I-A. The patent application specifically contemplates all combinations of the embodiments.
[0206] Another aspect of the invention provides a compound represented by Formula I-B: (I-B
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2C is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl
having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2. [0207] The definitions of variables in Formula I-B above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii). [0208] In certain embodiments, the compound is a compound of Formula I-B. [0209] As defined generally above, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0210] In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0211] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0212] In certain embodiments, R1 is hydroxyl. In certain embodiments, R1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R1 is methyl. In certain
embodiments, R1 represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R1 is trifluoromethyl. In certain embodiments, R1 represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R1 is -CH2OH. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R1 is methoxy. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R1 is -OCF3. [0213] In certain embodiments, R1 is selected from the groups depicted in the compounds in Table 2, below. [0214] As defined generally above, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). [0215] In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R2A represents independently for each occurrence halo or cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0216] In certain embodiments, R2A represents independently for each occurrence halo, cyano, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. [0217] In certain embodiments, R2A represents independently for each occurrence halo. In certain embodiments, R2A is fluoro. In certain embodiments, one instance of R2A is fluoro. In certain embodiments, one instance of R2A is fluoro attached at the 6-position of the imidazopyridinone ring. In certain embodiments, R2A represents independently for each
occurrence C1-4 alkyl. In certain embodiments, R2A is methyl. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R2A is trifluoromethyl. In certain embodiments, R2A is cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R2A is -CH2OH. In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R2A is methoxy. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R2A is -OCF3. In certain embodiments, R2A represents independently for each occurrence -N(R4)(R5). In certain embodiments, R2A is -NH2. In certain embodiments, R2A is selected from the groups depicted in the compounds in Table 2, below. [0218] As defined generally above, R2C is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R2C is hydrogen or C1-4 alkyl. In certain embodiments, R2C is C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R2C is hydrogen or C3-5 cycloalkyl. In certain embodiments, R2C is hydrogen or methyl. [0219] In certain embodiments, R2C is hydrogen. In certain embodiments, R2C is C1-4 alkyl. In certain embodiments, R2C is methyl. In certain embodiments, R2C is C3-5 cycloalkyl. In certain embodiments, R2C is cyclopropyl. In certain embodiments, R2C is selected from the groups depicted in the compounds in Table 2, below. [0220] As defined generally above, R3 is hydrogen or C1-4 alkyl. In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is C1-4 alkyl. In certain embodiments, R3 is methyl. In certain embodiments, R3 is selected from the groups depicted in the compounds in Table 2, below. [0221] As defined generally above, R4 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0222] In certain embodiments, R4 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 is hydrogen. In certain embodiments, R4 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R4 is selected from the groups depicted in the compounds in Table 2, below.
[0223] As defined generally above, R5 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0224] In certain embodiments, R5 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R5 is hydrogen. In certain embodiments, R5 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R5 is selected from the groups depicted in the compounds in Table 2, below. [0225] In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 and R5 are hydrogen. In certain embodiments, R4 and R5 each represent independently for each occurrence C1-4 alkyl. [0226] In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom. [0227] As defined generally above, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0228] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl.
[0229] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, - O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 alkyl, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -O- (C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl or -N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence –OCF3, -O-(cyclopropyl), –NH2, –CF3, –F, or –Cl. In certain embodiments, R6 represents independently for each occurrence –OCF3, –NH2, –CF3, fluoro, or chloro. In certain embodiments, R6 represents independently for each occurrence –OCF3 or –NH2. [0230] In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S- (C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)- (C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5), hydroxyl, halo, or cyano. In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0–4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5) or halo. In certain embodiments, one occurrence of R6 is C1-4 haloalkoxyl, C1-4 haloalkyl, -S-(C1-4 haloalkyl), or -O-(C3-4 cycloalkyl), and any further occurrences of R6 are –NH2. [0231] In certain embodiments, one occurrence of R6 is –OCF3, –CF3, –SCF3, or -O- (cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2.
[0232] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), or hydroxyl. In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5), halo, or cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl) or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl. [0233] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6 is –OCF3. In certain embodiments, R6 represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6 is methoxy. In certain embodiments, R6 represents independently for each occurrence -O-(C0–4 alkylene)-(C3-6 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C1-4 alkylene)-(C3-4 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C3-4 cycloalkyl). In certain embodiments, R6 is -O-(cyclopropyl). In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5). In certain embodiments, R6 is –NH2. In certain embodiments, R6 is hydroxyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6 is methyl. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6 is trifluoromethyl. In certain embodiments, R6 represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6 represents independently for each occurrence halo. In certain embodiments, R6 is fluoro or chloro. In certain embodiments, R6 is fluoro. In certain embodiments, R6 is chloro. In certain embodiments, R6 is cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl). In certain embodiments, R6 is -S-CF3. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 alkyl). [0234] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl.
[0235] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0236] In certain embodiments, R6 is selected from the groups depicted in the compounds in Table 2, below. [0237] As defined generally above, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0238] In certain embodiments, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0239] In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms
independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0240] In certain embodiments, A1 is phenyl substituted with m occurrences of R6. In certain
[0242] In certain embodiments, A1 is
. ce ta e bodiments, A1 is ertain embodiments, A1 is . nts, A1 is
ain embodiment 1
s, A is
[0243] In certain embodiments, A1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is . In ce
embodiments, A1 is
[0246] In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic
heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R6. In certain embodiments, A1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. [0247] In certain embodiments, A1 is selected from the groups depicted in the compounds in Table 2, below. [0248] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 2, below. [0249] As defined generally above, p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 2, below. [0250] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Table 2, below. [0251] The description above describes multiple embodiments relating to compounds of Formula I-B. The patent application specifically contemplates all combinations of the embodiments.
[0252] Another aspect of the invention provides a compound represented by Formula I-C: (I-C
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl
having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2. [0253] The definitions of variables in Formula I-C above encompass multiple chemical groups. The application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii). [0254] In certain embodiments, the compound is a compound of Formula I-C. [0255] As defined generally above, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0256] In certain embodiments, two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms. [0257] In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence hydroxyl, C1-4 alkoxyl, or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0258] In certain embodiments, R1 is hydroxyl. In certain embodiments, R1 is hydroxyl attached at the 4-position of the piperidine ring. In certain embodiments, R1 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R1 is methyl. In certain
embodiments, R1 represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R1 is trifluoromethyl. In certain embodiments, R1 represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R1 is -CH2OH. In certain embodiments, R1 represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R1 is methoxy. In certain embodiments, R1 represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R1 is -OCF3. [0259] In certain embodiments, R1 is selected from the groups depicted in the compounds in Table 3, below. [0260] As defined generally above, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). [0261] In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkyl, or cyano. In certain embodiments, R2A represents independently for each occurrence halo or C1-4 alkyl. In certain embodiments, R2A represents independently for each occurrence halo or cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, or C1-4 hydroxyalkyl. In certain embodiments, R2A represents independently for each occurrence C1-4 alkyl or C1-4 haloalkyl. [0262] In certain embodiments, R2A represents independently for each occurrence halo, cyano, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence halo, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5). In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl or C1-4 haloalkoxyl. [0263] In certain embodiments, R2A represents independently for each occurrence halo. In certain embodiments, R2A is fluoro. In certain embodiments, one instance of R2A is fluoro. In certain embodiments, one instance of R2A is fluoro attached at the 5-position of the dihydropyrrolopyridinone ring. In certain embodiments, R2A represents independently for each
occurrence C1-4 alkyl. In certain embodiments, R2A is methyl. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkyl. In certain embodiments, R2A is trifluoromethyl. In certain embodiments, R2A is cyano. In certain embodiments, R2A represents independently for each occurrence C1-4 hydroxyalkyl. In certain embodiments, R2A is -CH2OH. In certain embodiments, R2A represents independently for each occurrence C1-4 alkoxyl. In certain embodiments, R2A is methoxy. In certain embodiments, R2A represents independently for each occurrence C1-4 haloalkoxyl. In certain embodiments, R2A is -OCF3. In certain embodiments, R2A represents independently for each occurrence -N(R4)(R5). In certain embodiments, R2A is -NH2. In certain embodiments, R2A is selected from the groups depicted in the compounds in Table 3, below. [0264] As defined generally above, R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R2C represents independently for each occurrence C1-4 alkyl or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or C3-5 cycloalkyl. In certain embodiments, R2C represents independently for each occurrence hydrogen or methyl. [0265] In certain embodiments, R2C is hydrogen. In certain embodiments, R2C represents independently for each occurrence C1-4 alkyl. In certain embodiments, R2C is methyl. In certain embodiments, R2C represents independently for each occurrence C3-5 cycloalkyl. In certain embodiments, R2C is cyclopropyl. In certain embodiments, R2C is selected from the groups depicted in the compounds in Table 3, below. [0266] As defined generally above, R3 is hydrogen or C1-4 alkyl. In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is C1-4 alkyl. In certain embodiments, R3 is methyl. In certain embodiments, R3 is selected from the groups depicted in the compounds in Table 3, below. [0267] As defined generally above, R4 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0268] In certain embodiments, R4 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 is hydrogen. In certain embodiments, R4 represents
independently for each occurrence C1-4 alkyl. In certain embodiments, R4 is selected from the groups depicted in the compounds in Table 3, below. [0269] As defined generally above, R5 represents independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. [0270] In certain embodiments, R5 represents independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R5 is hydrogen. In certain embodiments, R5 represents independently for each occurrence C1-4 alkyl. In certain embodiments, R5 is selected from the groups depicted in the compounds in Table 3, below. [0271] In certain embodiments, R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl. In certain embodiments, R4 and R5 are hydrogen. In certain embodiments, R4 and R5 each represent independently for each occurrence C1-4 alkyl. [0272] In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom. In certain embodiments, R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 5-6 membered saturated ring having one nitrogen atom. [0273] As defined generally above, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0274] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, or cyano; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0,
1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0275] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, - O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 alkyl, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -O- (C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, -N(R4)(R5), C1-6 haloalkyl, or halo. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl or -N(R4)(R5). In certain embodiments, R6 represents independently for each occurrence –OCF3, -O-(cyclopropyl), –NH2, –CF3, –F, or –Cl. In certain embodiments, R6 represents independently for each occurrence –OCF3, –NH2, –CF3, fluoro, or chloro. In certain embodiments, R6 represents independently for each occurrence –OCF3 or –NH2. [0276] In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S- (C1-6 haloalkyl), or -O-(C0-4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)- (C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0-4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5), hydroxyl, halo, or cyano. In certain embodiments, one occurrence of R6 is C1-6 haloalkoxyl, C1-6 haloalkyl, -S-(C1-6 haloalkyl), or -O-(C0-4 alkylene)-(C3-6 cycloalkyl), and any further occurrences of R6 represent independently for each occurrence -N(R4)(R5) or halo. In certain embodiments, one occurrence of R6 is C1-4 haloalkoxyl, C1-4 haloalkyl, -S-(C1-4 haloalkyl), or -O-(C3-4 cycloalkyl), and any further occurrences of R6 are –NH2. [0277] In certain embodiments, one occurrence of R6 is –OCF3, –CF3, –SCF3, or -O- (cyclopropyl), and any further occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further
occurrences of R6 are independently –NH2, –F, or –Cl. In certain embodiments, one occurrence of R6 is –OCF3, –CF3, or -O-(cyclopropyl), and any further occurrences of R6 are independently –NH2. [0278] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), or hydroxyl. In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5), halo, or cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl) or -S-(C1-6 alkyl). In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl or C1-6 haloalkyl. [0279] In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkoxyl. In certain embodiments, R6 is –OCF3. In certain embodiments, R6 represents independently for each occurrence C1-6 alkoxyl. In certain embodiments, R6 is methoxy. In certain embodiments, R6 represents independently for each occurrence -O-(C0–4 alkylene)-(C3-6 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C1-4 alkylene)-(C3-4 cycloalkyl). In certain embodiments, R6 represents independently for each occurrence -O-(C3-4 cycloalkyl). In certain embodiments, R6 is -O-(cyclopropyl). In certain embodiments, R6 represents independently for each occurrence -N(R4)(R5). In certain embodiments, R6 is –NH2. In certain embodiments, R6 is hydroxyl. In certain embodiments, R6 represents independently for each occurrence C1-6 alkyl. In certain embodiments, R6 is methyl. In certain embodiments, R6 represents independently for each occurrence C1-6 haloalkyl. In certain embodiments, R6 is trifluoromethyl. In certain embodiments, R6 represents independently for each occurrence C1-6 hydroxyalkyl. In certain embodiments, R6 represents independently for each occurrence halo. In certain embodiments, R6 is fluoro or chloro. In certain embodiments, R6 is fluoro. In certain embodiments, R6 is chloro. In certain embodiments, R6 is cyano. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 haloalkyl). In certain embodiments, R6 is -S-CF3. In certain embodiments, R6 represents independently for each occurrence -S-(C1-6 alkyl).
[0280] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0281] In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. In certain embodiments, two occurrences of R6 are taken together with the intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 0, 1, or 2 heteroatoms independently selected from nitrogen and oxygen, wherein said ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl. [0282] In certain embodiments, R6 is selected from the groups depicted in the compounds in Table 3, below. [0283] As defined generally above, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0284] In certain embodiments, A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0285] In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is phenyl or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3
heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6. [0286] In certain embodiments, A1 is phenyl substituted with m occurrences of R6. In certain
[0289] In certain embodiments, A1 is a 5-6 membered monocyclic partially unsaturated oxo- heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo- heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is a 6- membered monocyclic partially unsaturated oxo-heterocyclyl having 1 or 2 nitrogen atoms; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is pyridin-2(1H)-on-3-yl substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6. In certain embodiments, A1 is . In ce
embodiments, A1 i
[0292] In certain embodiments, A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 5-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. In certain embodiments, A1 is a 6-membered monocyclic
heteroaryl having one or two nitrogen atoms; which is substituted with m occurrences of R6. In certain embodiments, A1 is an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; which is substituted with m occurrences of R6. [0293] In certain embodiments, A1 is selected from the groups depicted in the compounds in Table 3, below. [0294] As defined generally above, m is 0, 1, 2, or 3. In certain embodiments, m is 0. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 0 or 1. In certain embodiments, m is 1 or 2. In certain embodiments, m is 2 or 3. In certain embodiments, m is 0, 1, or 2. In certain embodiments, m is 1, 2, or 3. In certain embodiments, m is selected from the values represented in the compounds in Table 3, below. [0295] As defined generally above, p is 0, 1, or 2. In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 0 or 1. In certain embodiments, p is 1 or 2. In certain embodiments, p is selected from the values represented in the compounds in Table 3, below. [0296] As defined generally above, q is 0, 1, or 2. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 1 or 2. In certain embodiments, q is selected from the values represented in the compounds in Table 3, below. [0297] The description above describes multiple embodiments relating to compounds of Formula I-C. The patent application specifically contemplates all combinations of the embodiments. [0298] In certain embodiments, the compound is a compound in Table 1, 1-A, 2, 3, 4, 5, or 6 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, 2, 3, 4, 5, or 6, below. In certain embodiments, the compound is a compound in Table 1, 2, 3, 4, 5, or 6 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 2, 3, 4, 5, or 6, below.
[0299] In certain embodiments, the compound is a compound in Table 1, 1-A, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, 2, or 3, below. In certain embodiments, the compound is a compound in Table 1, 2, or 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 2, or 3, below. [0300] In certain embodiments, the compound is a compound in Table 1 or 1-A below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 1-A below. In certain embodiments, the compound is a compound in Table 1 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 below. In certain embodiments, the compound is a compound in Table 2 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 below. In certain embodiments, the compound is a compound in Table 3 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 3 below. [0301] In certain embodiments, the compound is a compound in Table 1, 1-A, or 4 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1, 1-A, or 4 below. In certain embodiments, the compound is a compound in Table 1 or 4 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 4 below. In certain embodiments, the compound is a compound in Table 2 or 5 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 or 5 below. In certain embodiments, the compound is a compound in Table 3 or 6 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 3 or 6 below.
TABLE 2.
TABLE 3.
TABLE 6.
[0302] Compounds may be further characterized according to their inhibitory activity against ERK5. In certain embodiments, a preferred compound has an IC50 less than 2 µM against ERK5. In certain embodiments, a more preferred compound has an IC50 less than 0.5 µM against ERK5. In certain embodiments, an even more preferred compound has an IC50 less than or equal to 0.05 µM against ERK5. [0303] Methods for preparing compounds described herein are illustrated in the following synthetic Schemes, and in the Examples below. The Schemes are given for the purpose of illustrating the invention, and are not intended to limit the scope or spirit of the invention. Starting materials shown in the Schemes can be obtained from commercial sources or can be prepared based on procedures described in the literature. [0304] In the Schemes, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting group chemistry and strategy is well known in the art, for example, as described in detail in “Protecting Groups in Organic Synthesis”, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entire contents of which are hereby incorporated by reference. [0305] The synthetic route illustrated in Scheme 1 is a general method for preparing substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds E. Transition-metal- mediated coupling of substituted pyridine A (wherein LG is a leaving group, such as a halide or sulfonate) with cyclic metal reagent B (wherein M is a metal, such as a boronic acid or ester, or a trialkylstannane; and PG is a protecting group, such as Boc), followed by reduction (using, for example, hydrogen and a transition-metal catalyst, such as Pd on carbon), affords protected 4- piperidinyl-pyridine C. Ring formation with carbonyl compound D (wherein R' is, for example, hydrogen; a leaving group, such as a halide; or a hydroxyl group that can be activated using, for example, an amide coupling reagent, such as HATU) affords 4-piperidinyl-imidazo[4,5- b]pyridine E. When R' is hydrogen (i.e. the carbonyl compound is an aldehyde), the ring formation proceeds, for example, by cyclocondensation (using, for example, heating, such as
with microwave irradiation), followed by oxidation (using, for example, an oxidant, such as PhI(OAc)2 or Na2S2O5). When R' is a leaving group or hydroxyl group (i.e. the carbonyl compound is a carboxylic acid or activated derivative), the ring formation proceeds, for example, by condensation (using, for example, a base, such as DIPEA, optionally in the presence of an activating agent, such as an amide coupling reagent, when R' is hydroxyl), followed by cyclocondensation (using, for example, an activating agent, such as cesium fluoride). Deprotection of 4-piperidinyl-imidazo[4,5-b]pyridine E (using, for example, an acid, such as HCl or TFA, when PG is Boc), followed by coupling with cyclic compound F (wherein LG' is a leaving group, such as a halide, or a hydroxyl group that can be activated using, for example, an amide coupling reagent, such as HATU), affords substituted 4-piperidinyl-imidazo[4,5- b]pyridines and related compounds G. SCHEME 1.
[0306] The synthetic route illustrated in Scheme 2 is an alternative general method for preparing substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds E. Transition-metal-mediated coupling of imidazo[4,5-b]pyridine A (wherein LG is a leaving group, such as a halide or sulfonate) with cyclic metal reagent B (wherein M is a metal, such as a boronic acid or ester, or a trialkylstannane; and PG is a protecting group, such as Boc), followed
by reduction (using, for example, hydrogen and a transition-metal catalyst, such as Pd on carbon), affords protected 4-piperidinyl-imidazo[4,5-b]pyridine C. Deprotection (using, for example, an acid, such as HCl or TFA, when PG is Boc), followed by coupling with cyclic compound D (wherein LG' is a leaving group, such as a halide, or a hydroxyl group that can be activated using, for example, an amide coupling reagent, such as HATU), affords substituted 4- piperidinyl-imidazo[4,5-b]pyridines and related compounds E. SCHEME 2.
[0307] The synthetic route illustrated in Scheme 3 is a general method for preparing substituted 7-piperidinyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones and related compounds D. Diaminopyridine A (wherein PG is a protecting group, such as Boc) is prepared, for example, by analogy to 4-piperidinyl-pyridine C in Scheme 1. Cyclization of diaminopyridine A (using, for example, a reagent such as CDI, phosgene, or triphosgene) affords protected 7-piperidinyl- 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one B. Deprotection (using, for example, an acid, such as HCl or TFA, when PG is Boc), followed by coupling with cyclic compound C (wherein LG' is a leaving group, such as a halide, or a hydroxyl group that can be activated using, for example,
an amide coupling reagent, such as HATU), affords substituted 7-piperidinyl-1,3-dihydro-2H- imidazo[4,5-b]pyridin-2-ones and related compounds D. SCHEME 3.
[0308] The synthetic route illustrated in Scheme 4 is a general method for preparing substituted 4-piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-ones and related compounds F. Transition-metal-mediated coupling of pyrrolo[2,3-b]pyridine A (wherein LG is a leaving group, such as a halide or a sulfonate) with cyclic metal reagent B (wherein M is a metal, such as a boronic acid or ester, or a trialkylstannane; and PG is a protecting group, such as Boc), followed by reduction (using, for example, hydrogen and a transition-metal catalyst, such as Pd on carbon), affords protected 4-piperidinyl-pyrrolo[2,3-b]pyridine C., which is further functionalized to prepare protected 4-piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one D. Functionalization proceeds, for example, by oxidation to form an α,α-dihalolactam (using, for example, NBS) followed by reduction (using, for example, a metal, such as zinc) to afford pyridinone D wherein each R2C is hydrogen. Introduction of other R2C groups is accomplished by functional group transformations well known in the art, such as, for example enolate alkylation (using, for example, a base, such as LHMDS, and an electrophile, such as methyl
iodide). Deprotection of 4-piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one D (using, for example, an acid, such as HCl or TFA, when PG is Boc), followed by coupling with cyclic compound E (wherein LG' is a leaving group, such as a halide, or a hydroxyl group that can be activated using, for example, an amide coupling reagent, such as HATU), affords substituted 4- piperidinyl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-ones and related compounds F. SCHEME 4.
[0309] The modular synthetic route illustrated in Schemes 1 through 4 can also be readily modified by one of skill in the art to provide additional substituted 4-piperidinyl-imidazo[4,5- b]pyridines and related compounds by conducting functional group transformations on the intermediate and final compounds. Such functional group transformations are well known in the art, as described in, for example, “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992). For example, the alkene functional group in the coupling product of pyridine or bicyclic heteroaryl A with cyclic metal reagent B in Schemes 1, 2, and 4, can be oxidized, instead of reduced, to afford, for example, an alcohol (using, for example, Mukaiyama hydration conditions) or a 1,2-diol (using, for example, OsO4 and a stoichiometric oxidant, such as NMO). The resulting alcohol(s) can be further functionalized, for example, by alkylation (using, for example, a base, such as NaH, and an electrophile, such as an alkyl halide).
II. Therapeutic Applications of Substituted 4-Piperidinyl-imidazo[4,5-b]pyridines and Related Compounds [0310] It is contemplated that the substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds described herein, such as a compound of Formula I, or other compounds in Section I, provide therapeutic benefits to subjects suffering from cancer and other disorders. Accordingly, one aspect of the invention provides a method of treating a disorder mediated by ERK5 in a subject. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, to a subject in need thereof to treat the disorder. In certain embodiments, the compound is a compound of Formula I, I-A, I-B, or I-C defined by one of the embodiments described above. [0311] The provided compounds are inhibitors of ERK5 and are therefore useful for treating one or more disorders associated with activity of ERK5. Thus, in certain aspects and embodiments, the present invention provides a method for treating an ERK5-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective compound of the present invention, or pharmaceutically acceptable composition thereof. [0312] As used herein, the term “ERK5-mediated” disorders, diseases, and/or conditions as used herein means any disease or other deleterious condition in which ERK5, or a variant or mutant thereof, is known to play a role. Accordingly, another aspect or embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which ERK5, or a variant or mutant thereof, are known to play a role. [0313] In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder characterized by or associated with increased ERK5 expression and/or increased ERK5 activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof. In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of ERK5 activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective
amount of a compound of the present invention, or pharmaceutically acceptable composition thereof. [0314] Without wishing to be bound by theory, inhibitor compounds described herein are believed to bind to and inhibit ERK5, leading to reduced translocation of ERK5 to the cell’s nucleus and/or reduction of ERK5-mediated gene transcription in the nucleus. The mitogen- activated protein kinases (MAPK) are a group of proteins able to translate environmental signals elicited by a plethora of stimuli, including growth factors and stresses, into different biological responses such as survival, apoptosis, proliferation, migration, and differentiation. The importance of MAPK is underlined by the abnormal signaling conveyed by members of the MAPK family in several human diseases, including Parkinson’s disease, inflammatory disorders, and cancer (see, for example, Kim, E.K.; Choi, E.J. Biochim. Biophys. Acta (2010), 1802, 396– 405; and Kim, S.C. et al. Blood (1999) 93, 3893–3899). In mammals, there are more than a dozen MAPK enzymes (Braicu, C. et al. Cancers (2019) Cancers (Basel).11(10):1618). Extracellular signal-regulated kinase 5 (ERK5, also known as Big MAPK 1, BMK1) is a member of this family, and consists of an amino-terminal kinase domain, with a relatively large carboxy- terminus of unique structure and function that makes it distinct from other MAPK members (Drew et al. Biochim. Biophys. Acta (2012) 1825(1): 37–48). [0315] In unstimulated cells and/or in the absence of oncogenic stimuli, cytosolic ERK5 is believed to be in an unphosphorylated inactive folded form, such that the Nuclear Localization Sequence (NLS) is hidden and nuclear translocation is prevented. After stimulus, ERK5 is thought to be activated through a MEK5-dependent phosphorylation at the Thr-Glu-Tyr (TEY) motif of ERK5. This phosphorylation can initiate the ERK5 kinase activity, which can phosphorylate itself in the C-terminus. Following phosphorylation of the C-terminus, ERK5 is understood to assume an open conformation, exposing the NLS sequence that allows ERK5 nuclear translocation. Once in the nucleus, ERK5 is reported to enhance gene transcription either by phosphorylating transcription factors or, in a kinase-independent manner, by interacting with transcription factors through the transactivation domain (TAD) domain (Tubita et al.(2020) Int. J. Mol. Sci.21(3), 938). In stimulated cells and/or in the presence of oncogenic stimuli or in response to several targeted therapies, ERK5 is believed to promote tumor growth by, for example, sustaining proliferative signals and evading growth suppressors.
[0316] Accordingly, in some aspects and embodiments, the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, an ERK5 inhibitor compound as described herein, or a pharmaceutical salt or composition thereof. In some embodiments, the cellular proliferative disorder is cancer. In some embodiments, the cancer is characterized by increased ERK5 expression and/or increased ERK5 activity, i.e., “increased activated ERK5.” In some embodiments, the cancer is characterized by ERK5 genomic amplification and/or constitutively active ERK5 signaling. [0317] As used herein, the terms "increased," "elevated," or "enhanced," are used interchangeably and encompass any measurable increase in a biological function and/or biological activity and/or a concentration. For example, an increase can be by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3- fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10- fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to a control or baseline amount of a function, or activity, or concentration. [0318] As used herein, the terms "increased expression" and/or "increased activity" of a substance, such as ERK5, in a sample or cancer or patient, refers to an increase in the amount of the substance, such as ERK5, of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6- fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to the amount of the substance, such as ERK5, in a control sample or control samples, such as an individual or group of individuals who are not suffering from the disease or disorder (e.g., cancer) or an internal control, as determined by techniques known in the art. A subject can also be determined to have an "increased expression" or "increased activity" of ERK5 if the expression and/or activity of ERK5 is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations,
five standard deviations, or more, relative to the mean (average) or median amount of ERK5 in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples. As practiced in the art, such control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples. [0319] As used herein, a "proliferative disease" refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990). A proliferative disease can be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes, such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis, as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases. Accordingly, in certain aspects and embodiments, the disorder is cancer. The cancer or proliferative disorder or tumor to be treated using the compounds and methods and uses described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a colorectal cancer, lung cancer, head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and a vascular cancer. [0320] In some embodiments of the methods and uses described herein, a cancer is treated by inhibiting or reducing or decreasing or arresting further growth or spread of the cancer or tumor. In some embodiments of the methods and uses described herein, a cancer is treated by inhibiting or reducing the size (e.g., volume or mass) of the cancer or tumor by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the size of the cancer or tumor prior to treatment. In some embodiments of the methods and uses described herein, a cancer is treated by reducing the quantity of the cancers or tumors in the patient by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% relative to the quantity of the cancers or tumors prior to treatment.
[0321] In some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. [0322] In some embodiments, the cancer is non-small cell lung cancer (NSCLC). In some embodiments, the cancer is a pancreatic cancer, such as an adenocarcinoma. In some embodiments, the cancer is colorectal cancer (CRC). In some embodiments, the cancer is a breast cancer, such as ductal breast carcinoma. In some embodiments, the cancer is an ovarian cancer. In some embodiments, the cancer is a brain cancer, such as glioblastoma. In some embodiments, the cancer is a kidney cancer. [0323] In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a melanoma, carcinoma, or blastoma. In certain embodiments, the cancer is a melanoma. In certain embodiments, the cancer is a carcinoma. In certain embodiments, the cancer is an adenocarcinoma. In certain embodiments, the cancer is a blastoma. [0324] In certain embodiments, the cancer is breast cancer, lung cancer, pancreatic cancer, cervical cancer, colorectal cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer. In certain embodiments, the cancer is breast cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is pancreatic cancer. In certain embodiments, the cancer is cervical cancer. In certain embodiments, the cancer is colorectal cancer. In certain embodiments, the cancer is prostate cancer. In certain embodiments, the cancer is gastric cancer. In certain embodiments, the cancer is skin cancer. In certain embodiments, the cancer is liver cancer. In certain embodiments, the cancer is bile duct cancer. In certain embodiments, the cancer is nervous system cancer. [0325] In certain embodiments, the cancer is breast adenocarcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, prostate adenocarcinoma, gastric adenocarcinoma, melanoma, lung squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, or neuroblastoma. In certain embodiments, the cancer is breast adenocarcinoma. In certain embodiments, the cancer is lung adenocarcinoma. In certain embodiments, the cancer is pancreatic adenocarcinoma. In certain embodiments, the cancer is cervical adenocarcinoma. In certain embodiments, the cancer is prostate adenocarcinoma. In certain embodiments, the cancer is gastric adenocarcinoma. [0326] In certain embodiments, the cancer is melanoma.
[0327] In certain embodiments, the cancer is lung squamous cell carcinoma, hepatocellular carcinoma, or cholangiocarcinoma. In certain embodiments, the cancer is lung squamous cell carcinoma. In certain embodiments, the cancer is hepatocellular carcinoma. In certain embodiments, the cancer is cholangiocarcinoma. [0328] In certain embodiments, the cancer is glioblastoma or neuroblastoma. In certain embodiments, the cancer is glioblastoma. In certain embodiments, the cancer is neuroblastoma. [0329] In certain embodiments, the cancer is lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In certain embodiments, the cancer is lung cancer. In certain embodiments, the cancer is non-small cell lung cancer. [0330] In certain embodiments, the cancer has elevated ERK5 activity. In certain embodiments, the cancer overexpresses ERK5. In certain embodiments, the cancer has genomically amplified ERK5. In certain embodiments, the cancer has constitutively active ERK5 signaling. [0331] In some embodiments, the cancer is a KRAS mutant cancer. In some embodiments, the KRAS mutant cancer harbors the KRAS G12C mutation. In some embodiments, the KRAS mutant cancer harbors the KRAS G12D mutation. In some embodiments, the KRAS mutant cancer harbors the KRAS G12V mutation. In some embodiments, the KRAS mutant cancer harbors the KRAS G13 mutation. In some embodiments, the KRAS mutant cancer harbors one or more KRAS mutations selected from a KRAS G12C, a KRAS G12D mutation, a KRAS G12V mutation, and a KRAS G13 mutation. [0332] In some embodiments, the cancer is a KRAS mutant lung cancer. [0333] In certain embodiments, the cancer is a leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin’s disease or non-Hodgkin’s disease), Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, or a solid tumor such as a sarcoma or carcinoma (e.g., fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, and retinoblastoma). [0334] In some embodiments, the cancer is glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma. [0335] In some embodiments, the cancer is acoustic neuroma, astrocytoma (e.g. Grade I – Pilocytic Astrocytoma, Grade II – Low-grade Astrocytoma, Grade III – Anaplastic Astrocytoma, or Grade IV – Glioblastoma (GBM)), chordoma, CNS lymphoma, craniopharyngioma, brain stem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumors, primitive neuroectodermal (PNET) tumor, or schwannoma. In some embodiments, the cancer is a type found more commonly in children than adults, such as brain stem glioma, craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor. [0336] In some embodiments, the cancer is mesothelioma, hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the
vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, non-Hodgkins’s lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination of one or more of the foregoing cancers. [0337] In some embodiments, the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal/stomach (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma. [0338] In some embodiments, the cancer is hepatocellular carcinoma, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), prostate cancer, testicular cancer, gallbladder cancer, hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, gastrointestinal stromal tumor (GIST) cancer, lymphoma, squamous cell carcinoma of the head and neck (SCCHN), salivary gland cancer, glioma, or brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma.
[0339] In some embodiments, the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical adenoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma. [0340] In some embodiments, the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic ductal carcinoma or pancreatic adenocarcinoma; gastrointestinal/stomach (GIST) cancer; lymphoma; squamous cell carcinoma of the head and neck (SCCHN); salivary gland cancer; glioma, or brain cancer; neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST); Waldenstrom’s macroglobulinemia; and medulloblastoma. [0341] In some embodiments, the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic ductal carcinoma or pancreatic adenocarcinoma; gastrointestinal stromal tumor (GIST) cancer; lymphoma; squamous cell
carcinoma of the head and neck (SCCHN); salivary gland cancer; glioma, or brain cancer; neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST); Waldenstrom’s macroglobulinemia; and medulloblastoma. [0342] In some embodiments, the cancer is renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoblastoma, colorectal carcinoma, colorectal cancer, colon cancer, rectal cancer, anal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, brain cancer, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma. [0343] In some embodiments, the cancer is hepatocellular carcinoma (HCC), hepatoblastoma, colon cancer, rectal cancer, ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, fallopian tube cancer, papillary serous cystadenocarcinoma, uterine papillary serous carcinoma (UPSC), hepatocholangiocarcinoma, soft tissue and bone synovial sarcoma, rhabdomyosarcoma, osteosarcoma, anaplastic thyroid cancer, adrenocortical carcinoma, pancreatic cancer, pancreatic ductal carcinoma, pancreatic adenocarcinoma, glioma, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), Waldenstrom’s macroglobulinemia, or medulloblastoma. [0344] In some embodiments, the cancer is hepatocellular carcinoma (HCC). In some embodiments, the cancer is hepatoblastoma. In some embodiments, the cancer is colon cancer. In some embodiments, the cancer is rectal cancer. In some embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian epithelial cancer. In some embodiments, the cancer is fallopian tube cancer. In some embodiments, the cancer is papillary serous cystadenocarcinoma. In some embodiments, the cancer is uterine papillary serous carcinoma (UPSC). In some embodiments, the cancer is hepatocholangiocarcinoma. In some embodiments, the cancer is soft tissue and bone synovial sarcoma. In some embodiments, the cancer is rhabdomyosarcoma. In some embodiments, the cancer is osteosarcoma. In some embodiments, the cancer is anaplastic thyroid cancer. In some embodiments, the cancer is
adrenocortical carcinoma. In some embodiments, the cancer is pancreatic cancer, or pancreatic ductal carcinoma. In some embodiments, the cancer is pancreatic adenocarcinoma. In some embodiments, the cancer is glioma. In some embodiments, the cancer is malignant peripheral nerve sheath tumors (MPNST). In some embodiments, the cancer is neurofibromatosis-1 associated MPNST. In some embodiments, the cancer is Waldenstrom’s macroglobulinemia. In some embodiments, the cancer is medulloblastoma. [0345] In certain embodiments, the subject is a human. In certain embodiments, the subject is an adult human. In certain embodiments, the subject is a pediatric human. In certain embodiments, the subject is a companion animal. In certain embodiments, the subject is a canine, feline, or equine. [0346] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein, such as cancer. [0347] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, or other compounds in Section I) for treating a medical disorder, such as a medical disorder described herein (for example, cancer). [0348] Further, it is contemplated that the compounds described herein, such as a compound of Formula I, or other compounds in Section I, can inhibit ERK5 activity. Accordingly, another aspect of the invention provides a method of inhibiting ERK5 activity. The method comprises contacting ERK5 with an effective amount of a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein, such as a compound of Formula I, or other compounds in Section I, to inhibit ERK5 activity. In certain embodiments, the compound is a compound of Formula I, I-A, I-B, or I-C defined by one of the embodiments described above. III. Combination Therapy [0349] Another aspect of the invention provides for combination therapy. Substituted 4- piperidinyl-imidazo[4,5-b]pyridine or related compounds described herein (e.g., a compound of Formula I, or other compounds in Section I) or their pharmaceutically acceptable salts may be
used in combination with additional therapeutic agents to treat medical disorders, such as a cancer. [0350] In some embodiments, the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In some embodiments, the method includes co-administering one additional therapeutic agent. In some embodiments, the method includes co-administering two additional therapeutic agents. In some embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically. [0351] One or more other therapeutic agents may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, or 24 hours from one another. In some embodiments, one or more other therapeutic agent and a compound or composition of the invention are administerd as a multiple dosage regimen more than 24 hours aparts. [0352] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention can be administered with one or more other therapeutic agent(s) simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, one or more other therapeutic agent(s), and a pharmaceutically acceptable carrier, adjuvant, or vehicle. [0353] The amount of a compound of the invention and one or more other therapeutic agent(s) (in those compositions which comprise an additional therapeutic agent, such as a second anti-cancer agent, as described above) that can be combined with the carrier materials to produce
a single dosage form varies depending upon the host treated and the particular mode of administration. Preferably, a composition of the invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of a compound of the invention can be administered. [0354] In those compositions which comprise one or more other therapeutic agent(s), the one or more other therapeutic agent(s) and a compound of the invention can act synergistically. Therefore, the amount of the one or more other therapeutic agent(s) in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 g/kg body weight/day of the one or more other therapeutic agent(s) can be administered. [0355] The amount of one or more other therapeutic agent(s) present in the compositions of this invention is preferably no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of one or more other therapeutic agent(s) in the presently disclosed compositions ranges from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent. In some embodiments, one or more other therapeutic agent(s) is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent. As used herein, the phrase "normally administered" means the amount an FDA- approved therapeutic agent is approved for dosing per the FDA label insert. [0356] Accordingly, another aspect of the invention provides a method of treating cancer in a subject. The method comprises administering to a subject in need thereof (i) a therapeutically effective amount of a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein and (ii) a second anti-cancer agent, in order to treat the cancer. [0357] In certain embodiments, the second anti-cancer agent is an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin- Dependent Kinase Inhibitor, a DNA-PK Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor plus 2-chloro-deoxyadenosine, an HDAC Inhibitor, a Hedgehog Signaling Pathway Inhibitor, an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a
MEK Inhibitor, a MELK Inhibitor, a MTH1 Inhibitor, a PARP Inhibitor, a Phosphoinositide 3- Kinase Inhibitor, an Inhibitor of both PARP1 and DHODH, a Proteasome Inhibitor, a Topoisomerase-II Inhibitor, a Tyrosine Kinase Inhibitor, a VEGFR Inhibitor, or a WEE1 Inhibitor. [0358] In certain embodiments, the second anti-cancer agent is an ALK Inhibitor. In certain embodiments, the second anti-cancer agent is an ALK Inhibitor comprisng ceritinib, crizotinib, or alectinib. In certain embodiments, the second anti-cancer agent is an ALK Inhibitor comprisng ceritinib or crizotinib. [0359] In certain embodiments, the second anti-cancer agent is an ATR Inhibitor. In certain embodiments, the second anti-cancer agent is an ATR Inhibitor comprising AZD6738 or VX- 970. [0360] In certain embodiments, the second anti-cancer agent is an A2A Antagonist. In certain embodiments, the second anti-cancer agent is a Base Excision Repair Inhibitor comprising methoxyamine. In certain embodiments, the second anti-cancer agent is a Base Excision Repair Inhibitor, such as methoxyamine. [0361] In certain embodiments, the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (SPRYCEL®, Bristol Myers Squibb); bosutinib (BOSULIF®, Pfizer); and ponatinib (INCLUSIG®, Ariad Pharmaceuticals). In certain embodiments, the second anti-cancer agent is a Bcr-Abl Tyrosine Kinase Inhibitor comprising dasatinib or nilotinib. [0362] In certain embodiments, the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor comprising ibrutinib or AVL-292. In certain embodiments, the second anti-cancer agent is a Bruton's Tyrosine Kinase Inhibitor comprising ibrutinib. Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention, can be found in WO2008/039218 and WO2011/090760, the entirety of which are incorporated herein by reference.
[0363] In certain embodiments, the second anti-cancer agent is a CDC7 Inhibitor. In certain embodiments, the second anti-cancer agent is a CDC7 Inhibitor comprising RXDX-103 or AS- 141. [0364] In certain embodiments, the second anti-cancer agent is a CHK1 Inhibitor. In certain embodiments, the second anti-cancer agent is a CHK1 Inhibitor comprising MK-8776, ARRY- 575, or SAR-020106. [0365] In certain embodiments, the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor, such as a CDK4/CDK6 inhibitor. In certain embodiments, the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics). In certain embodiments, the second anti-cancer agent is a Cyclin-Dependent Kinase Inhibitor comprising palbociclib. [0366] In certain embodiments, the second anti-cancer agent is a DNA-PK Inhibitor. In certain embodiments, the second anti-cancer agent is a DNA-PK Inhibitor comprising MSC2490484A. In certain embodiments, the second anti-cancer agent is Inhibitor of both DNA- PK and mTOR. In certain embodiments, the second anti-cancer agent comprises CC-115. [0367] In certain embodiments, the second anti-cancer agent is a DNMT1 Inhibitor. In certain embodiments, the second anti-cancer agent is a DNMT1 Inhibitor comprising decitabine, RX-3117, guadecitabine, NUC-8000, or azacytidine. In certain embodiments, the second anti- cancer agent comprises a DNMT1 Inhibitor and 2-chloro-deoxyadenosine. In certain embodiments, the second anti-cancer agent comprises ASTX-727. [0368] In certain embodiments, the second anti-cancer agent is a histone deacetylase (HDAC) Inhibitor. In certain embodiments, the second anti-cancer agent is a HDAC Inhibitor comprising OBP-801, CHR-3996, etinostate, resminostate, pracinostat, CG-200745, panobinostat, romidepsin, mocetinostat, belinostat, AR-42, ricolinostat, KA-3000, or ACY-241. [0369] In certain embodiments, the second anti-cancer agent is a Hedgehog Signaling Pathway Inhibitor. In certain embodiments, the second anti-cancer agent is a Hedgehog
Signaling Pathway Inhibitor comprising sonidegib (ODOMZO®, Sun Pharmaceuticals) or vismodegib (ERIVEDGE®, Genentech). [0370] In certain embodiments, the second anti-cancer agent is an IDO Inhibitor. In certain embodiments, the second anti-cancer agent is an IDO Inhibitor comprising INCB024360. [0371] In certain embodiments, the second anti-cancer agent is a JAK Inhibitor. In certain embodiments, the second anti-cancer agent is a JAK Inhibitor comprising ruxolitinib or tofacitinib. [0372] In certain embodiments, the second anti-cancer agent is a mTOR Inhibitor. In certain embodiments, the second anti-cancer agent is a mTOR Inhibitor comprising everolimus or temsirolimus. [0373] In certain embodiments, the second anti-cancer agent is a MEK Inhibitor. In certain embodiments, the second anti-cancer agent is a MEK Inhibitor comprising cobimetinib or trametinib. [0374] In certain embodiments, the second anti-cancer agent is a MELK Inhibitor. In certain embodiments, the second anti-cancer agent is a MELK Inhibitor comprising ARN-7016, APTO- 500, or OTS-167. [0375] In certain embodiments, the second anti-cancer agent is a MTH1 Inhibitor. In certain embodiments, the second anti-cancer agent is a MTH1 Inhibitor comprising (S)-crizotinib, TH287, or TH588. [0376] In certain embodiments, the second anti-cancer agent is a Poly ADP ribose polymerase (PARP) Inhibitor. In certain embodiments, the second anti-cancer agent is a PARP Inhibitor comprising MP-124, olaparib (LYNPARZA®, AstraZeneca), BGB-290 (BeiGene, Inc.), talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin), veliparib (ABT-888, AbbVie), niraparib (ZEJULA®, Tesaro), E7449, rucaparib (RUBRACA®, Clovis Oncology), or ABT-767. [0377] In certain embodiments, the second anti-cancer agent is a Phosphoinositide 3-Kinase (PI3 Kinase) Inhibitor. In certain embodiments, the second anti-cancer agent is a Phosphoinositide 3-Kinase Inhibitor comprising idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941,
Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); or TGR1202 (formerly RP5230, TG Therapeutics). In certain embodiments, the second anti-cancer agent is a Phosphoinositide 3- Kinase Inhibitor comprising idelalisib. In certain embodiments, the second anti-cancer agent is an inhibitor of both PARP1 and DHODH (i.e., an agent that inhibits both poly ADP ribose polymerase 1 and dihydroorotate dehydrogenase). [0378] In certain embodiments, the second anti-cancer agent is a Proteasome Inhibitor. In certain embodiments, the second anti-cancer agent is a Proteasome Inhibitor comprising bortezomib (VELCADE®, Takeda), carfilzomib (KYPROLIS®, Amgen), or ixazomib (NINLARO®, Takeda). In certain embodiments, the second anti-cancer agent is a Proteasome Inhibitor comprising bortezomib or carfilzomib. [0379] In certain embodiments, the second anti-cancer agent is a Topoisomerase-II Inhibitor. In certain embodiments, the second anti-cancer agent is a Topoisomerase-II Inhibitor comprising vosaroxin. [0380] In some embodiments, the second anti-cancer agent is a topoisomerase inhibitor. Approved topoisomerase inhibitors useful in the present invention include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals) and topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (PIXUVRI®, CTI Biopharma). [0381] In certain embodiments, the second anti-cancer agent is a Tyrosine Kinase Inhibitor. In certain embodiments, the second anti-cancer agent is a Tyrosine Kinase Inhibitor comprising bosutinib (BOSULIF®, Pfizer), cabozantinib (COMETRIQ®, Exelexis), imatinib (GLEEVEC®, Novartis), or ponatinib (INCLUSIG®, Ariad Pharmaceuticals). In certain embodiments, the Tyrosine Kinase Inhibitor is an inhibitor of ROS1 and/or NTRK, such as taletrectinib (DS- 6051b, AB-106, AnHeart Therapeutics Co., Ltd.). [0382] In certain embodiments, the second anti-cancer agent is a VEGFR Inhibitor. In certain embodiments, the second anti-cancer agent is a VEGFR Inhibitor comprising regorafenib (STIVARGA®, Bayer). In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor. In certain embodiments, the second anti-cancer agent is a WEE1 Inhibitor comprising AZD1775.
[0383] In some embodiments, the second anti-cancer agent is a compound targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor). [0384] In some embodiments, the second anti-cancer agent is a KRAS inhibitor. In some embodiments, the second anti-cancer agent is a KRAS inhibitor, such as adagrasib (MRTX849, Mirati Therapeutics) or sotorasib (Amgen). In some embodiments, the KRAS inhibitor is a KRAS G12C inhibitor, such as adagrasib (MRTX849, Mirati Therapeutics), sotorasib (AMG510, Amgen), D-1553 (InventisBio Inc.), GDC-6036, or JNJ-74699157/ARS-3248 (Janssen Biotech and Wellspring Biosciences). In some embodiments, the KRAS inhibitor is a KRAS G12D inhibitor, such as MRTX1133 (Mirati Therapeutics), RM-030/031 (Revolution Medicines), STX200 (SyntheX), JAB-22000 (JacoBio). In some embodiments, the KRAS inhibitor is a KRAS G12V inhibitor, such as JAB-23000 (JacoBio). In some embodiments, the KRAS inhibitor is a pan-KRAS inhibitor, such as BI-1701963 (Boehringer Ingelheim). Non-limiting examples of KRAS inhibitors for use as the second anti-cancer agent in the methods and uses described herein include, but are not limited to, those described in WO2020/097537, WO2020/132597, WO2020/035031, WO2020/243103, WO2020/212895, WO2021/041671, WO2021/081212, WO2021/106231, WO2021/107160, WO2021/108683, WO2021/119343, and WO2021/127404, the contents of each of which are herein incorporated by reference in their entireties. [0385] In some embodiments, the second anti-cancer agent is a SOS1 inhibitor, such as BI- 3406. [0386] In certain embodiments, the second anti-cancer agent is an agonist of OX40, CD137, CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS. In certain embodiments, the second anti-
cancer agent is an agonist of OX40, CD137, CD40, or GITR. In certain embodiments, the second anti-cancer agent is an agonist of CD27, HVEM, TNFRSF25, or ICOS. [0387] In certain embodiments, the second anti-cancer agent is a therapeutic antibody. In certain embodiments, the therapeutic antibody targets one of the following: CD20, CD30, CD33, CD52, EpCAM, CEA, gpA33, a mucin, TAG-72, CAIX, PSMA, a folate-binding protein, a ganglioside, Le, VEGF, VEGFR, VEGFR2, integrin αVβ3, integrin α5β1, EGFR, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, tenascin, CD19, KIR, NKG2A, CD47, CEACAM1, c-MET, VISTA, CD73, CD38, BAFF, interleukin-1 beta, B4GALNT1, interleukin-6, and interleukin-6 receptor. [0388] In certain embodiments, the second anti-cancer agent is a therapeutic antibody selected from the group consisting of rituximab, ibritumomab tiuxetan, tositumomab, obinutuzumab, ofatumumab, brentuximab vedotin, gemtuzumab ozogamicin, alemtuzumab, IGN101, adecatumumab, labetuzumab, huA33, pemtumomab, oregovomab, minetumomab, cG250, J591, Mov18, farletuzumab, 3F8, ch14.18, KW-2871, hu3S193, lgN311, bevacizumab, IM-2C6, pazopanib, sorafenib, axitinib, CDP791, lenvatinib, ramucirumab, etaracizumab, volociximab, cetuximab, panitumumab, nimotuzumab, 806, afatinib, erlotinib, gefitinib, osimertinib, vandetanib, trastuzumab, pertuzumab, MM-121, AMG 102, METMAB, SCH 900105, AVE1642, IMC-A12, MK-0646, R1507, CP 751871, KB004, IIIA-4, mapatumumab, HGS-ETR2, CS-1008, denosumab, sibrotuzumab, F19, 81C6, MEDI551, lirilumab, MEDI9447, daratumumab, belimumab, canakinumab, dinutuximab, siltuximab, and tocilizumab. [0389] In certain embodiments, the second anti-cancer agent is a cytokine. In certain embodiments, the cytokine is IL-12, IL-15, GM-CSF, or G-CSF. [0390] In certain embodiments, the second anti-cancer agent is sipuleucel-T, aldesleukin (a human recombinant interleukin-2 product having the chemical name des-alanyl-1, serine-125 human interleukin-2), dabrafenib (a kinase inhibitor having the chemical name N-{3-[5-(2- aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamide), vemurafenib (a kinase inhibitor having the chemical name propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4- difluoro-phenyl}-amide), or 2-chloro-deoxyadenosine.
[0391] In certain embodiments, the second anti-cancer agent is a placental growth factor, an antibody-drug conjugate, an oncolytic virus, or an anti-cancer vaccine. In certain embodiments, the second anti-cancer agent is a placental growth factor. In certain embodiments, the second anti-cancer agent is a placental growth factor comprising ziv-aflibercept. In certain embodiments, the second anti-cancer agent is an antibody-drug conjugate. In certain embodiments, the second anti-cancer agent is an antibody-drug conjugate selected from the group consisting of brentoxumab vedotin and trastuzumab emtransine. [0392] In certain embodiments, the second anti-cancer agent is an oncolytic virus. In certain embodiments, the second anti-cancer agent is the oncolytic virus talimogene laherparepvec. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine. In certain embodiments, the second anti-cancer agent is an anti-cancer vaccine selected from the group consistint of a GM-CSF tumor vaccine, a STING/GM-CSF tumor vaccine, and NY-ESO-1. In certain embodiments, the second anti-cancer agent is a cytokine selected from IL-12, IL-15, GM- CSF, and G-CSF. [0393] In certain embodiments, the second anti-cancer agent is an immune checkpoint inhibitor (also referred to as immune checkpoint blockers). Immune checkpoint inhibitors are a class of therapeutic agents that have the effect of blocking immune checkpoints. See, for example, Pardoll in Nature Reviews Cancer (2012) vol.12, pages 252-264. In certain embodiments, the immune checkpoint inhibitor is an agent that inhibits one or more of (i) cytotoxic T‑lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAB3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3. [0394] In some embodiments, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab. In certain embodiments, the immune checkpoint inhibitor is ipilumumab. In certain embodiments, the immune checkpoint inhibitor is pembrolizumab. In certain embodiments, the immune checkpoint inhibitor is nivolumab. [0395] In certain embodiments, the second anti-cancer agent is a monoclonal antibody that targets a non-checkpoint target (e.g., herceptin). In certain embodiments, the second anti-cancer agent is a non-cytoxic agent (e.g., a tyrosine-kinase inhibitor).
[0396] In certain embodiments, the second anti-cancer agent is selected from mitomycin, ribomustin, vincristine, tretinoin, etoposide, cladribine, gemcitabine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, cytarabine, bicalutamide, vinorelbine, vesnarinone, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, leutinizing hormone releasing factor, interferon-alpha, interferon-2 alpha, interferon-beta, interferon- gamma. [0397] In certain embodiments, the second anti-cancer agent is radiation therapy. [0398] In certain embodiments, the second anti-cancer agent is a MEK Inhibitor. In certain embodiments, the second anti-cancer agent is binimetinib (MEK162, ARRY-438162, ARRAY BIOPHARMA INC.), cobimetinib (COTELLIC®, Exelexis/Genentech/Roche), refametinib (BAY 86–9766, RDEA119; Bayer AG), selumetinib (AZD6244, ARRY-142886; ASTRAZENECA), trametinib (MEKINIST®, Novartis), mirdametinib (PD-0325901, Spring Works Therapeutics), pimasertib (AS703026, MSC1936369B, Merck KGaA) or a pharmaceutically acceptable salt and/or solvate of any of the foregoing. In certain embodiments, the second anti-cancer agent is binimetinib, cobimetinib, selumetinib, trametinib, mirdametinib, pimasertib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing. [0399] In certain embodiments, the second anti-cancer agent is binimetinib, cobimetinib, refametinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing. In certain embodiments, the second anti-cancer agent is binimetinib, cobimetinib, selumetinib, trametinib, or a pharmaceutically acceptable salt and/or solvate of any of the foregoing. [0400] In certain embodiments, the second anti-cancer agent is trametinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti- cancer agent is trametinib or a pharmaceutically acceptable solvate thereof. In certain
embodiments, the second anti-cancer agent is trametinib dimethylsulfoxide. In certain embodiments, the second anti-cancer agent is trametinib. [0401] In certain embodiments, the second anti-cancer agent is binimetinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti- cancer agent is cobimetinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is refametinib or a pharmaceutically acceptable salt and/or solvate thereof. In certain embodiments, the second anti-cancer agent is selumetinib or a pharmaceutically acceptable salt and/or solvate thereof. [0402] In certain embodiments, the second anti-cancer agent is binimetinib. In certain embodiments, the second anti-cancer agent is cobimetinib. In certain embodiments, the second anti-cancer agent is refametinib. In certain embodiments, the second anti-cancer agent is selumetinib. [ In some embodiments, the second anti-cancer agent is selected from:
or a pharmaceutically acceptable salt and/or solvate thereof. [0404] Other examples of MEK inhibitors for use as a second anti-cancer agent in the methods described herein include, but are not limited to, E6201 (Eisai Co Ltd./Strategia Theraputics), GDC-0623 (RG 7421, Genentech, Inc.), CH5126766 (RO5126766, Chugai
Pharmaceutical Co., Roche), HL-085 (Shanghai Kechow Pharma, Inc.), SHR7390 (HENGRUI MEDICINE), TQ-B3234 (CHIATAI TIANQING), CS-3006 (CSTONE Pharmaceuticals), FCN- 159 (Fosun Pharmaceuticals), VS-6766 (Verastem Oncology), and IMM-1-104 (Immuneering Corp.). Other examples of MEK inhibitors for use as second anti-cancer agents in the methods and uses described herein include, but are not limited to, those described in WO2005/121142, WO2014/169843, WO2016/035008, WO2016/168704, WO2020/125747, WO2021/142144, WO2021/142345, WO2021/149776, the contents of each of which are herein incorporated by reference in their entireties. [0405] In some embodiments, the second anti-cancer agent is WX-554. WX-554 is a selective, noncompetitive MEK1/2 inhibitor, which has been tested in dose-escalation phase I/II studies (ClinicalTrials.gov: NCT01859351, NCT01581060). [0406] In some embodiments, the second anti-cancer agent is HL-085 (Shanghai Kechow Pharma, Inc.). HL-085 is an orally active, selective MEK inhibitor, which has been tested in phase I clinical study. [0407] In some embodiments, the second anti-cancer agent is FCN-159 (Fosun Pharmaceuticals). [0408] In some embodiments, the second anti-cancer agent is selected from:
or a pharmaceutically acceptable salt and/or solvate thereof. [0409] In certain embodiments, the second anti-cancer agent is a TEAD inhibitor.
TEAD Inhibitors of Formulae A, and A-1 to A-50 [0410] In certain embodiments, a TEAD inhibitor is selected from those described in WO 2020/243415, the contents of which are herein incorporated by reference in their entirety. [0411] In certain embodiments, a TEAD inhibitor is a compound of Formula A
, pharmaceutically acceptable salt thereof, wherein L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, - OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-; Ring A is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8- 10 membered bicyclic aromatic ring, or a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Ring B is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8- 10 membered bicyclic aromatic ring, a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Rw is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and each R is independently -H or optionally substituted -C1-6 aliphatic.
[0412] In certain embodiments, a TEAD inhibitor is a compound of Formula A-1:
, pharmaceutically acceptable salt thereof, wherein L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, - OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-; Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A is optionally substituted 1-2 times by -halogen, -CN, –NO2, or -C1-6 aliphatic substituted 0-6 times by - halogen, -CN, or –NO2; R2 is -H, or an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R3 is -H; R4 is -H, halogen, -S(O)2N(R)2, -S(O)N(R)2, or -C(O)N(R)2; R6 is -H or -C1-6 aliphatic substituted 0-6 times by -halogen, -CN, or –NO2; and each R is independently -H or optionally substituted -C1-6 aliphatic. [0413] As defined generally above, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, - (R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, - (R)NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-. [0414] In some embodiments, L1 is a covalent bond, or a C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, - N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -
SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or - (R)NC(S)N(R)-. [0415] In some embodiments, L1 is a covalent bond. [0416] In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -CH(OR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, or -N(R)C(O)N(R)-. In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are optionally replaced with -CH(SR)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, - OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-. In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, or -N(R)-. In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -CH(OR)-, -CH(SR)-, or –CH(N(R)2)-. In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -C(O)-, -C(O)O-, - OC(O)-, -SO-, -SO2-, -C(S)-, -C(S)O-, or -OC(S)-. [0417] In some embodiments, L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -SO2N(R)-, -(R)NSO2-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-. In some embodiments, L1 is -O-, -CH(OR)-, - CH(SR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, - C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-. In some embodiments, L1 is -O- , -CH(OR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, - OC(O)N(R)-, -(R)NC(O)O-, or -N(R)C(O)N(R)-. In some embodiments, L1 is -CH(SR)-, -S-, - SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or - (R)NC(S)N(R)-. [0418] In some embodiments, L1 is -O-, -S-, or -N(R)-. In some embodiments, L1 is -O-. In some embodiments, L1 is -S-. In some embodiments, L1 is -N(R)-. In some embodiments, L1 is - NH-. In some embodiments, L1 is -CH(OR)-, -CH(SR)-, or –CH(N(R)2)-. In some embodiments,
L1 is -CH(OR)-. In some embodiments, L1 is -CH(SR)-. In some embodiments, L1 is – CH(N(R)2)-. [0419] In some embodiments, L1 is -C(O)-, -C(O)O-, -OC(O)-, -SO-, -SO2-, -C(S)-, -C(S)O-, or -OC(S)-. In some embodiments, L1 is -C(O)-. In some embodiments, L1 is -C(O)O-. In some embodiments, L1 is -OC(O)-. In some embodiments, L1 is -SO-. In some embodiments, L1 is - SO2-. In some embodiments, L1 is -C(S)-. In some embodiments, L1 is -C(S)O-. In some embodiments, L1 is -OC(S)-. [0420] In some embodiments, L1 is -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, - N(R)C(O)N(R)-, -SO2N(R)-, -(R)NSO2-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-. In some embodiments, L1 is -C(O)N(R)-. In some embodiments, L1 is -(R)NC(O)-. In some embodiments, L1 is -OC(O)N(R)-. In some embodiments, L1 is -(R)NC(O)O-. In some embodiments, L1 is -N(R)C(O)N(R)-. In some embodiments, L1 is -SO2N(R)-. In some embodiments, L1 is -(R)NSO2-. In some embodiments, L1 is -C(S)N(R)-. In some embodiments, L1 is -(R)NC(S)-. or In some embodiments, L1 is -(R)NC(S)N(R)-. [0421] In some embodiments, L1 is –CH2-, -CH(CH3)-, -NH-CH2-, -NH-CH(CH3)-, -C(O)- NH-, or –N(CH3)-. In some embodiments, L1 is ,
[0422] In some embodiments, L1 is selected from those depicted in Table A, below. [0423] As defined generally above, Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A is optionally substituted 1-2 times by halogen, -CN, –NO2, or -C1-6 aliphatic substituted 0-6 times by halogen, -CN, or –NO2. [0424] In some embodiments, Ring A is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8-10 membered bicyclic aromatic ring, or a 8-10 membered
bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0425] In some embodiments, Ring A is optionally substituted phenyl. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0426] In some embodiments, Ring A is optionally substituted phenyl, a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen, or a 10-membered bicyclic heteroaromatic ring having 1-2 nitrogen. [0427] In some embodiments, Ring A is optionally substituted , ,
[0428] In some embodiments, Ring A is optionally substituted 1-2 times by -halogen, -CN, – NO2, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O-C1-6 aliphatic is independently substituted 0-6 times by -halogen, -CN, or –NO2. In some embodiments, Ring A is optionally substituted 1-2 times by halogen, -CN, –NO2, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O-C1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen, -CN, or –NO2. In some embodiments, Ring A is optionally substituted 1- 2 times by halogen, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O- C1-6 aliphatic is independently substituted 1, 2, 3, 4, 5, or 6 times by halogen. [0429] In some embodiments, Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is cyclohexyl. In some embodiments, Ring A is phenyl. In some embodiments, Ring A is a 4-, 5-, or 6- membered
saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0430] In some embodiments, Ring A is a 8-10 membered bicyclic aromatic ring. In some embodiments, Ring A is a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0431] In some embodiments, Ring A is optionally substituted 1-2 times by halogen, -CN, – NO2, or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen, -CN, or –NO2. In some embodiments, Ring A is optionally substituted 1-2 times by halogen, or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen. [0432] In some embodiments, Ring A is selected from
wherein each of R1 and R7 is independently as described herein. In some embodiments, Ring A is
[0433] In some embodiments, R1 is -H, -halogen, -CN, –NO2, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O-C1-6 aliphatic is substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R1 is unsubstituted –O-C1-6 aliphatic. In some embodiments, R1 is –OCH3. In some embodiments, R1 is –O-C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R1 is –O-C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R1 is –O-C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R1 is –OCF3. In some embodiments, R1 is
[0434] In some embodiments, R1 is -H, -halogen, -CN, –NO2, or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R1 is –H. In some embodiments, R1 is –halogen. In some embodiments, R1 is –F. In some embodiments, R1 is –Cl. In some embodiments, R1 is –Br. In some embodiments, R1 is –CN. In some embodiments, R1 is –NO2. In some embodiments, R1 is unsubstituted -C1-6 aliphatic. In some embodiments, R1 is –
CH3. In some embodiments, R1 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R1 is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R1 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R1 is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R1 is –CF3. In some embodiments, R1 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –CN. In some embodiments, R1 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –NO2. [0435] In some embodiments, R7 is -H, -halogen, -CN, –NO2, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O-C1-6 aliphatic is substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R7 is unsubstituted –O-C1-6 aliphatic. In some embodiments, R7 is –OCH3. In some embodiments, R7 is –O-C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R7 is –O-C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R7 is –O-C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R7 is –OCF3. In some embodiments, R7 is . [0436] In some embodiments, R7 is -H, -halogen, -CN, –NO2, or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R7 is –H. In some embodiments, R7 is –halogen. In some embodiments, R7 is –F. In some embodiments, R7 is –Cl. In some embodiments, R7 is –Br. In some embodiments, R7 is –CN. In some embodiments, R7 is –NO2. In some embodiments, R7 is unsubstituted -C1-6 aliphatic. In some embodiments, R1 is – CH3. In some embodiments, R7 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R7 is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –halogen. In some embodiments, R7 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R7 is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R7 is –CF3. In some embodiments, R7 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –CN. In some embodiments, R7 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –NO2. [0437] In some embodiments, Ring A is ,
[0438] In some embodiments, Ring A is selected from those depicted in Table A, below. [0439] As defined generally above, Ring B is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8-10 membered bicyclic aromatic ring, a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0440] In some embodiments, Ring B is optionally substituted phenyl. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments,
Ring B is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0441] In some embodiments, Ring B is optionally substituted phenyl or a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen.
[0443] In some embodiments, Ring B is optionally substituted 1-4 times by halogen, - S(O)2N(R)2, -S(O)N(R)2, -C(O)N(R)2, -C(O)OR, -C1-6 aliphatic, or –O-C1-6 aliphatic, wherein each of -C1-6 aliphatic and –O-C1-6 aliphatic is independently substituted 0-6 times by halogen, - CN, or –NO2. In some embodiments, Ring B is optionally substituted 1-4 times by –F, -Cl, -Br-, -S(O)2NHCH3, -S(O)NHCH3, -C(O)N(CH3)2, -C(O)NHCH3, -C(O)OH, -C(O)OCH3, -CH3, – OCH3, or -C(CH3)3.
[0445] In some embodiments, Ring B is selected from those depicted in Table A, below. [0446] As defined generally above, R2 is -H, or an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0447] In some embodiments, R2 is –H. [0448] In some embodiments, R2 is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R2 is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C1-6 alkyl. [0449] In some embodiments, R2 is , w described herein. In some
embodiments, R2 is R is as described herein.
[0450] In some embodiments, R2 is . ments, R2 is ,
[0451] In some embodiments, R2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen. In some embodiments, R2 is selected from , ,
n some embodiments, R2 is or ments, R2 is
[0452] In some embodiments, R2 is selected from those depicted in Table A, below. [0453] As defined generally above, in some embodiments, R3 is –H. [0454] In some embodiments, R3 is
iments, R3 is , ,
[0455] In some embodiments, R3 is selected from those depicted in Table A, below. [0456] As defined generally above, R4 is -H, halogen, -S(O)2N(R)2, -S(O)N(R)2, or - C(O)N(R)2. [0457] In some embodiments, R4 is -H, halogen, -S(O)2N(R)2, -S(O)N(R)2, -C(O)N(R)2, or - C(O)OR. In some embodiments, R4 is –H. In some embodiments, R4 is halogen. In some embodiments, R4 is -F. In some embodiments, R4 is -Cl. In some embodiments, R4 is -Br. [0458] In some embodiments, R4 is -S(O)2N(R)2, -S(O)N(R)2, or -C(O)N(R)2. In some embodiments, R4 is -S(O)2N(R)2. In some embodiments, R4 is -S(O)N(R)2. In some embodiments, R4 is -C(O)N(R)2. In some embodiments, R4 is -S(O)2NHCH3. In some embodiments, R4 is -S(O)NHCH3, -C(O)N(CH3)2, -C(O)NHCH3, -C(O)OH, or -C(O)OCH3. [0459] In some embodiments, R4 is . diments, R4 is , ,
[0460] In some embodiments, R4 is selected from those depicted in Table A, below. [0461] As defined generally above, R6 is -H or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2.
[0462] In some embodiments, R6 is –H, -halogen, -CN, –NO2, -C1-6 aliphatic, -OC1-6 aliphatic, or a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally substituted 1-3 times by -C1-6 aliphatic or -OC1-6 aliphatic, wherein each of -C1-6 aliphatic and -OC1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. [0463] In some embodiments, R6 is –H. In some embodiments, R6 is –F. In some embodiments, R6 is –Cl. In some embodiments, R6 is –Br. In some embodiments, R6 is –CN. In some embodiments, R6 is –NO2. [0464] In some embodiments, R6 is -C1-6 aliphatic, substituted 0, 1, 2, 3, 4, 5, or 6 times by - halogen, -CN, or –NO2. In some embodiments, R6 is unsubstituted -C1-6 aliphatic. In some embodiments, R6 is –CH3. In some embodiments, R6 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R6 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -F. In some embodiments, R6 is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R6 is –CF3. [0465] In some embodiments, R6 is -OC1-6 aliphatic, substituted 0, 1, 2, 3, 4, 5, or 6 times by - halogen, -CN, or –NO2. In some embodiments, R6 is unsubstituted -OC1-6 aliphatic. In some embodiments, R6 is –OCH3. In some embodiments, R6 is -OC1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R6 is -OC1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -F. In some embodiments, R6 is -OC1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R6 is –OCF3. [0466] In some embodiments, R6 is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally substituted 1-3 times by -C1-6 aliphatic or -OC1-6 aliphatic, wherein each of -C1-6 aliphatic and -OC1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R6 is a 5-membered ring having 1, 2, 3, or 4 nitrogen optionally substituted 1-3 times by -C1-6 aliphatic. In some embodiments, R6 is .
[0467] In some embodiments, R6 is selected from those depicted in Table A, below. [0468] As defined generally above, Rw is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0469] In some embodiments, Rw is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Rw is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C1-6 alkyl. [0470] In some embodiments, Rw is , described herein. In some
embodiments, Rw is is as described herein.
[0471] In some embodiments, Rw is a 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-3 times by -C1-6 alkyl. In some embodiments, Rw is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen. In some embodiments, Rw is ,
[0472] In some embodiments, Rw is [0473] In some embodiments, Rw is
[0474] In some embodiments, Rw is selected from those depicted in Table A, below. [0475] As defined generally above, R is independently -H or optionally substituted -C1-6 aliphatic. [0476] In some embodiments, R is –H. In some embodiments, R is optionally substituted -C1- 6 aliphatic. In some embodiments, R is unsubstituted -C1-6 aliphatic. In some embodiments, R is
–CH3. In some embodiments, R is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by – F. In some embodiments, R is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F. In some embodiments, R is –CF3. [0477] In some embodiments, R is selected from those depicted in Table A, below. [0478] In some embodiments, a TEAD inhibitor is a compound of Formula A-2:
, harmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, R6, R7, and L1 is independently as defined and described in embodiments in Section of TEAD Inhibitors of Formulae A, and A-1 to A-50. [0479] In some embodiments, the present invention provides a compound of Formula A-2, or a pharmaceutically acceptable salt thereof, wherein: (a): L1 is -O- or -S-; R1 is -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen; R2 is an optionally substituted 5-membered aromatic ring having 1, 2, 3, or 4 nitrogen; R3 is -H; R4 is -S(O)2N(R)2; -S(O)N(R)2, or -C(O)N(R)2, each R independently is selected -H and optionally substituted -C1-6 aliphatic; R6 is -H or -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by halogen; and R7 is -H; or (b): L1 is -NH-; R1 is -C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen; R2 is an optionally substituted 5-membered aromatic ring having 1, 2, 3, or 4 nitrogen; R3 is -H; R4 is -S(O)2N(R)2, -S(O)N(R)2, or -C(O)N(R)2, each R independently is selected from -H and optionally substituted -C1-6 aliphatic;
R6 is -C1-6 aliphatic; and R7 is -H. [0480] In some embodiments, a TEAD inhibitor is a compound of Formula:
A-18 or a pharmaceutically acceptable salt thereof, wherein each of X is independently C or N, and each of Ring A, Rw, R1, R2, R3, R4, R6, R7, and L1 is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50.
[0481] In some embodiments, a TEAD inhibitor is a compound of Formula A, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl, a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen, or a 10-membered bicyclic heteroaromatic ring having 1-2 nitrogen; Ring B is phenyl or a 6-membered monocyclic heteroaromatic ring having 1 or 2 nitrogen; and each of Rw and L1 is as defined above and described in embodiments herein, both singly and in combination. [0482] In some embodiments, a TEAD inhibitor is a compound selected from the following: i. Formula (A-19) or (A-20):
A-19 A-20 wherein L1 is a C2-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-, and each of R2, R4, R6, and R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; ii. Formula (A-21) or (A-22):
wherein L1 is a C2-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-, and each of R2, R6, and R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; iii. Formula (A-23) or (A-24):
wherein L1 is a C2-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, each of R2 and R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; iv. Formula (A-25) or (A-26):
wherein L1 is a C2-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, R is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; v. Formula (A-27) or (A-28):
A-27 A-28 wherein L1 is a C2-6 bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, R is optionally substituted -C1-6 aliphatic, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; vi. Formula (A-29) or (A-30):
A-29 A-30 wherein L1 is a C2-6 bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; vii. Formula (A-31) or (A-32):
wherein R2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen; viii. Formula (A-33) or (A-34):
(A-33) (A-34) wherein R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; ix. Formula (A-35) or (A-36): A- 1
wherein L is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-, and each of R2, R4, R6, and R is independently
as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; x. Formula (A-37) or (A-38):
wherein L1 is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-, and each of R2, R6, and R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; xi. Formula (A-39) or (A-40):
wherein L1 is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, each of R2 and R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; xii. Formula (A-41) or (A-42):
wherein L1 is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, R is -C1-3 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50;
xiii. Formula (A-43) or (A-44):
wherein L1 is a C1-6 bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, R is optionally substituted -C1-6 aliphatic, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; xiv. Formula (A-45) or (A-46):
wherein L1 is a C1-6 bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, and R2 is as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50; xv. Formula (A-47) or (A-48):
wherein R2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen; or xvi. Formula (A-49) or (A-50):
wherein R is independently as defined and described in embodiments in the section of TEAD Inhibitors of Formulae A, and A-1 to A-50.
[0483] In some embodiments, a TEAD inhibitor is selected from those listed in Table A, or a pharmaceutically acceptable salt thereof. Table A. Exemplary TEAD Inhibitors
[0484] In certain embodiments, a TEAD inhibitor is T-A-31, T-A-32, T-A-56, T-A- 57, T-A- 60, T-A-63, T-A-68, T-A-74, T-A-83, T-A-94, T-A-96, or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-31 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-32 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-56 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A- 57 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A- 60 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T- A-63 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-68 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-74 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-83 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-94 or a pharmaceutically acceptable salt thereof. In certain embodiments, a TEAD inhibitor is T-A-96 or a pharmaceutically acceptable salt thereof. [0485] In certain embodiments, a TEAD inhibitor is T-A-31, T-A-32, T-A-56, T-A- 57, T-A- 60, T-A-63, T-A-68, T-A-74, T-A-83, T-A-94, or T-A-96. In certain embodiments, a TEAD inhibitor is T-A-31. In certain embodiments, a TEAD inhibitor is T-A-32. In certain embodiments, a TEAD inhibitor is T-A-56. In certain embodiments, a TEAD inhibitor is T-A- 57. In certain embodiments, a TEAD inhibitor is T-A-60. In certain embodiments, a TEAD inhibitor is T-A-63. In certain embodiments, a TEAD inhibitor is T-A-68. In certain
embodiments, a TEAD inhibitor is T-A-74. In certain embodiments, a TEAD inhibitor is T-A- 83. In certain embodiments, a TEAD inhibitor is T-A-94. In certain embodiments, a TEAD inhibitor is T-A-96. TEAD Inhibitors of Formulae B and B-1 [0486] In certain embodiments, a TEAD inhibitor is selected from those described in WO 2020/243423, the contents of which are herein incorporated by reference in their entirety. [0487] In certain embodiments, a TEAD inhibitor is a compound of Formula B:
, pharmaceutically acceptable salt thereof, wherein L1 is a covalent bond, or a C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, - CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, - (R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, - (R)NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-; Ring A is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8- 10 membered bicyclic aromatic ring, or a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Ring B is an optionally substituted ring selected from phenyl, a 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 8- 10 membered bicyclic aromatic ring, a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Rw is a warhead group; wherein when Rw is a saturated or partially unsaturated monocyclic carbocyclic or heterocyclic ring, it optionally forms a spiro bicyclic ring with Ring B; and each R is independently -H or optionally substituted -C1-6 aliphatic.
[0488] In certain embodiments, a TEAD inhibitor is a compound of formula B-1
eutically acceptable salt thereof, wherein L1 is C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, - (R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, - OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-; Ring A is a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A is optionally substituted 1-2 times by halogen, -CN, –NO2, or -C1-6 aliphatic substituted 0-6 times by halogen, -CN, or –NO2; R2 is -H, or a warhead group; R3 is -H or a warhead group; R4 is -H, halogen, -S(O)2N(R)2, -S(O)N(R)2, -C(O)N(R)2, or a warhead group; R6 is -H or -C1-6 aliphatic substituted 0-6 times by halogen, -CN, or –NO2; and each R is independently -H or optionally substituted -C1-6 aliphatic. [0489] In some embodiments, L1 is -O-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(O)-, - C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, - N(R)C(O)N(R)-, -S-, -SO-, -SO2-, -SO2N(R)-, -(R)NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)- , -(R)NC(S)-, or -(R)NC(S)N(R)-. In some embodiments, L1 is -O-, -S-, or -N(R)-. In some embodiments, L1 is -O-. In some embodiments, L1 is -S-. In some embodiments, L1 is -N(R)-. In some embodiments, L1 is -NH-. In some embodiments, L1 is selected from those depicted in Table B, below. [0490] In some embodiments, Ring A is optionally substituted phenyl. In some embodiments, Ring A is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is optionally
substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments, Ring A is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0491] In some embodiments, Ring A is ,
, ,
[0493] In some embodiments, Ring A is selected from those depicted in Table B, below.
[0494] In some embodiments, Ring B is optionally substituted phenyl. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6-membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring B is optionally substituted 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic aromatic ring. In some embodiments, Ring B is optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0496] In some embodiments, Ring B is selected from those depicted in Table B, below.
[0497] In some embodiments, R2 is –H. In some embodiments, R2 is a warhead group. In some embodiments, R2 is
[0498] In some embodiments, R2 is selected from those depicted in Table B, below. [0499] In some embodiments, R3 is –H. In some embodiments, R3 is a warhead group. In some embodiments, R3 is ,
[0500] In some embodiments, R3 is selected from those depicted in Table B, below. [0501] In some embodiments, R4 is –H. In some embodiments, R4 is halogen. In some embodiments, R4 is -F. In some embodiments, R4 is -Cl. In some embodiments, R4 is -Br. In some embodiments, R4 is -S(O)2N(R)2. In some embodiments, R4 is -S(O)N(R)2. In some embodiments, R4 is -C(O)N(R)2. In some embodiments, R4 is -S(O)2NHCH3.
[0502] In some embodiments, R4 is a warhead group. In some embodiments, R4 is ,
[0503] In some embodiments, R4 is selected from those depicted in Table B, below. [0504] In some embodiments, R6 is -H. In some embodiments, R6 is -C1-6 aliphatic substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, -CN, or –NO2. In some embodiments, R6 is selected from those depicted in Table B, below.
iments, Rw is selected from
those depicted in Table B, below. [0506] In some embodiments, R is –H. In some embodiments, R is optionally substituted -C1- 6 aliphatic. In some embodiments, R is unsubstituted -C1-6 aliphatic. In some embodiments, R is –CF3. In some embodiments, R is –CH3, –C(CH3)3, –CHF2, cyclopropyl, –CF2CF3, or .
[0507] A “warhead group,” as used herein, is capable of covalently binding to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified) present in the binding pocket of a target protein, for example, TEAD, thereby irreversibly inhibiting the protein. In some embodiments, a warhead group is as defined and described in embodiments in WO 2020/243423, the content of which is herein incorporated by reference in its entirety. [0508] In some embodiments, a TEAD inhibitor is selected from those listed in Table B, or a pharmaceutically acceptable salt thereof. Table B. Exemplary TEAD Inhibitors
Additional Second Anti-Cancer Agents [0509] In some embodiments, the second anti-cancer agent is a Poly ADP ribose polymerase (PARP) inhibitor. In some embodiments, a PARP inhibitor is selected from olaparib (LYNPARZA®, AstraZeneca); rucaparib (RUBRACA®, Clovis Oncology); niraparib (ZEJULA®, Tesaro); talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin); veliparib (ABT-888, AbbVie); and BGB-290 (BeiGene, Inc.). [0510] In some embodiments, the second anti-cancer agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, an HDAC inhibitor is selected from vorinostat (ZOLINZA®, Merck); romidepsin (ISTODAX®, Celgene); panobinostat (FARYDAK®, Novartis); belinostat (BELEODAQ®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (EPIDAZA®, HBI-8000, Chipscreen Biosciences, China). [0511] In some embodiments, the second anti-cancer agent is a CDK inhibitor, such as a CDK4/CDK6 inhibitor. In some embodiments, a CDK 4/6 inhibitor is selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics). [0512] In some embodiments, the second anti-cancer agent is a phosphatidylinositol 3 kinase (PI3K) inhibitor. In some embodiments, a PI3K inhibitor is selected from idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics).
[0513] In some embodiments, the second anti-cancer agent is a platinum-based therapeutic, also referred to as platins. Platins cause cross-linking of DNA, such that they inhibit DNA repair and/or DNA synthesis, mostly in rapidly reproducing cells, such as cancer cells. In some embodiments, a platinum-based therapeutic is selected from cisplatin (PLATINOL®, Bristol Myers Squibb); carboplatin (PARAPLATIN®, Bristol Myers Squibb; also, Teva; Pfizer); oxaliplatin (ELOXITIN® Sanofi-Aventis); nedaplatin (AQUPLA®, Shionogi), picoplatin (Poniard Pharmaceuticals); and satraplatin (JM-216, Agennix). [0514] In some embodiments, the second anti-cancer agent is a taxane compound, which causes disruption of microtubules, which are essential for cell division. In some embodiments, a taxane compound is selected from paclitaxel (TAXOL®, Bristol Myers Squibb), docetaxel (TAXOTERE®, Sanofi-Aventis; DOCEFREZ®, Sun Pharmaceutical), albumin-bound paclitaxel (ABRAXANE®; Abraxis/Celgene), cabazitaxel (JEVTANA®, Sanofi-Aventis), and SID530 (SK Chemicals, Co.) (NCT00931008). [0515] In some embodiments, the second anti-cancer agent is a nucleoside inhibitor, or a therapeutic agent that interferes with normal DNA synthesis, protein synthesis, cell replication, or will otherwise inhibit rapidly proliferating cells. [0516] In some embodiments, a nucleoside inhibitor is selected from trabectedin (guanidine alkylating agent, YONDELIS®, Janssen Oncology), mechlorethamine (alkylating agent, VALCHLOR®, Aktelion Pharmaceuticals); vincristine (ONCOVIN®, Eli Lilly; VINCASAR®, Teva Pharmaceuticals; MARQIBO®, Talon Therapeutics); temozolomide (prodrug to alkylating agent 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC) TEMODAR®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analog, Pfizer); lomustine (alkylating agent, CEENU®, Bristol Myers Squibb; GLEOSTINE®, NextSource Biotechnology); azacitidine (pyrimidine nucleoside analog of cytidine, VIDAZA®, Celgene); omacetaxine mepesuccinate (cephalotaxine ester) (protein synthesis inhibitor, SYNRIBO®; Teva Pharmaceuticals); asparaginase Erwinia chrysanthemi (enzyme for depletion of asparagine, ELSPAR®, Lundbeck; ERWINAZE®, EUSA Pharma); eribulin mesylate (microtubule inhibitor, tubulin-based antimitotic, HALAVEN®, Eisai); cabazitaxel (microtubule inhibitor, tubulin-based antimitotic, JEVTANA®, Sanofi-Aventis); capacetrine (thymidylate synthase inhibitor, XELODA®, Genentech); bendamustine (bifunctional mechlorethamine derivative, believed to form interstrand DNA cross-links, TREANDA®, Cephalon/Teva); ixabepilone (semi-synthetic analog
of epothilone B, microtubule inhibitor, tubulin-based antimitotic, IXEMPRA®, Bristol Myers Squibb); nelarabine (prodrug of deoxyguanosine analog, nucleoside metabolic inhibitor, ARRANON®, Novartis); clorafabine (prodrug of ribonucleotide reductase inhibitor, competitive inhibitor of deoxycytidine, CLOLAR®, Sanofi-Aventis); and trifluridine and tipiracil (thymidine-based nucleoside analog and thymidine phosphorylase inhibitor, LONSURF®, Taiho Oncology). [0517] In some embodiments, the second anti-cancer agent is a kinase inhibitor or VEGF-R antagonist. Approved VEGF inhibitors and kinase inhibitors useful in the present invention include: bevacizumab (AVASTIN®, Genentech/Roche) an anti-VEGF monoclonal antibody; ramucirumab (CYRAMZA®, Eli Lilly), an anti-VEGFR-2 antibody and ziv-aflibercept, also known as VEGF Trap (ZALTRAP®; Regeneron/Sanofi). VEGFR inhibitors, such as regorafenib (STIVARGA®, Bayer); vandetanib (CAPRELSA®, AstraZeneca); axitinib (INLYTA®, Pfizer); and lenvatinib (LENVIMA®, Eisai); Raf inhibitors, such as sorafenib (NEXAVAR®, Bayer AG and Onyx); dabrafenib (TAFINLAR®, Novartis); and vemurafenib (ZELBORAF®, Genentech/Roche); MEK inhibitors, such as cobimetanib (COTELLIC®, Exelexis/Genentech/Roche); trametinib (MEKINIST®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (SPRYCEL®, Bristol Myers Squibb); bosutinib (BOSULIF®, Pfizer); and ponatinib (INCLUSIG®, Ariad Pharmaceuticals); Her2 and EGFR inhibitors, such as gefitinib (IRESSA®, AstraZeneca); erlotinib (TARCEEVA®, Genentech/Roche/Astellas); lapatinib (TYKERB®, Novartis); afatinib (GILOTRIF®, Boehringer Ingelheim); osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca); and brigatinib (ALUNBRIG®, Ariad Pharmaceuticals); c- Met and VEGFR2 inhibitors, such as cabozanitib (COMETRIQ®, Exelexis); and multikinase inhibitors, such as sunitinib (SUTENT®, Pfizer); pazopanib (VOTRIENT®, Novartis); ALK inhibitors, such as crizotinib (XALKORI®, Pfizer); ceritinib (ZYKADIA®, Novartis); and alectinib (ALECENZa®, Genentech/Roche); Bruton’s tyrosine kinase inhibitors, such as ibrutinib (IMBRUVICA®, Pharmacyclics/Janssen); and Flt3 receptor inhibitors, such as midostaurin (RYDAPT®, Novartis). [0518] Other kinase inhibitors and VEGF-R antagonists that are in development and may be used in the present invention include tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer/Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib
(Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (SUPECT®, IY5511, Il-Yang Pharmaceuticals, S. Korea); ruxolitinib (JAKAFI®, Incyte Corporation); PTC299 (PTC Therapeutics); CP-547,632 (Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo) and motesanib (Amgen/Takeda). [0519] In some embodiments, the second anti-cancer agent is an mTOR inhibitor, which inhibits cell proliferation, angiogenesis and glucose uptake. In some embodiments, an mTOR inhibitor is everolimus (AFINITOR®, Novartis); temsirolimus (TORISEL®, Pfizer); and sirolimus (RAPAMUNE®, Pfizer). [0520] In some embodiments, the second anti-cancer agent is a proteasome inhibitor. Approved proteasome inhibitors useful in the present invention include bortezomib (VELCADE®, Takeda); carfilzomib (KYPROLIS®, Amgen); and ixazomib (NINLARO®, Takeda). [0521] In some embodiments, the second anti-cancer agent is a growth factor antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or epidermal growth factor (EGF) or its receptor (EGFR). Approved PDGF antagonists which may be used in the present invention include olaratumab (LARTRUVO®; Eli Lilly). Approved EGFR antagonists which may be used in the present invention include cetuximab (ERBITUX®, Eli Lilly); necitumumab (PORTRAZZA®, Eli Lilly), panitumumab (VECTIBIX®, Amgen); and osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca). [0522] In some embodiments, the second anti-cancer agent is an aromatase inhibitor. In some embodiments, an aromatase inhibitor is selected from exemestane (AROMASIN®, Pfizer); anastazole (ARIMIDEX®, AstraZeneca) and letrozole (FEMARA®, Novartis). [0523] In some embodiments, the second anti-cancer agent is an antagonist of the hedgehog pathway. Approved hedgehog pathway inhibitors which may be used in the present invention include sonidegib (ODOMZO®, Sun Pharmaceuticals); and vismodegib (ERIVEDGE®, Genentech), both for treatment of basal cell carcinoma. [0524] In some embodiments, the second anti-cancer agent is a folic acid inhibitor. Approved folic acid inhibitors useful in the present invention include pemetrexed (ALIMTA®, Eli Lilly).
[0525] In some embodiments, the second anti-cancer agent is a CC chemokine receptor 4 (CCR4) inhibitor. CCR4 inhibitors being studied that may be useful in the present invention include mogamulizumab (POTELIGEO®, Kyowa Hakko Kirin, Japan). [0526] In some embodiments, the second anti-cancer agent is an isocitrate dehydrogenase (IDH) inhibitor. IDH inhibitors being studied which may be used in the present invention include AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081); IDH305 (Novartis, NCT02987010). [0527] In some embodiments, the second anti-cancer agent is an arginase inhibitor. Arginase inhibitors being studied which may be used in the present invention include AEB1102 (pegylated recombinant arginase, Aeglea Biotherapeutics), which is being studied in Phase 1 clinical trials for acute myeloid leukemia and myelodysplastic syndrome (NCT02732184) and solid tumors (NCT02561234); and CB-1158 (Calithera Biosciences). [0528] In some embodiments, the second anti-cancer agent is a glutaminase inhibitor. Glutaminase inhibitors being studied which may be used in the present invention include CB-839 (Calithera Biosciences). [0529] In some embodiments, the second anti-cancer agent is an antibody that binds to tumor antigens, that is, proteins expressed on the cell surface of tumor cells. Approved antibodies that bind to tumor antigens which may be used in the present invention include rituximab (RITUXAN®, Genentech/BiogenIdec); ofatumumab (anti-CD20, ARZERRA®, GlaxoSmithKline); obinutuzumab (anti-CD20, GAZYVA®, Genentech), ibritumomab (anti- CD20 and Yttrium-90, ZEVALIN®, Spectrum Pharmaceuticals); daratumumab (anti-CD38, DARZALEX®, Janssen Biotech), dinutuximab (anti-glycolipid GD2, UNITUXIN®, United Therapeutics); trastuzumab (anti-HER2, HERCEPTIN®, Genentech); ado-trastuzumab emtansine (anti-HER2, fused to emtansine, KADCYLA®, Genentech); and pertuzumab (anti- HER2, PERJETA®, Genentech); and brentuximab vedotin (anti-CD30-drug conjugate, ADCETRIS®, Seattle Genetics). [0530] In some embodiments, the second anti-cancer agent is a topoisomerase inhibitor. Approved topoisomerase inhibitors useful in the present invention include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals); topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (PIXUVRI®, CTI Biopharma).
[0531] In some embodiments, the second anti-cancer agent is an inhibitor of anti-apoptotic proteins, such as BCL-2. Approved anti-apoptotics which may be used in the present invention include venetoclax (VENCLEXTA®, AbbVie/Genentech); and blinatumomab (BLINCYTO®, Amgen). Other therapeutic agents targeting apoptotic proteins which have undergone clinical testing and may be used in the present invention include navitoclax (ABT-263, Abbott), a BCL-2 inhibitor (NCT02079740). [0532] In some embodiments, the second anti-cancer agent is an androgen receptor inhibitor. Approved androgen receptor inhibitors useful in the present invention include enzalutamide (XTANDI®, Astellas/Medivation); approved inhibitors of androgen synthesis include abiraterone (ZYTIGA®, Centocor/Ortho); approved antagonist of gonadotropin-releasing hormone (GnRH) receptor (degaralix, FIRMAGON®, Ferring Pharmaceuticals). [0533] In some embodiments, the second anti-cancer agent is a selective estrogen receptor modulator (SERM), which interferes with the synthesis or activity of estrogens. Approved SERMs useful in the present invention include raloxifene (EVISTA®, Eli Lilly). [0534] In some embodiments, the second anti-cancer agent is an inhibitor of bone resorption. An approved therapeutic which inhibits bone resorption is Denosumab (XGEVA®, Amgen), an antibody that binds to RANKL, prevents binding to its receptor RANK, found on the surface of osteoclasts, their precursors, and osteoclast-like giant cells, which mediates bone pathology in solid tumors with osseous metastases. Other approved therapeutics that inhibit bone resorption include bisphosphonates, such as zoledronic acid (ZOMETA®, Novartis). [0535] In some embodiments, the second anti-cancer agent is an inhibitor of interaction between the two primary p53 suppressor proteins, MDMX and MDM2. Inhibitors of p53 suppression proteins being studied which may be used in the present invention include ALRN- 6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being evaluated in clinical trials for the treatment of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL) (NCT02909972; NCT02264613). [0536] In some embodiments, the second anti-cancer agent is an inhibitor of transforming growth factor-beta (TGF-beta or TGFß). Inhibitors of TGF-beta proteins being studied which may be used in the present invention include NIS793 (Novartis), an anti-TGF-beta antibody being tested in the clinic for treatment of various cancers, including breast, lung, hepatocellular,
colorectal, pancreatic, prostate and renal cancer (NCT 02947165). In some embodiments, the inhibitor of TGF-beta proteins is fresolimumab (GC1008; Sanofi-Genzyme), which is being studied for melanoma (NCT00923169); renal cell carcinoma (NCT00356460); and non-small cell lung cancer (NCT02581787). Additionally, in some embodiments, the additional therapeutic agent is a TGF-beta trap, such as described in Connolly et al. (2012) Int’l J. Biological Sciences 8:964-978. One therapeutic compound currently in clinical trials for treatment of solid tumors is M7824 (Merck KgaA - formerly MSB0011459X), which is a bispecific, anti-PD-L1/TGF-β trap compound (NCT02699515); and (NCT02517398). M7824 is comprised of a fully human IgG1 antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II, which functions as a TGF-β“trap.” [0537] In some embodiments, the second anti-cancer agent is selected from glembatumumab vedotin-monomethyl auristatin E (MMAE) (Celldex), an anti-glycoprotein NMB (gpNMB) antibody (CR011) linked to the cytotoxic MMAE. gpNMB is a protein overexpressed by multiple tumor types associated with cancer cells’ ability to metastasize. [0538] In some embodiments, the second anti-cancer agents is an antiproliferative compound. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17- DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, TEMODAL CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide (TEMODAL®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as
ARRY142886 from Array BioPharma, AZd6244 from AstraZeneca, PD181461 from Pfizer and leucovorin. [0539] The term “aromatase inhibitor” as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name AROMASIN™. Formestane is marketed under the trade name LENTARON™. Fadrozole is marketed under the trade name AFEMA™. Anastrozole is marketed under the trade name ARIMIDEX™. Letrozole is marketed under the trade names FEMARA™ or FEMAr™. Aminoglutethimide is marketed under the trade name ORIMETEN™. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors. [0540] The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name NOLVADEX™. Raloxifene hydrochloride is marketed under the trade name EVISTA™. Fulvestrant can be administered under the trade name FASLODEX™. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors. [0541] The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX™). The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin, and goserelin acetate. Goserelin can be administered under the trade name ZOLADEX™. [0542] The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR™. Topotecan is marketed under the trade name HYCAMPTIN™.
[0543] The term "topoisomerase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as CAELYX™), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name ETOPOPHOS™. Teniposide is marketed under the trade name VM 26-Bristol Doxorubicin is marketed under the trade name ACRIBLASTIN™ or ADRIAMYCIN™. Epirubicin is marketed under the trade name FARMORUBICIN™. Idarubicin is marketed. under the trade name ZAVEDOS™. Mitoxantrone is marketed under the trade name NOVANTRON™. [0544] The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof. Paclitaxel is marketed under the trade name TAXOL™. Docetaxel is marketed under the trade name TAXOTERE™. Vinblastine sulfate is marketed under the trade name VINBLASTIN R.P™. Vincristine sulfate is marketed under the trade name FARMISTIN™. [0545] The term "alkylating agent" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name CYCLOSTIN™. Ifosfamide is marketed under the trade name HOLOXAN™. [0546] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA). [0547] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name XELODA™. Gemcitabine is marketed under the trade name GEMZAR™. [0548] The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is
marketed, e.g., under the trademark CARBOPLAT™. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN™. [0549] The term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds" as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I receptor, or antibodies that target the extracellular domain of IGF-I receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the AxI receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases, which are part of the PDGFR family, such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, such as imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS- 354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine
derivatives, such as midostaurin; examples of further compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC™) or tyrphostin such as Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); l) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR1 ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab (HERCEPTIN™), cetuximab (ERBITUX™), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3- d]pyrimidine derivatives; m) compounds targeting, decreasing or inhibiting the activity of the c- Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF, n) compounds targeting, decreasing or inhibiting the kinase activity of one or more JAK family members (JAK1/JAK2/JAK3/TYK2 and/or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting, decreasing or inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib; and; and q) compounds targeting, decreasing or inhibiting the signaling effects of hedgehog protein (Hh) or smoothened receptor (SMO) pathways, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926 (saridegib).
[0550] The term “PI3K inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including, but not limited to PI3Kα, PI3Kγ, PI3Kδ, PI3Kβ, PI3K-C2α, PI3K-C2β, PI3K- C2γ, Vps34, p110-α, p110-β, p110-γ, p110-δ, p85-α, p85-β, p55-γ, p150, p101, and p87. Examples of PI3K inhibitors useful in this invention include but are not limited to ATU-027, SF- 1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib. In some embodiments, the PI3K inhibitor is alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation). [0551] The term “Bcl-2 inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and analogs thereof), dual Bcl-2/Bcl-xL inhibitors (Infinity Pharmaceuticals/Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see WO2008118802), navitoclax (and analogs thereof, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see WO2004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ. of Michigan), and venetoclax. In some embodiments the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments the Bcl-2 inhibitor is a peptidomimetic. [0552] The term “BTK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against Bruton’s Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib. [0553] The term “SYK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib. [0554] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2008039218 and WO2011090760, the entirety of which are incorporated herein by reference. [0555] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2003063794, WO2005007623, and WO2006078846, the entirety of which are incorporated herein by reference.
[0556] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554, and WO2007044729 the entirety of which are incorporated herein by reference. [0557] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246, and WO2007070514, the entirety of which are incorporated herein by reference. [0558] Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition e.g., thalidomide (THALOMID™) and TNP-470. [0559] Examples of proteasome inhibitors useful for use in combination with compounds of the invention include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708. [0560] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof. [0561] Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, α- γ- or δ- tocopherol or α- γ- or δ-tocotrienol. [0562] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox- 2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX™), rofecoxib (VIOXX™), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib. [0563] The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. Etridonic acid is marketed under the trade name DIDRONEL™. Clodronic acid is marketed under the trade name BONEFOS™. Tiludronic acid is marketed under the trade name Skelid™. Pamidronic acid is marketed under the trade name AREDIA™. Alendronic acid is marketed under the trade name FOSAMAX™. Ibandronic acid is marketed under the trade name
BONDRANAT™. Risedronic acid is marketed under the trade name ACTONEL™. Zoledronic acid is marketed under the trade name ZOMETA™. The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (RAPAMUNE®), everolimus (CERTICAN™), CCI- 779 and ABT578. [0564] The term "heparanase inhibitor" as used herein refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88. The term "biological response modifier" as used herein refers to a lymphokine or interferons. [0565] The term "inhibitor of Ras oncogenic isoforms", such as H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or R115777 (ZARNESTRA™). The term "telomerase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin. [0566] The term "methionine aminopeptidase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or a derivative thereof. [0567] The term "proteasome inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (VELCADE™) and MLN 341. [0568] The term "matrix metalloproteinase inhibitor" or ("MMP" inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211 , MMI270B or AAJ996. [0569] The term "compounds used in the treatment of hematologic malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R);
interferon, 1-β-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase. [0570] Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518. [0571] The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors. [0572] The term "antiproliferative antibodies" as used herein includes, but is not limited to, trastuzumab (HERCEPTIN™), Trastuzumab-DM1, erbitux, bevacizumab (AVASTIN™), rituximab (RITUXAN®), PRO64553 (anti-CD40) and 2C4 Antibody. By antibodies is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity. [0573] For the treatment of acute myeloid leukemia (AML), compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412. [0574] Other anti-leukemic compounds include, for example, Ara-C, a pyrimidine analog, which is the 2'-alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HDAC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA,
FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N- hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt. Somatostatin receptor antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230. Tumor cell damaging approaches refer to approaches such as ionizing radiation. The term "ionizing radiation" referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X- rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4th Edition, Vol.1 , pp.248-275 (1993). [0575] Also included are EDG binders and ribonucleotide reductase inhibitors. The term “EDG binders” as used herein refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720. The term “ribonucleotide reductase inhibitors” refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1 ,3-dione derivatives. [0576] Also included are in particular those compounds, proteins or monoclonal antibodies of VEGF such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; ANGIOSTATIN™; ENDOSTATIN™; anthranilic acid amides; ZD4190; Zd6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab (AVASTIN™). [0577] Photodynamic therapy as used herein refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as VISUDYNE™ and porfimer sodium.
[0578] Angiostatic steroids as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11-α-epihydrocotisol, cortexolone, 17α-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone. [0579] Implants containing corticosteroids refers to compounds, such as fluocinolone and dexamethasone. [0580] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action. [0581] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patents International (e.g., IMS World Publications). Exemplary Immuno-Oncology Agents [0582] In some embodiments, the second anti-cancer agent is an immuno-oncology agent. As used herein, the term “an immuno-oncology agent” refers to an agent which is effective to enhance, stimulate, and/or up-regulate immune responses in a subject. In some embodiments, the administration of an immuno-oncology agent with a compound of the invention has a synergic effect in treating a cancer. [0583] An immuno-oncology agent can be, for example, a small molecule drug, an antibody, or a biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In some embodiments, an antibody is a monoclonal antibody. In some embodiments, a monoclonal antibody is humanized or human. [0584] In some embodiments, an immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses. [0585] Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7- H6. Another family of membrane bound ligands that bind to co-stimulatory or co-inhibitory
receptors is the TNF family of molecules that bind to cognate TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin α/TNFβ, TNFR2, TNFα, LTβR, Lymphotoxin α1β2, FAS, FASL, RELT, DR6, TROY, NGFR. [0586] In some embodiments, an immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response. [0587] In some embodiments, a combination of a compound of the invention and an immuno- oncology agent can stimulate T cell responses. In some embodiments, an immuno-oncology agent is: (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4; or (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H. [0588] In some embodiments, an immuno-oncology agent is an antagonist of inhibitory receptors on NK cells or an agonist of activating receptors on NK cells. In some embodiments, an immuno-oncology agent is an antagonist of KIR, such as lirilumab. [0589] In some embodiments, an immuno-oncology agent is an agent that inhibits or depletes macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357). [0590] In some embodiments, an immuno-oncology agent is selected from agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1
interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell energy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites. [0591] In some embodiments, an immuno-oncology agent is a CTLA-4 antagonist. In some embodiments, a CTLA-4 antagonist is an antagonistic CTLA-4 antibody. In some embodiments, an antagonistic CTLA-4 antibody is YERVOY (ipilimumab) or tremelimumab. [0592] In some embodiments, an immuno-oncology agent is a PD-1 antagonist. In some embodiments, a PD-1 antagonist is administered by infusion. In some embodiments, an immuno-oncology agent is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, a PD-1 antagonist is an antagonistic PD-1 antibody. In some embodiments, an antagonistic PD-1 antibody is OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI- 0680 (AMP-514; WO2012/145493). In some embodiments, an immuno-oncology agent may be pidilizumab (CT-011). In some embodiments, an immuno-oncology agent is a recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224. [0593] In some embodiments, an immuno-oncology agent is a PD-L1 antagonist. In some embodiments, a PD-L1 antagonist is an antagonistic PD-L1 antibody. In some embodiments, a PD-L1 antibody is MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS- 936559 (WO2007/005874), and MSB0010718C (WO2013/79174). [0594] In some embodiments, an immuno-oncology agent is a LAG-3 antagonist. In some embodiments, a LAG-3 antagonist is an antagonistic LAG-3 antibody. In some embodiments, a LAG3 antibody is BMS-986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO009/44273). [0595] In some embodiments, an immuno-oncology agent is a CD137 (4-1BB) agonist. In some embodiments, a CD137 (4-1BB) agonist is an agonistic CD137 antibody. In some embodiments, a CD137 antibody is urelumab or PF-05082566 (WO12/32433). [0596] In some embodiments, an immuno-oncology agent is a GITR agonist. In some embodiments, a GITR agonist is an agonistic GITR antibody. In some embodiments, a GITR
antibody is BMS-986153, BMS-986156, TRX-518 (WO006/105021, WO009/009116), or MK- 4166 (WO11/028683). [0597] In some embodiments, an immuno-oncology agent is an indoleamine (2,3)- dioxygenase (IDO) antagonist. In some embodiments, an IDO antagonist is selected from epacadostat (INCB024360, Incyte); indoximod (NLG-8189, NewLink Genetics Corporation); capmanitib (INC280, Novartis); GDC-0919 (Genentech/Roche); PF-06840003 (Pfizer); BMS:F001287 (Bristol Myers Squibb); Phy906/KD108 (Phytoceutica); an enzyme that breaks down kynurenine (Kynase, Ikena Oncology, formerly known as Kyn Therapeutics); and NLG- 919 (WO09/73620, WO009/1156652, WO11/56652, WO12/142237). [0598] In some embodiments, an immuno-oncology agent is an OX40 agonist. In some embodiments, an OX40 agonist is an agonistic OX40 antibody. In some embodiments, an OX40 antibody is MEDI-6383 or MEDI-6469. [0599] In some embodiments, an immuno-oncology agent is an OX40L antagonist. In some embodiments, an OX40L antagonist is an antagonistic OX40 antibody. In some embodiments, an OX40L antagonist is RG-7888 (WO06/029879). [0600] In some embodiments, an immuno-oncology agent is a CD40 agonist. In some embodiments, a CD40 agonist is an agonistic CD40 antibody. In some embodiments, an immuno-oncology agent is a CD40 antagonist. In some embodiments, a CD40 antagonist is an antagonistic CD40 antibody. In some embodiments, a CD40 antibody is lucatumumab or dacetuzumab. [0601] In some embodiments, an immuno-oncology agent is a CD27 agonist. In some embodiments, a CD27 agonist is an agonistic CD27 antibody. In some embodiments, a CD27 antibody is varlilumab. [0602] In some embodiments, an immuno-oncology agent is MGA271 (to B7H3) (WO11/109400). [0603] In some embodiments, an immuno-oncology agent is abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolimab, avelumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, or tremelimumab.
[0604] In some embodiments, an immuno-oncology agent is an immunostimulatory agent. For example, antibodies blocking the PD-1 and PD-L1 inhibitory axis can unleash activated tumor-reactive T cells and have been shown in clinical trials to induce durable anti-tumor responses in increasing numbers of tumor histologies, including some tumor types that conventionally have not been considered immunotherapy sensitive. See, e.g., Okazaki, T. et al. (2013) Nat. Immunol. 14, 1212–1218; Zou et al. (2016) Sci. Transl. Med. 8. The anti-PD-1 antibody nivolumab (OPDIVO®, Bristol Myers Squibb, also known as ONO-4538, MDX1106 and BMS-936558), has shown potential to improve the overall survival in patients with RCC who had experienced disease progression during or after prior anti-angiogenic therapy. [0605] In some embodiments, the immunomodulatory therapeutic specifically induces apoptosis of tumor cells. Approved immunomodulatory therapeutics which may be used in the present invention include pomalidomide (POMALYST®, Celgene); lenalidomide (REVLIMID®, Celgene); ingenol mebutate (PICATO®, LEO Pharma). [0606] In some embodiments, an immuno-oncology agent is a cancer vaccine. In some embodiments, the cancer vaccine is selected from sipuleucel-T (PROVENGE®, Dendreon/Valeant Pharmaceuticals), which has been approved for treatment of asymptomatic, or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer; and talimogene laherparepvec (IMLYGIC®, BioVex/Amgen, previously known as T-VEC), a genetically modified oncolytic viral therapy approved for treatment of unresectable cutaneous, subcutaneous and nodal lesions in melanoma. In some embodiments, an immuno-oncology agent is selected from an oncolytic viral therapy such as pexastimogene devacirepvec (PexaVec/JX-594, SillaJen/formerly Jennerex Biotherapeutics), a thymidine kinase- (TK-) deficient vaccinia virus engineered to express GM-CSF, for hepatocellular carcinoma (NCT02562755) and melanoma (NCT00429312); pelareorep (REOLYSIN®, Oncolytics Biotech), a variant of respiratory enteric orphan virus (reovirus) which does not replicate in cells that are not RAS-activated, in numerous cancers, including colorectal cancer (NCT01622543); prostate cancer (NCT01619813); head and neck squamous cell cancer (NCT01166542); pancreatic adenocarcinoma (NCT00998322); and non-small cell lung cancer (NSCLC) (NCT 00861627); enadenotucirev (NG-348, PsiOxus, formerly known as ColoAd1), an adenovirus engineered to express a full length CD80 and an antibody fragment specific for the T-cell receptor CD3 protein, in ovarian cancer (NCT02028117); metastatic or advanced epithelial
tumors such as in colorectal cancer, bladder cancer, head and neck squamous cell carcinoma and salivary gland cancer (NCT02636036); ONCOS-102 (Targovax/formerly Oncos), an adenovirus engineered to express GM-CSF, in melanoma (NCT03003676); and peritoneal disease, colorectal cancer or ovarian cancer (NCT02963831); GL-ONC1 (GLV-1h68/GLV-1h153, Genelux GmbH), vaccinia viruses engineered to express beta-galactosidase (beta-gal)/beta- glucoronidase or beta-gal/human sodium iodide symporter (hNIS), respectively, were studied in peritoneal carcinomatosis (NCT01443260); fallopian tube cancer, ovarian cancer (NCT 02759588); or CG0070 (Cold Genesys), an adenovirus engineered to express GM-CSF, in bladder cancer (NCT02365818). [0607] In some embodiments, an immuno-oncology agent is selected from JX-929 (SillaJen/formerly Jennerex Biotherapeutics), a TK- and vaccinia growth factor-deficient vaccinia virus engineered to express cytosine deaminase, which is able to convert the prodrug 5- fluorocytosine to the cytotoxic drug 5-fluorouracil; TG01 and TG02 (Targovax/formerly Oncos), peptide-based immunotherapy agents targeted for difficult-to-treat RAS mutations; and TILT- 123 (TILT Biotherapeutics), an engineered adenovirus designated: Ad5/3-E2F-delta24-hTNFα- IRES-hIL20; and VSV-GP (ViraTherapeutics) a vesicular stomatitis virus (VSV) engineered to express the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), which can be further engineered to express antigens designed to raise an antigen-specific CD8+ T cell response. [0608] In some embodiments, an immuno-oncology agent is a T-cell engineered to express a chimeric antigen receptor, or CAR. The T-cells engineered to express such chimeric antigen receptor are referred to as a CAR-T cells. [0609] CARs have been constructed that consist of binding domains, which may be derived from natural ligands, single chain variable fragments (scFv) derived from monoclonal antibodies specific for cell-surface antigens, fused to endodomains that are the functional end of the T-cell receptor (TCR), such as the CD3-zeta signaling domain from TCRs, which is capable of generating an activation signal in T lymphocytes. Upon antigen binding, such CARs link to endogenous signaling pathways in the effector cell and generate activating signals similar to those initiated by the TCR complex. [0610] For example, in some embodiments the CAR-T cell is one of those described in U.S. Patent 8,906,682 (June et al.; hereby incorporated by reference in its entirety), which discloses
CAR-T cells engineered to comprise an extracellular domain having an antigen binding domain (such as a domain that binds to CD19), fused to an intracellular signaling domain of the T cell antigen receptor complex zeta chain (such as CD3 zeta). When expressed in the T cell, the CAR is able to redirect antigen recognition based on the antigen binding specificity. In the case of CD19, the antigen is expressed on malignant B cells. Over 200 clinical trials are currently in progress employing CAR-T in a wide range of indications. [https://clinicaltrials.gov/ct2/results?term=chimeric+antigen+receptors&pg=1]. [0611] In some embodiments, an immunostimulatory agent is an activator of retinoic acid receptor-related orphan receptor γ (RORγt). RORγt is a transcription factor with key roles in the differentiation and maintenance of Type 17 effector subsets of CD4+ (Th17) and CD8+ (Tc17) T cells, as well as the differentiation of IL-17 expressing innate immune cell subpopulations such as NK cells. In some embodiments, an activator of RORγt is LYC-55716 (Lycera), which is currently being evaluated in clinical trials for the treatment of solid tumors (NCT02929862). [0612] In some embodiments, an immunostimulatory agent is an agonist or activator of a toll- like receptor (TLR). Suitable activators of TLRs include an agonist or activator of TLR9 such as SD-101 (Dynavax). SD-101 is an immunostimulatory CpG which is being studied for B-cell, follicular and other lymphomas (NCT02254772). Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCT02124850) and ovarian cancer (NCT02431559). [0613] Other immuno-oncology agents that can be used in the present invention include urelumab (BMS-663513, Bristol Myers Squibb), an anti-CD137 monoclonal antibody; varlilumab (CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS- 986178 (Bristol Myers Squibb), an anti-OX40 monoclonal antibody; lirilumab (IPH2102/BMS- 986015, Innate Pharma, Bristol Myers Squibb), an anti-KIR monoclonal antibody; monalizumab (IPH2201, Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab (GS-5745, Gilead Sciences), an anti-MMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR monoclonal antibody. [0614] In some embodiments, an immunostimulatory agent is selected from elotuzumab, mifamurtide, an agonist or activator of a toll-like receptor, and an activator of RORγt.
[0615] In some embodiments, an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-15). rhIL-15 has been tested in the clinic as a therapy for melanoma and renal cell carcinoma (NCT01021059 and NCT01369888) and leukemias (NCT02689453). In some embodiments, an immunostimulatory agent is recombinant human interleukin 12 (rhIL-12). In some embodiments, an IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-15, Novartis/Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL15:sIL-15RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck squamous cell carcinoma (NCT02452268). In some embodiments, a recombinant human interleukin 12 (rhIL-12) is NM-IL-12 (Neumedicines, Inc.), NCT02544724, or NCT02542124. [0616] In some embodiments, an immuno-oncology agent is selected from those described in Jerry L. Adams et al., “Big opportunities for small molecules in immuno-oncology,” Cancer Therapy 2015, Vol.14, pages 603-622, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is selected from the examples described in Table 1 of Jerry L. Adams et al. In some embodiments, an immuno-oncology agent is a small molecule targeting an immuno-oncology target selected from those listed in Table 2 of Jerry L. Adams et al. In some embodiments, an immuno-oncology agent is a small molecule agent selected from those listed in Table 2 of Jerry L. Adams et al. [0617] In some embodiments, an immuno-oncology agent is selected from the small molecule immuno-oncology agents described in Peter L. Toogood, “Small molecule immuno-oncology therapeutic agents,” Bioorganic & Medicinal Chemistry Letters 2018, Vol. 28, pages 319-329, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is an agent targeting the pathways as described in Peter L. Toogood. [0618] In some embodiments, an immuno-oncology agent is selected from those described in Sandra L. Ross et al., “Bispecific T cell engager (BITE® ) antibody constructs can mediate bystander tumor cell killing”, PLoS ONE 12(8): e0183390, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is a bispecific T cell engager (BITE®) antibody construct. In some embodiments, a bispecific T cell engager (BITE®) antibody construct is a CD19/CD3 bispecific antibody construct. In some embodiments, a bispecific T cell engager (BITE®) antibody construct is an EGFR/CD3
bispecific antibody construct. In some embodiments, a bispecific T cell engager (BITE®) antibody construct activates T cells. In some embodiments, a bispecific T cell engager (BITE®) antibody construct activates T cells, which release cytokines inducing upregulation of intercellular adhesion molecule 1 (ICAM-1) and FAS on bystander cells. In some embodiments, a bispecific T cell engager (BITE®) antibody construct activates T cells which result in induced bystander cell lysis. In some embodiments, the bystander cells are in solid tumors. In some embodiments, the bystander cells being lysed are in proximity to the BITE®-activated T cells. In some embodiments, the bystander cells comprises tumor-associated antigen (TAA) negative cancer cells. In some embodiment, the bystander cells comprise EGFR-negative cancer cells. In some embodiments, an immuno-oncology agent is an antibody which blocks the PD-L1/PD1 axis and/or CTLA4. In some embodiments, an immuno-oncology agent is an ex vivo expanded tumor-infiltrating T cell. In some embodiments, an immuno-oncology agent is a bispecific antibody construct or chimeric antigen receptors (CARs) that directly connect T cells with tumor-associated surface antigens (TAAs). Exemplary Immune Checkpoint Inhibitors [0619] In some embodiments, an immuno-oncology agent is an immune checkpoint inhibitor as described herein. [0620] The terms “immune checkpoint inhibitor” and “checkpoint inhibitor” as used herein relate to agents useful in preventing cancer cells from avoiding the immune system of the patient. One of the major mechanisms of anti-tumor immunity subversion is known as “T-cell exhaustion,” which results from chronic exposure to antigens that has led to up-regulation of inhibitory receptors. These inhibitory receptors serve as immune checkpoints in order to prevent uncontrolled immune reactions. [0621] PD-1 and co-inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin domain-3 (Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often referred to as a checkpoint regulators. They act as molecular “gatekeepers” that allow extracellular information to dictate whether cell cycle progression and other intracellular signaling processes should proceed. [0622] In some embodiments, an immune checkpoint inhibitor is an antibody to PD-1. PD-1 binds to the programmed cell death 1 receptor (PD-1) to prevent the receptor from binding to the
inhibitory ligand PDL-1, thus overriding the ability of tumors to suppress the host anti-tumor immune response. [0623] In some embodiments, the checkpoint inhibitor is a biologic therapeutic or a small molecule. In some embodiments, the checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof. In some embodiments, the checkpoint inhibitor inhibits a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In some embodiments, the checkpoint inhibitor interacts with a ligand of a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In some embodiments, the checkpoint inhibitor is an immunostimulatory agent, a T cell growth factor, an interleukin, an antibody, a vaccine or a combination thereof. In some embodiments, the interleukin is IL-7 or IL-15. In some embodiments, the interleukin is glycosylated IL-7. In an additional aspect, the vaccine is a dendritic cell (DC) vaccine. [0624] Checkpoint inhibitors include any agent that blocks or inhibits in a statistically significant manner, the inhibitory pathways of the immune system. Such inhibitors can include small molecule inhibitors or can include antibodies, or antigen binding fragments thereof, that bind to and block or inhibit immune checkpoint receptors or antibodies that bind to and block or inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules that can be targeted for blocking or inhibition include, but are not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is expressed on all NK, γδ, and memory CD8+ (αβ) T cells), CD160 (also referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases, A2aR, and various B-7 family ligands. B7 family ligands include, but are not limited to, B7- 1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include antibodies, or antigen binding fragments thereof, other binding proteins, biologic therapeutics, or small molecules, that bind to and block or inhibit the activity of one or more of CTLA-4, PDL1, PDL2, PD1, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD 160 and CGEN-15049. Illustrative immune checkpoint inhibitors include, but are not limited to, Tremelimumab (CTLA- 4 blocking antibody), anti-OX40, PD-L1 monoclonal Antibody (Anti-B7-Hl; MEDI4736), MK-
3475 (PD-1 blocker), Nivolumab (anti-PD1 antibody), CT-011 (anti-PD1 antibody), BY55 monoclonal antibody, AMP224 (anti-PDL1 antibody), BMS- 936559 (anti-PDL1 antibody), MPLDL3280A (anti-PDL1 antibody), MSB0010718C (anti-PDL1 antibody), and ipilimumab (anti-CTLA-4 checkpoint inhibitor). Checkpoint protein ligands include, but are not limited to PD-L1, PD-L2, B7-H3, B7-H4, CD28, CD86 and TIM-3. [0625] In certain embodiments, the immune checkpoint inhibitor is selected from a PD-1 antagonist, a PD-L1 antagonist, and a CTLA-4 antagonist. In some embodiments, the checkpoint inhibitor is selected from the group consisting of nivolumab (OPDIVO®), ipilimumab (YERVOY®), and pembrolizumab (KEYTRUDA®). In some embodiments, the checkpoint inhibitor is selected from nivolumab (anti-PD-1 antibody, OPDIVO®, Bristol Myers Squibb); pembrolizumab (anti-PD-1 antibody, KEYTRUDA®, Merck); ipilimumab (anti-CTLA- 4 antibody, YERVOY®, Bristol Myers Squibb); durvalumab (anti-PD-L1 antibody, IMFINZI®, AstraZeneca); and atezolizumab (anti-PD-L1 antibody, TECENTRIQ®, Genentech). [0626] In some embodiments, the checkpoint inhibitor is selected from the group consisting of lambrolizumab (MK-3475), nivolumab (BMS-936558), pidilizumab (CT-011), AMP-224, MDX-1105, MEDI4736, MPDL3280A, BMS-936559, ipilimumab, lirlumab, IPH2101, pembrolizumab (KEYTRUDA®), and tremelimumab. [0627] In some embodiments, an immune checkpoint inhibitor is REGN2810 (Regeneron), an anti-PD-1 antibody tested in patients with basal cell carcinoma (NCT03132636); NSCLC (NCT03088540); cutaneous squamous cell carcinoma (NCT02760498); lymphoma (NCT02651662); and melanoma (NCT03002376); pidilizumab (CureTech), also known as CT- 011, an antibody that binds to PD-1, in clinical trials for diffuse large B-cell lymphoma and multiple myeloma; avelumab (BAVENCIO®, Pfizer/Merck KGaA), also known as MSB0010718C), a fully human IgG1 anti-PD-L1 antibody, in clinical trials for non-small cell lung cancer, Merkel cell carcinoma, mesothelioma, solid tumors, renal cancer, ovarian cancer, bladder cancer, head and neck cancer, and gastric cancer; or PDR001 (Novartis), an inhibitory antibody that binds to PD-1, in clinical trials for non-small cell lung cancer, melanoma, triple negative breast cancer and advanced or metastatic solid tumors. Tremelimumab (CP-675,206; Astrazeneca) is a fully human monoclonal antibody against CTLA-4 that has been in studied in clinical trials for a number of indications, including: mesothelioma, colorectal cancer, kidney cancer, breast cancer, lung cancer and non-small cell lung cancer, pancreatic ductal
adenocarcinoma, pancreatic cancer, germ cell cancer, squamous cell cancer of the head and neck, hepatocellular carcinoma, prostate cancer, endometrial cancer, metastatic cancer in the liver, liver cancer, large B-cell lymphoma, ovarian cancer, cervical cancer, metastatic anaplastic thyroid cancer, urothelial cancer, fallopian tube cancer, multiple myeloma, bladder cancer, soft tissue sarcoma, and melanoma. AGEN-1884 (Agenus) is an anti-CTLA4 antibody that is being studied in Phase 1 clinical trials for advanced solid tumors (NCT02694822). [0628] In some embodiments, a checkpoint inhibitor is an inhibitor of T-cell immunoglobulin mucin containing protein-3 (TIM-3). TIM-3 inhibitors that may be used in the present invention include TSR-022, LY3321367 and MBG453. TSR-022 (Tesaro) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT02817633). LY3321367 (Eli Lilly) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT03099109). MBG453 (Novartis) is an anti- TIM-3 antibody which is being studied in advanced malignancies (NCT02608268). [0629] In some embodiments, a checkpoint inhibitor is an inhibitor of T cell immunoreceptor with Ig and ITIM domains, or TIGIT, an immune receptor on certain T cells and NK cells. TIGIT inhibitors that may be used in the present invention include BMS-986207 (Bristol Myers Squibb), an anti-TIGIT monoclonal antibody (NCT02913313); OMP-313M32 (Oncomed); and anti-TIGIT monoclonal antibody (NCT03119428). [0630] In some embodiments, a checkpoint inhibitor is an inhibitor of Lymphocyte Activation Gene-3 (LAG-3). LAG-3 inhibitors that may be used in the present invention include BMS- 986016 and REGN3767 and IMP321. BMS-986016 (Bristol Myers Squibb), an anti-LAG-3 antibody, is being studied in glioblastoma and gliosarcoma (NCT02658981). REGN3767 (Regeneron), is also an anti-LAG-3 antibody, and is being studied in malignancies (NCT03005782). IMP321 (Immutep S.A.) is an LAG-3-Ig fusion protein, being studied in melanoma (NCT02676869); adenocarcinoma (NCT02614833); and metastatic breast cancer (NCT00349934). [0631] Checkpoint inhibitors that can be used in the present invention include OX40 agonists. OX40 agonists that are being studied in clinical trials include PF-04518600/PF-8600 (Pfizer), an agonistic anti-OX40 antibody, in metastatic kidney cancer (NCT03092856) and advanced cancers and neoplasms (NCT02554812; NCT05082566); GSK3174998 (Merck), an agonistic anti-OX40 antibody, in Phase 1 cancer trials (NCT02528357); MEDI0562 (Medimmune/AstraZeneca), an agonistic anti-OX40 antibody, in advanced solid tumors
(NCT02318394 and NCT02705482); MEDI6469, an agonistic anti-OX40 antibody (Medimmune/AstraZeneca), in patients with colorectal cancer (NCT02559024), breast cancer (NCT01862900), head and neck cancer (NCT02274155) and metastatic prostate cancer (NCT01303705); and BMS-986178 (Bristol Myers Squibb) an agonistic anti-OX40 antibody, in advanced cancers (NCT02737475). [0632] Checkpoint inhibitors that can be used in the present invention include CD137 (also called 4-1BB) agonists. CD137 agonists that are being studied in clinical trials include utomilumab (PF-05082566, Pfizer) an agonistic anti-CD137 antibody, in diffuse large B-cell lymphoma (NCT02951156) and in advanced cancers and neoplasms (NCT02554812 and NCT05082566); urelumab (BMS-663513, Bristol Myers Squibb), an agonistic anti-CD137 antibody, in melanoma and skin cancer (NCT02652455) and glioblastoma and gliosarcoma (NCT02658981); and CTX-471 (Compass Therapeutics), an agonistic anti-CD137 antibody in metastatic or locally advanced malignancies (NCT03881488). [0633] Checkpoint inhibitors that can be used in the present invention include CD27 agonists. CD27 agonists that are being studied in clinical trials include varlilumab (CDX-1127, Celldex Therapeutics) an agonistic anti-CD27 antibody, in squamous cell head and neck cancer, ovarian carcinoma, colorectal cancer, renal cell cancer, and glioblastoma (NCT02335918); lymphomas (NCT01460134); and glioma and astrocytoma (NCT02924038). [0634] Checkpoint inhibitors that can be used in the present invention include glucocorticoid- induced tumor necrosis factor receptor (GITR) agonists. GITR agonists that are being studied in clinical trials include TRX518 (Leap Therapeutics), an agonistic anti-GITR antibody, in malignant melanoma and other malignant solid tumors (NCT01239134 and NCT02628574); GWN323 (Novartis), an agonistic anti-GITR antibody, in solid tumors and lymphoma (NCT02740270); INCAGN01876 (Incyte/Agenus), an agonistic anti-GITR antibody, in advanced cancers (NCT02697591 and NCT03126110); MK-4166 (Merck), an agonistic anti- GITR antibody, in solid tumors (NCT02132754) and MEDI1873 (Medimmune/AstraZeneca), an agonistic hexameric GITR-ligand molecule with a human IgG1 Fc domain, in advanced solid tumors (NCT02583165). [0635] Checkpoint inhibitors that can be used in the present invention include inducible T- cell co-stimulator (ICOS, also known as CD278) agonists. ICOS agonists that are being studied in clinical trials include MEDI-570 (Medimmune), an agonistic anti-ICOS antibody, in
lymphomas (NCT02520791); GSK3359609 (Merck), an agonistic anti-ICOS antibody, in Phase 1 (NCT02723955); JTX-2011 (Jounce Therapeutics), an agonistic anti-ICOS antibody, in Phase 1 (NCT02904226). [0636] Checkpoint inhibitors that can be used in the present invention include killer IgG-like receptor (KIR) inhibitors. KIR inhibitors that are being studied in clinical trials include lirilumab (IPH2102/BMS-986015, Innate Pharma/Bristol Myers Squibb), an anti-KIR antibody, in leukemias (NCT01687387, NCT02399917, NCT02481297, NCT02599649), multiple myeloma (NCT02252263), and lymphoma (NCT01592370);IPH2101 (1-7F9, Innate Pharma) in myeloma (NCT01222286 and NCT01217203); and IPH4102 (Innate Pharma), an anti-KIR antibody that binds to three domains of the long cytoplasmic tail (KIR3DL2), in lymphoma (NCT02593045). [0637] Checkpoint inhibitors that can be used in the present invention include CD47 inhibitors of interaction between CD47 and signal regulatory protein alpha (SIRPa). CD47/SIRPa inhibitors that are being studied in clinical trials include ALX-148 (Alexo Therapeutics), an antagonistic variant of (SIRPa) that binds to CD47 and prevents CD47/SIRPa- mediated signaling, in phase 1 (NCT03013218); TTI-621 (SIRPa-Fc, Trillium Therapeutics), a soluble recombinant fusion protein created by linking the N-terminal CD47-binding domain of SIRPa with the Fc domain of human IgG1, acts by binding human CD47, and preventing it from delivering its “do not eat” signal to macrophages, is in clinical trials in Phase 1 (NCT02890368 and NCT02663518); CC-90002 (Celgene), an anti-CD47 antibody, in leukemias (NCT02641002); and Hu5F9-G4 (Forty Seven, Inc.), in colorectal neoplasms and solid tumors (NCT02953782), acute myeloid leukemia (NCT02678338) and lymphoma (NCT02953509). [0638] Checkpoint inhibitors that can be used in the present invention include CD73 inhibitors. CD73 inhibitors that are being studied in clinical trials include MEDI9447 (Medimmune), an anti-CD73 antibody, in solid tumors (NCT02503774); and BMS-986179 (Bristol Myers Squibb), an anti-CD73 antibody, in solid tumors (NCT02754141). [0639] Checkpoint inhibitors that can be used in the present invention include agonists of stimulator of interferon genes protein (STING, also known as transmembrane protein 173, or TMEM173). Agonists of STING that are being studied in clinical trials include MK-1454 (Merck), an agonistic synthetic cyclic dinucleotide, in lymphoma (NCT03010176); and ADU- S100 (MIW815, Aduro Biotech/Novartis), an agonistic synthetic cyclic dinucleotide, in Phase 1 (NCT02675439 and NCT03172936).
[0640] Checkpoint inhibitors that can be used in the present invention include CSF1R inhibitors. CSF1R inhibitors that are being studied in clinical trials include pexidartinib (PLX3397, Plexxikon), a CSF1R small molecule inhibitor, in colorectal cancer, pancreatic cancer, metastatic and advanced cancers (NCT02777710) and melanoma, non-small cell lung cancer, squamous cell head and neck cancer, gastrointestinal stromal tumor (GIST) and ovarian cancer (NCT02452424); and IMC-CS4 (LY3022855, Lilly), an anti-CSF-1R antibody, in pancreatic cancer (NCT03153410), melanoma (NCT03101254), and solid tumors (NCT02718911); and BLZ945 (4-[2((1R,2R)-2-hydroxycyclohexylamino)-benzothiazol-6- yloxyl]-pyridine-2-carboxylic acid methylamide, Novartis), an orally available inhibitor of CSF1R, in advanced solid tumors (NCT02829723). [0641] Checkpoint inhibitors that can be used in the present invention include NKG2A receptor inhibitors. NKG2A receptor inhibitors that are being studied in clinical trials include monalizumab (IPH2201, Innate Pharma), an anti-NKG2A antibody, in head and neck neoplasms (NCT02643550) and chronic lymphocytic leukemia (NCT02557516). [0642] In some embodiments, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab. Additional Combination Therapy Considerations [0643] In certain embodiments, the method further comprises administering to the subject a third anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fourth anti-cancer agent. In certain embodiments, the method further comprises administering to the subject a fifth anti-cancer agent. [0644] In certain embodiments, the third anti-cancer agent is one of the second anti-cancer agents described above. In certain embodiments, the fourth anti-cancer agent is one of the second anti-cancer agents described above. In certain embodiments, the fifth anti-cancer agent is one of the second anti-cancer agents described above. [0645] The doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician. In certain embodiments, the substituted 4- piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) (e.g. the second, third, or fourth, or fifth anti-cancer agent, described above) are administered in doses
commonly employed when such agents are used as monotherapy for treating the disorder. In other embodiments, the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) (e.g. the second, third, or fourth, or fifth anti-cancer agent, described above) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder. In certain embodiments, the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) (e.g. the second, third, or fourth, or fifth anti-cancer agent, described above) are present in the same composition, which is suitable for oral administration. [0646] In certain embodiments, the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I) and the additional therapeutic agent(s) (e.g. the second, third, or fourth, or fifth anti- cancer agent, described above) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy. [0647] Another aspect of this invention is a kit comprising a therapeutically effective amount of the substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described herein (e.g., a compound of Formula I, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above. IV. Pharmaceutical Compositions and Dosing Considerations [0648] As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. The pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for
application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. In certain embodiments, the invention provides a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula I, I-A, I-B, or I-C) and a pharmaceutically acceptable carrier. [0649] The phrase “therapeutically effective amount” as used herein means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, a therapeutically effective amount is an amount sufficient for inhibition of ERK5. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating a proliferative disease, such as cancer. [0650] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. [0651] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. [0652] Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0653] Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent. [0654] In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention. [0655] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. [0656] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
[0657] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. [0658] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. [0659] The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. [0660] Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. [0661] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. [0662] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. [0663] Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[0664] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. [0665] Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required. [0666] The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. [0667] Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. [0668] Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel. [0669] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. [0670] Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable
solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. [0671] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. [0672] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. [0673] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. [0674] Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
[0675] When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier. [0676] The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred. [0677] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. [0678] The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. [0679] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually. [0680] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
[0681] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. [0682] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. [0683] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. [0684] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone. [0685] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day. [0686] The invention further provides a unit dosage form (such as a tablet or capsule) comprising a substituted 4-piperidinyl-imidazo[4,5-b]pyridine or related compound described
herein in a therapeutically effective amount for the treatment of a medical disorder described herein. EXAMPLES [0687] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention. Starting materials described herein can be obtained from commercial sources or may be readily prepared from commercially available materials using transformations known to those of skill in the art. [0688] Abbreviations used in the Examples are described below. Any abbreviations not described are intended to convey their generally accepted meaning. Abbreviations Ac acetyl (C(O)CH3) aq aqueous Ar Aromatic ring BEH ethylene bridged hybrid Bz benzyl (CH2-phenyl) Boc tert-butyloxycarbonyl protecting group CSH charged surface hybrid d doublet DCM dichloromethane dioxane 1,4-dioxane DIPEA N,N-Diisopropylethylamine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide Eq Molar equivalents (ES+) electrospray ionisation, positive mode (ES-) electrospray ionisation, negative mode
ESI electrospray ionisation Et ethyl g grams Hal halogen HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HPLC high performance liquid chromatography h hour(s) H2 Hydrogen gas IC50 50% inhibitory concentration iPr iso-propyl LCMS liquid chromatography-mass spectrometry LHMDS lithium hexamethyldisilazide (M+H)+ protonated molecular ion (M-H)- unprotonated molecular ion M molar concentration mL millilitre mm millimiter mmol millimole Me methyl Mn(dpm)3 Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)manganese(III) MHz megahertz min minute(s) MSD mass selective detector m/z mass-to-charge ratio N2 nitrogen gas nm nanometre NMR nuclear magnetic resonance (spectroscopy) O2 oxygen gas P4HB poly-4-hydroxybutyrate Pd/C Palladium on Carbon
Pd-170 XPhos Pd(crotyl)Cl Pd-171 RuPhos Pd(crotyl)Cl PDA photodiode array Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) PMB 4-methoxybenzyl prep HPLC preparative high performance liquid chromatography Ph phenyl pos/neg positive/negative q quartet RT room temperature Rt retention time RP reverse phase RuPhos 2-Dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl s singlet sat saturated SCX solid supported cation exchange (resin) t triplet tBu tert-butyl TFA Trifluoroacetic acid THF tetrahydrofuran UPLC ultra performance liquid chromatography UV ultraviolet v/v volume/volume VWD variable wave detector wt weight µm micrometre µL microlitre XPhos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl ˚C degrees Celsius [0689] Compounds containing one or more stereocenters are a mixture of stereoisomers, unless otherwise stated or described (for example, with use of dashed or wedged bonds denoting
stereochemistry). All starting materials and solvents were obtained either from commercial sources or prepared according to the literature. Unless otherwise stated all reactions were stirred. Organic solutions were routinely dried over anhydrous magnesium sulfate. EXAMPLE 1 -- Synthesis of (2-Amino-4-(trifluoromethoxy)phenyl)(4-(2-(tetrahydro-2H- pyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperidin-1-yl)methanone (I-7)
Part I – Synthesis of tert-butyl 2-amino-3-nitro-3,6-dihydro-2H-[4,4-bipyridine]-1- carboxylate
[0690] A solution of 4-chloro-3-nitropyridin-2-amine (8.80 g, 50.703 mmol, 1.00 equiv), tert- butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (23.52 g, 76.054 mmol, 1.50 equiv), K2CO3 (21.02 g, 152.109 mmol, 3.00 equiv) and Pd(dppf)Cl2CH2Cl2 (2.07 g, 2.535 mmol, 0.05 equiv) in dioxane (160.00 mL)/H2O (40.00 mL) was stirred overnight at room temperature under nitrogen atmosphere. The resulting mixture was extracted with EtOAc (5 x 200 mL). The combined organic layers were dried over anhydrous Na2SO4. The resulting mixture was washed with 300 mL of brine. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeOH in water, 10%-15% gradient in 50 min; detector, UV 254 nm. This resulted in tert-butyl 2-amino-3-nitro-3,6- dihydro-2H-[4,4-bipyridine]-1-carboxylate (13 g, 80.04%) as a yellow solid.
Part II – Synthesis of tert-butyl 4-(2,3-diaminopyridin-4-yl)piperidine-1-carboxylate
[0691] Into a 300 mL pressure tank reactor were added tert-butyl 2-amino-3-nitro-3,6-dihydro- 2H-[4,4-bipyridine]-1-carboxylate (11.70 g, 36.523 mmol, 1.00 equip), Pd/C (5.83 g, 54.784 mmol, 1.50 equiv) and CH3OH (300.00 mL) at 60 °C. The resulting mixture was stirred overnight at 60 °C under hydrogen atmosphere. The resulting mixture was filtered; the filter cake was washed with EtOAc (3 x 50mL). The resulting mixture was washed with 400 mL of brine. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl 4-(2,3-diaminopyridin-4- yl)piperidine-1-carboxylate (12.3 g) as a yellow solid. The product was used in the next step directly without further purification. Part III – Synthesis of tert-butyl 4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate
[0692] A mixture of tert-butyl 4-(2,3-diaminopyridin-4-yl)piperidine-1-carboxylate (2.00 g, 6.243 mmol, 1.00 equiv) and oxane-4-carbaldehyde (0.71 g, 6.243 mmol, 1.00 equiv) in MeOH under nitrogen atmosphere was irradiated with microwave radiation for 15 min at 120 °C. The resulting mixture was concentrated under reduced pressure. [0693] The resulting residue was dissolved in THF (10.00 mL), PhI(OAc)2 (1 equiv) was added, and the resulting mixture was stirred for 2 h at room temperature under nitrogen atmosphere. The reaction was quenched with water (200 mL) at room temperature, and the resulting mixture was
extracted with EtOAc (3 x 100 mL). The combined organics were washed with 100 mL of brine, and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl 4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate (1.2 g, 49.73%) as a yellow solid. Part IV – Synthesis of 4-[2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine
[0694] A solution of tert-butyl 4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1- carboxylate (1.00 g, 2.587 mmol, 1.00 equiv) and HCl (gas) in 1,4-dioxane (10.00 mL, 175.175 mmol, 67.70 equiv) in CH2Cl2 (20.00 mL) was stirred for 2h at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in 4- [2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine (1.3g, 175.45%) as a yellow solid. The crude product was used in the next step directly without further purification. Part V – Synthesis of tert-butyl N-(2-[4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carbonyl]-5-(trifluoromethoxy) phenyl) carbamate
[0695] Into a 100 mL round-bottom flask were added 4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine (150.00 mg, 0.524 mmol, 1.00 equiv), 2-[(tert-butoxycarbonyl)amino]-4- (trifluoromethoxy) benzoic acid (84.13 mg, 0.262 mmol, 0.50 equiv), EDCI (150.61 mg, 0.786 mmol, 1.50 equiv), HOBT (106.16 mg, 0.786 mmol, 1.50 equiv), DIEA (270.78 mg, 2.095
mmol, 4.00 equiv) and DMF (10.00 mL) at room temperature. The resulting mixture was stirred overnight at 50 °C under nitrogen atmosphere. The reaction was quenched by the addition of water (100 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100 mL). The resulting mixture was washed with 50 mL of brine. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl N-(2-[4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carbonyl]-5-(trifluoromethoxy) phenyl) carbamate (290 mg, 93.90%) as a yellow solid. The crude product was used in the next step directly without further purification. Part VI – Synthesis of (2-Amino-4-(trifluoromethoxy)phenyl)(4-(2-(tetrahydro-2H-pyran-4- yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperidin-1-yl)methanone (I-7)
[0696] Into a 100 mL round-bottom flask were added tert-butyl N-(2-[4-[2-(oxan-4-yl)-3H- imidazo[4,5-b] pyridin-7-yl] piperidine-1-carbonyl]-5-(trifluoromethoxy) phenyl) carbamate (290.00 mg, 0.492 mmol, 1.00 equiv), HCl (gas) in 1,4-dioxane (2.50 mL) and CH2Cl2 (10.00 mL) at room temperature. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. The crude product was purified by Prep-HPLC with the following conditions (Column, YMC-Actus Triart C18, 30 mm x 150 mm, 5um; mobile phase, Water (10 mmol/L NH4HCO3) and ACN (5% PhaseB up to 65% in 8 min); Detector, UV 220nm). This resulted in 2-[4-[2-(oxan-4-yl)-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carbonyl]-5- (trifluoromethoxy) aniline (33.9 mg, 14.08%) as a white solid. LCMS (ES, m/z): 490.20 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.16 (d, J = 5.1 Hz, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.07 (t, J = 5.2 Hz, 1H), 6.67 (d, J = 2.9 Hz, 1H), 6.53 – 6.46 (m, 1H), 5.62 (d, J = 14.0 Hz, 2H), 4.02 – 3.91 (m, 4H), 3.47 (td, J = 11.4, 2.9 Hz, 3H), 3.13 (dq, J = 10.7, 5.6, 4.4 Hz, 3H), 1.97 – 1.86 (m, 8H).
EXAMPLE 2 -- Synthesis of Enantiomer 1 of 2-(4-{2-[morpholin-2-yl]-3H-imidazo[4,5- b]pyridin-7-yl}piperidine-1-carbonyl)-5-(trifluoromethoxy)aniline (I-14)
Enantiomer 1 Part I – Synthesis of Benzyl 2-([2-amino-4-[1-(tert-butoxycarbonyl)piperidin-4-yl]pyridin- 3-yl]carbamoyl)morpholine- 4-carboxylate
[0697] To a mixture of tert-butyl 4-(2,3-diaminopyridin-4-yl)piperidine-1-carboxylate (2.00 g, 6.84 mmol, 1.00 equiv), 4-[(benzyloxy)carbonyl]morpholine-2-carboxylic acid (1.91g, 7.18 mmol, 1.05 equiv) and DIEA (1.77 g, 13.68 mmol, 2.00 equiv) in DMF (30.00 mL) was added HATU (3.25 g, 8.55 mmol, 1.25 equiv). The reaction mixture was stirred at 25 °C for 30 mins. On completion, the reaction mixture was poured into ice water 150 mL and extracted with EA (3 X 60 mL), the organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude product benzyl 2-([2-amino-4-[1-(tert- butoxycarbonyl)piperidin-4-yl]pyridin-3-yl]carbamoyl)morpholine- 4-carboxylate (4.20 g, 85.34%) as a brown gum and used into the next step directly.
[0698] Part II – Synthesis of Benzyl 2-[7-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3H- imidazo[4,5-b]pyridin-2-yl]morpholine-4-carboxylate
[0699] To a solution of benzyl 2-([2-amino-4-[1-(tert-butoxycarbonyl)piperidin-4-yl]pyridin-3- yl]carbamoyl)morpholine- 4-carboxylate (4.20 g, 5.837 mmol, 1.00 equiv) in DMF (30.00 mL) was added CsF (2.66 g, 17.511 mmol, 3.00 equiv). The reaction mixture was stirred at 100 °C for 5 hrs. On completion, the reaction mixture was poured into ice water 120 mL and extracted with EA (3 X 60 mL), the organic phase was collected, dried over anhydrous sodium sulfate, concentrated in vacuo to give a residue, the residue was purified by column flash (PE:EA = 2:1 to 1:2) to give the title compound benzyl 2-[7-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3H- imidazo[4,5-b]pyridin-2-yl]morpholine-4-carboxylate (1.8 g) as a white solid. Part III – Synthesis of Enantiomer 1 and Enantiomer 2 of Benzyl 2-{7-[1-(tert- butoxycarbonyl)piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-yl}morpholine-4-carboxylate
Enantiomer 1 Enantiomer 2 [0700] The racemate benzyl 2-[7-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3H-imidazo[4,5- b]pyridin-2-yl]morpholine-4-carbo- xylate (1.8 g) was separated by Chiral-Prep-HPLC with the following conditions (XA-Prep SFC350-1: Column, CHIRAL ART Cellulose-SB, 5*25 cm, 5 um; Mobile Phase A: CO2, Mobile Phase B: MeOH-Preparative; Flow rate: 160 mL/min; Gradient: isocratic 40% B; Column Temperature: 35℃; Back Pressure: 100 bar; Wave Length: 220 nm; RT1: 5.93 min; RT2: 7.01 min; Sample Solvent: MeOH:DCM = 1: 1; Injection Volume: 4 mL) to afford Enantiomer 1 of benzyl 2-{7-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3H-
imidazo[4,5-b]pyridin-2-yl}morpholine-4-carboxylate (0.95 g) and Enantiomer 2 of benzyl 2-{7- [1-(tert-butoxycarbonyl)piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-yl}morpholine-4- carboxylate (0.85 g). Part IV – Synthesis of Enantiomer 1 of Benzyl 2-[7-(piperidin-4-yl)-3H-imidazo[4,5- b]pyridin-2-yl]morpholine- 4-carboxylate
Enantiomer 1 [0701] Enantiomer 1 of benzyl 2-{7-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3H-imidazo[4,5- b]pyridin-2-yl}morpholine-4-carboxylate (550 mg, 1.054 mmol, 1.00 equiv) was dissolved in 2 M HCl in EA (10 mL, 102.151 mmol, 96.88 equiv). The mixture was stirred at room temperature for 2 hrs. On completion, the reaction mixture was concentrated in vacuo to get a residue. The residue was basified with saturated NaHCO3 to pH greater than 7, and then the mixture was extracted with DCM (3 x 20 mL). The combined organics were dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford Enantiomer 1 of benzyl 2-[7-(piperidin-4-yl)-3H-imidazo[4,5-b]pyridin-2-yl]morpholine- 4-carboxylate (310 mg, 69.75%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J = 4.9 Hz, 1H), 7.44 – 7.33 (m, 4H), 7.37 – 7.28 (m, 1H), 7.06 (d, J = 5.0 Hz, 1H), 5.15 (s, 2H), 4.80 (dd, J = 10.3, 3.0 Hz, 1H), 4.27 (d, J = 13.3 Hz, 1H), 4.02 (d, J = 11.6 Hz, 1H), 3.90 (d, J = 13.4 Hz, 1H), 3.71 (td, J = 11.6, 2.9 Hz, 1H), 3.33 - 3.20 (m, 1H), 3.10 (d, J = 12.9 Hz, 4H), 2.72 (t, J = 12.1 Hz, 2H), 1.87 - 1.69 (m, 5H).
Part V – Synthesis of Enantiomer 1 of Benzyl 2-[7-(1-{2-[(tert-butoxycarbonyl)amino]-4- (trifluoromethoxy)benzoyl}piperidin-4-yl)-3H-imidazo[4,5-b]pyridin-2-yl]morpholine-4- carboxylate
Enantiomer 1 [0702] To a solution of 2-[(tert-butoxycarbonyl)amino]-4-(trifluoromethoxy)benzoic acid (75.45 mg, 0.235 mmol, 1.1 equiv) in DMF (2 mL) was added DIEA (110.39 mg, 0.856 mmol, 4 equiv) and HATU (121.78 mg, 0.321 mmol, 1.5 equiv), then the resulting mixture was stirred for 5 mins and Enantiomer 1 of benzyl 2-[7-(piperidin-4-yl)-3H-imidazo[4,5-b]pyridin-2-yl]- morpholine-4-carboxylate (90.00 mg, 0.214 mmol, 1.00 equiv) was added. The mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was poured into ice water (15 mL) and extracted with ethyl acetate three times. The combined organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue. The residue was purified by column flash chromatography (DCM:MeOH = 30:1 to 15:1) to afford Enantiomer 1 of benzyl 2-[7-(1-{2-[(tert-butoxycarbonyl)amino]-4-(trifluoromethoxy)benzoyl}piperidin-4-yl)-3H- imidazo[4,5-b]pyridin-2-yl]morpholine-4-carboxylate (110 mg, 71.08%) as a bubble solid. Part VI – Synthesis of Enantiomer 1 of 2-(4-{2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin- 7-yl}piperidine-1-carbonyl)-5-(trifluoromethoxy)aniline (I-14)
Enantiomer 1
[0703] Enantiomer 1 of benzyl 2-[7-(1-{2-[(tert-butoxycarbonyl)amino]-4- (trifluoromethoxy)benzoyl} piperidin-4-yl)-3H-imidazo[4,5-b]pyridin-2-yl]morpholine-4- carboxylate (110 mg, 0.152 mmol, 1.00 equiv) was dissolved in TFA (2.00 mL, 26.93 mmol, 177.40 equiv), the reaction mixture was stirred at 60 °C for 2 hrs. On completion, the reaction mixture was concentrated in vacuo to get a residue. The residue was purified by prep-HPLC (Column, XBridge Shield RP18 OBD Column,, 19*150 mm, 5µm; mobile phase, Water (0.05%NH3H2O) and ACN (20% ACN up to 55% in 8 min) to afford Enantiomer 1 of 2-(4-{2- [morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl}piperidine-1-carbonyl)-5-(trifluoromethoxy) aniline (50.0 mg, 67.16%) as a white solid. LCMS m/z: 491.3 [M+H ]+.1H NMR (400 MHz, DMSO-d6) δ 12.86 (s, 1H), 8.23 (d, J = 5.0 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 5.0 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 6.49 (dd, J = 8.4, 2.3 Hz, 1H), 5.60 (s, 2H), 4.69 (dd, J = 9.9, 2.8 Hz, 1H), 4.22 – 4.02 (m, 1H), 3.97- 3.88 (m, 1H), 3.68 – 3.65 (m, 1H), 3.49 – 3.43 (m, 1H), 3.13 (d, J = 11.5 Hz, 3H), 2.92 (dd, J = 12.5, 9.9 Hz, 1H), 2.85 – 2.77 (m, 2H), 2.67- 2.60 (m, 1H), 1.87 - 1.82 (m, 4H). EXAMPLE 3 -- Synthesis of 2-{4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5- b]pyridin-7-yl]piperidine-1-carbonyl}-5-(trifluoromethoxy)aniline (I-35)
Part I – Synthesis of tert-butyl 4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5- b]pyridin-7-yl]piperidine-1-carboxylate
[0704] A solution of tert-butyl 4-(2,3-diamino-5-fluoropyridin-4-yl)piperidine-1-carboxylate (250 mg, 0.805 mmol, 1.00 equiv), 1-methylpyrazole-4-carbaldehyde (97.57 mg, 0.886 mmol, 1.1 equiv) and Na2S2O5 (229.69 mg, 1.208 mmol, 1.5 equiv) in DMF (5 mL) was stirred for 6 h at 100 °C under nitrogen atmosphere. The resulting mixture was diluted with 20 ml H2O. The aqueous layer was extracted with EtOAc (3 x 30 mL). The resulting mixture was washed with brine (3 x 30 mL). The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:2) to afford tert-butyl 4-[6- fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carboxylate (185 mg, 57.35%) as a yellow solid. LCMS m/z: 401.2 (M+H)+. Part II – Synthesis of 4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine hydrochloride
[0705] A solution of tert-butyl 4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin- 7-yl]piperidine-1-carboxylate (185 mg, 0.462 mmol, 1.00 equiv) in 2 M HCl (in EA, 4.62 mL, 9.240 mmol, 20 equiv) was stirred overnight at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in 4-[6-fluoro-2- (1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine hydrochloride (124 mg, 79.70%) as a yellow solid. The crude product was used in the next step directly without further purification. LCMS (ES, m/z): 301.1 (M+H)+.1H NMR (300 MHz, DMSO-d6) ppm δ 9.16 (s, 1H), 8.89 (d, J = 24.9 Hz, 1H), 8.51 (d, J = 46.6 Hz, 2H), 4.00 (s, 3H), 3.08 (d, J = 11.8 Hz, 1H), 2.18 (s, 1H), 2.04 – 1.84 (m, 2H), 1.36 (s, 4H).
Part III – Synthesis of 2-{4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carbonyl}-5-(trifluoromethoxy)aniline (I-35)
[0706] A solution of 4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine hydrochloride (60 mg, 0.178 mmol, 1.00 equiv) and 2-amino-4- (trifluoromethoxy)benzoic acid (47.27 mg, 0.214 mmol, 1.2 equiv), EDCI (68.30 mg, 0.356 mmol, 2 equiv), and HOBT (36.11 mg, 0.267 mmol, 1.5 equiv) in DMF (2 mL) was stirred for 16 h at rt under nitrogen atmosphere. The crude product was purified by Prep-HPLC with the following conditions Column: Sunfire Prep C18 OBD Column, 50*250 mm, 5μm 10nm; Mobile Phase A: Water (20 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 20% B to 55% B in 12 min, 55% B; Wave Length: 220nm; RT1(min): 12. This afforded 2-{4-[6-fluoro-2-(1-methylpyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1- carbonyl}-5-(trifluoromethoxy)aniline (26 mg, 28.99%) as a white solid. LCMS (ES, m/z): 504.2 (M+H)+. 1H NMR (300 MHz, DMSO-d6, ppm) δ 13.31 (s, 1H), 8.39 (s, 1H), 8.16 (d, J = 3.2 Hz, 1H), 8.10 (s, 1H), 7.17 (d, J = 8.4 Hz, 1H), 6.69 (s, 1H), 6.58 – 6.49 (m, 1H), 5.63 (s, 2H), 3.95 (s, 3H), 3.57 (t, J = 12.1 Hz, 1H), 3.09 (s, 2H), 2.31 (s, 2H), 1.81 (d, J = 13.3 Hz, 2H). EXAMPLE 4 -- Synthesis of 2-(4-[2-cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine- 1-carbonyl)-5-(trifluoromethoxy) aniline (I-4)
Part I – Synthesis of tert-butyl 4-[2-cyclopropyl-3H-imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate
[0707] A mixture of tert-butyl 4-(2,3-diaminopyridin-4-yl) piperidine-1-carboxylate (2.00 g, 6.840 mmol, 1.00 equiv) and cyclopropanecarbaldehyde (0.48g,6.840mmol,1.00equiv) in MeOH under nitrogen atmosphere. The final reaction mixture was irradiated with microwave radiation for 15min at 120 degrees C. The resulting mixture was concentrated under reduced pressure. To the above mixture was added PhI(OAc)2 (2.20 g, 6.840 mmol, 1.00 equiv) and THF (10.00 mL). The resulting mixture was stirred for additional 2h at room temperature. The reaction was quenched by the addition of Water (200mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 100mL). The resulting mixture was washed with 100 mL of brine. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl 4-[2-cyclopropyl-3H- imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate (1g,42.69%) as a yellow solid. Part II – Synthesis of 4-[2-cyclopropyl-3H-imidazo[4,5-b] pyridin-7-yl] piperidine
[0708] Into a 100mL round-bottom flask were added tert-butyl 4-[2-cyclopropyl-3H- imidazo[4,5-b] pyridin-7-yl] piperidine-1-carboxylate (800.00 mg, 2.336 mmol, 1.00 equiv), HCl (gas)in 1,4-dioxane (8.00 mL, 116.788 mmol, 59.99 equiv) and CH2Cl2(20.00 mL) at room temperature. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in 4-
[2-cyclopropyl-3H-imidazo[4,5-b] pyridin-7-yl] piperidine (920 mg) as a yellow solid. The crude product was used in the next step directly without further purification. Part III – Synthesis of tert-butyl N-[2-(4-[2-cyclopropyl-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carbonyl)-5-(trifluoromethoxy) phenyl] carbamate
[0709] Into a 40mL vial were added 4-[2-cyclopropyl-3H-imidazo[4,5-b] pyridin-7-yl] piperidine (200.00 mg, 0.825 mmol, 1.00 equiv) ,2-[(tert-butoxycarbonyl) amino]-4- (trifluoromethoxy) benzoic acid (132.57 mg, 0.413 mmol, 0.50 equiv), EDCI (237.33 mg, 1.238 mmol, 1.50 equiv), HOBT (167.28 mg, 1.238 mmol, 1.50 equiv), DIEA (426.68 mg, 3.301 mmol, 4.00 equiv) and DMF (10.00 mL) at room temperature. The resulting mixture was stirred for 4h at 50 degrees C. The resulting mixture was extracted with EtOAc (3 x 100mL). The combined organic layers were dried over anhydrous Na2SO4. The resulting mixture was washed with 100 mL of brine. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions (Column, YMC-Actus Triart C18, 30 mm X 150 mm, 5um; mobile phase, Water(10 mmol/L NH4HCO3) and ACN (50% PhaseB up to 65% in 6 min); Detector, uv220nm.This resulted in tert-butyl N-[2-(4-[2- cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carbonyl)-5-(trifluoromethoxy) phenyl] carbamate (117 mg, 18.88%) as a light yellow solid.
Part IV – Synthesis of 2-(4-[2-cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1- carbonyl)-5-(trifluoromethoxy) aniline (I-4)
[0710] Into a 100 mL round-bottom flask were added tert-butyl N-[2-(4-[2-cyclopropyl-3H- imidazo[4,5-b] pyridin-7-yl] piperidine-1-carbonyl)-5-(trifluoromethoxy) phenyl]carbamate (117.00 mg, 0.214 mmol, 1.00 equiv),HCl(gas)in 1,4-dioxane (2.00 mL) and CH2Cl2 (10.00 mL) at room temperature. The resulting mixture was stirred for 3h at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions (Column, XBridge Prep OBD C18 Column, 30x150 mm; mobile phase, Water(10 mmol/L NH4HCO3) and ACN (10% PhaseB up to 65% in 8 min); Detector, uv220nm). This resulted in 2-(4-[2-cyclopropyl-3H-imidazo[4,5- b]pyridin-7-yl]piperidine-1-carbonyl)-5-(trifluoromethoxy) aniline (86.2 mg, 90.23%) as a white solid. LCMS (ES, m/z): 446.25 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ 12.49 (s, 1H), 8.10 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 5.0 Hz, 1H), 6.69 – 6.64 (m, 1H), 6.50 (ddd, J = 8.4, 2.5, 1.2 Hz, 1H), 5.61 (s, 2H),5.01-3.56 (s,1H),3.25 (s, 1H), 3.07 (s, 2H), 2.17 – 2 (m,1H), 1.86 (s, 4H), 1.08 (d, J = 5.6 Hz, 4H). EXAMPLE 5 -- Synthesis of 4-[3H-imidazo[4,5-b] pyridin-7-yl]piperidine hydrochloride
Part I – Synthesis of tert-butyl 4-[3H-imidazo[4,5-b]pyridin-7-yl]-3,6–dihydro-2H-pyridine- 1-carboxylate
[0711] To a solution of 7-chloro-3H-imidazo[4,5-b]pyridine (1.10 g, 7.16 mmol, 1.0 equiv) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1- carboxylate (2.66 g, 8.59 mmol, 1.2 equiv) in dioxane (40 mL) and H2O (10 mL) were added K2CO3 (1.98 g, 14.33 mmol, 2.0 equiv) and Pd(dppf)Cl2.CH2Cl2 (0.58 g, 0.72 mmol, 0.1 equiv). After stirring for 16 h at 100 degrees C under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2/MeOH (10:1) to afford tert-butyl 4-[3H-imidazo[4,5- b]pyridin-7-yl]-3,6 –dihydro-2H-pyridine-1-carboxylate (880 mg, 40.90%) as a brown solid. Part II – Synthesis of tert-butyl 4-[3H-imidazo[4,5-b] pyridine-7-yl]piperidine-1- carboxylate
[0712] To a solution of tert-butyl 4-[3H-imidazo[4,5-b]pyridin-7-yl]-3,6-dihydro-2H-pyridine- 1-carboxylate (150 mg, 0.50 mmol, 1.0 equiv) in MeOH (10.00 mL) was added Pd/C (10%, 50 mg) under nitrogen atmosphere in a 100 mL round-bottom flask. The mixture was hydrogenated at room temperature for 72 h under hydrogen atmosphere using a hydrogen balloon, filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeOH in water, 10% to 65% gradient in 10 min; detector, UV 220 nm. This resulted in
tert-butyl 4-[3H-imidazo[4,5-b] pyridine-7-yl]piperidine-1-carboxylate (600 mg, 85.14%) as a white solid. Part III – Synthesis of 4-[3H-imidazo[4,5-b] pyridin-7-yl]piperidine hydrochloride
[0713] A mixture of tert-butyl 4-[3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carboxylate (500 mg, 1.65 mmol, 1.0 equiv) in DCM (10 mL) and MeOH (2 mL) was added HCl (gas) in 1,4-dioxane (10 mL), and the mixture was stirred at 20 degrees C for 14h. The product was precipitated by the addition of 20 mL DCM. This resulted in 4-[3H-imidazo[4,5-b] pyridin-7- yl]piperidine hydrochloride (396 mg, 99.57%) as a white solid. LCMS (ES, m/z): 202.8 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 9.34 (s, 2H), 8.66 (d, J = 5.6 Hz, 1H), 7.51 (d, J = 5.6 Hz, 1H), 3.82 – 3.70 (m, 1H), 3.44 (d, J = 12.0 Hz, 2H), 3.15 – 3.00 (m, 2H), 2.10 (tt, J = 5.6, 3.0 Hz, 4H). EXAMPLE 6 -- Synthesis of 2-{4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carbonyl}-5-(trifluoromethoxy)aniline (I-58)
Part I – Synthesis of 4-bromo-2,5-difluoropyridine
[0714] In a 2000-mL round bottom flask, to a solution of 2,5-difluoropyridine (50 g, 434.469 mmol, 1.00 equiv) in THF (500 mL) was added dropwise n-BuLi in hexanes (191 mL, 2.4 M, 456.192 mmol, 1.05 equiv) at -78 °C under N2 atmosphere. The reaction mixture was stirred at - 78 °C for 60 mins. To the above mixture was added dibromotetrafluoroethane (118.53 g, 456.192 mmol, 1.05 equiv) in THF (500 mL) dropwise at -78 °C in 60 mins. The resulting mixture was then warmed to room temprature over 2 h. The reaction was quenched with sat. NH4Cl (500 mL), and extracted with ether (2 x 200 mL). The combined organic extracts were washed with brine (300 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to yield the crude product 4-bromo-2,5-difluoropyridine (70 g, 83.06%) as a yellow oil. Part II – Synthesis of 4-bromo-5-fluoropyridin-2-amine
[0715] To a solution of 4-bromo-2,5-difluoropyridine (70 g, 360.864 mmol, 1.00 equiv) in DMSO (700 mL) was added NH3•H2O (210 mL, 5392.943 mmol, 14.94 equiv) in a pressure tank. The resulting mixture was stirred for 24 hours at 110 °C, and then allowed to cool down to room temperature. The mixture was then diluted with EtOAc (1000 mL) and washed with brine (3 x 300 mL). The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography, eluted with PE/EA = 5:1 to afford 4-bromo-5-fluoropyridin-2-amine (30 g, 40.48%) as a yellow solid. Part III – Synthesis of 4-bromo-5-fluoro-N-nitropyridin-2-amine
[0716] To a stirred mixture of 4-bromo-5-fluoropyridin-2-amine (10 g, 52.355 mmol, 1.00 equiv) in H2SO4 (100 mL, 1876.058 mmol, 35.83 equiv) was added fuming HNO3 (10 mL, 222.971 mmol, 4.26 equiv) dropwise at 0 °C. The resulting mixture was stirred for 1 hour at 0 °C under nitrogen gas atmosphere. The resulting mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The organic phase was collected and concentrated under
reduced pressure to give the title compound 4-bromo-5-fluoro-N-nitropyridin-2-amine (10 g, 80.93%) as a yellow solid. Part IV – Synthesis of 4-bromo-5-fluoro-3-nitropyridin-2-amine
[0717] A mixture of 4-bromo-5-fluoro-N-nitropyridin-2-amine (10 g, 42.373 mmol, 1.00 equiv) in sulfuric acid (200 mL, 2039.360 mmol, 48.13 equiv) was stirred for 12 hours at 5-10 °C. The resulting mixture was diluted with water (300 mL) and extracted with EtOAc (3 x 100 mL). The organic phase was collected and concentrated under reduced pressure to afford 4-bromo-5- fluoro-3-nitropyridin-2-amine (3 g, 30.00%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.12 (s, 2H). Part V – Synthesis of tert-butyl 2'-amino-5'-fluoro-3'-nitro-3,6-dihydro-2H-[4,4'- bipyridine]-1-carboxylate
[0718] To a solution of 4-bromo-5-fluoro-3-nitropyridin-2-amine (3 g, 12.712 mmol, 1.00 equiv) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1- carboxylate (7.86 g, 25.424 mmol, 2 equiv) in dioxane (60 mL, 708.245 mmol, 55.72 equiv) and H2O (30 mL, 1665.251 mmol, 131.00 equiv) were added K2CO3 (5.27 g, 38.136 mmol, 3 equiv) and Pd(dppf)Cl2 (1.04 g, 1.271 mmol, 0.1 equiv). After stirring for 4 hours at 90 °C under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA = 1:1 to afford tert-butyl 2'-amino-5'-fluoro-3'-nitro-3,6-dihydro-2H-[4,4'-bipyridine]-1-carboxylate (3 g, 69.75%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.10 (s, 2H), 5.71 (s, 1H), 3.91 (s, 2H), 3.52 (t, J = 5.4 Hz, 2H), 2.27 (s, 2H), 1.44 (s, 9H).
Part VI – Synthesis of tert-butyl 4-(2,3-diamino-5-fluoropyridin-4-yl)piperidine-1- carboxylate
[0719] To a solution of tert-butyl 2'-amino-5'-fluoro-3'-nitro-3,6-dihydro-2H-[4,4'-bipyridine]- 1-carboxylate (3 g, 8.867 mmol, 1.00 equiv) in MeOH (30 mL) was added Pd/C (10%, 3 g) in a pressure tank. The mixture was hydrogenated at room temperature under 30 psi of hydrogen pressure for 72 hours. On completion, the reaction mixture was filtered through a Celite pad and concentrated under reduced pressure to give tert-butyl 4-(2,3-diamino-5-fluoropyridin-4- yl)piperidine-1-carboxylate (2.20 g, 79.94%) as a brown solid. Part VII – Synthesis of tert-butyl 4-[2-amino-5-fluoro-3-(oxane-4-amido)pyridin-4- yl]piperidine- 1-carboxylate
[0720] To a stirred solution of tert-butyl 4-(2,3-diamino-5-fluoropyridin-4-yl)piperidine-1- carboxylate (300 mg, 0.967 mmol, 1.00 equiv) and oxane-4-carboxylic acid (125.79 mg, 0.967 mmol, 1.0 equiv) in pyridine (10 mL, 126.422 mmol, 130.79 equiv) was added EDCI (277.94 mg, 1.450 mmol, 1.5 equiv). The reaction mixture was stirred at room temperature for 2 hours. On completion, the reaction mixture was concentrated under vacuum. The resulting residue was separated between water (15 mL) and ethyl acetate (15 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated under reduce pressure to give tert- butyl 4-[2-amino-5-fluoro-3-(oxane-4-amido)pyridin-4-yl]piperidine-1-carboxylate (350 mg, 85.70%) as a brown solid, which was used directly in the next step.
Part VIII – Synthesis of tert-butyl 4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carboxylate
[0721] To a stirred solution of tert-butyl 4-[2-amino-5-fluoro-3-(oxane-4-amido)pyridin-4- yl]piperidine-1-carboxylate (350 mg, 0.828 mmol, 1.00 equiv) in DMF (10 mL, 129.218 mmol, 155.98 equiv) was added CsF (377.51 mg, 2.484 mmol, 3 equiv). The rection mixture was stirred at 100 °C for 3 hours. On completion, the reaction mixture was added ice water (50 mL) and extracted with EA (3 x 30 mL). The combined organic layers were washed with bine (50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography, eluted with PE/EA = 1:1 to 0:1 to afford tert-butyl 4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin- 7-yl]piperidine-1-carboxylate (180 mg, 53.72%) as a light yellow solid. Part IX – Synthesis of 4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine
[0722] To a stirred solution of tert-butyl 4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carboxylate (180 mg, 0.445 mmol, 1.00 equiv) in dioxane (4 mL) was added HCl (gas) in 1,4-dioxane (4 mol/L, 4 mL). The reaction mixture was stirred at room temperature for 2 hours. On completion, the reaction mixture was concentrated in vacuo to afford 4-[6-fluoro-2- (oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine (135 mg, 99.67%) as a light yellow solid.
Part X – Synthesis of 2-{4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7- yl]piperidine-1-carbonyl}-5-(trifluoromethoxy)aniline (I-58)
[0723] A mixture of 4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine (65 mg, 0.214 mmol, 1.00 equiv), 2-amino-4-(trifluoromethoxy)benzoic acid (51.95 mg, 0.235 mmol, 1.1 equiv), EDCI (81.88 mg, 0.428 mmol, 2 equiv), HOBt (43.28 mg, 0.321 mmol, 1.5 equiv) and DIEA (110.40 mg, 0.856 mmol, 4 equiv) in DMF (6 mL, 77.531 mmol, 363.04 equiv) was stirred for 10 hour at 25 °C. On completion, the reaction mixture was quenched with ice water (30 mL) and extracted with EA (3 x 10 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by Prep-HPLC-001: Column, Sunfire Prep C18 OBD Column, 50*250 mm, 5µm 10nm; mobile phase, Water (0.05%NH3H2O) and ACN (25% ACN up to 60% in 12 min) to give the title compound 2-{4-[6-fluoro-2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carbonyl}- 5-(trifluoromethoxy)aniline (31 mg, 28.60%) as a white solid. EXAMPLE 7 – Synthesis of Additional 4-Piperidinyl-imidazo[4,5-b]pyridines and Related Compounds [0724] The compounds listed in Table 7 and 7-A below were prepared using experimental procedures described in the Examples and Detailed Description. Table 7 and 7-A also list each compound’s 1H NMR characterization data and mass-to-charge ratio observed by LC/MS. Chemical structures are presented in Tables 1 and 1-A above.
TABLE 7.
TABLE 7-A.
EXAMPLE 8 -- Synthesis of 7-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)- 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (II-3)
Part I – Synthesis of tert-Butyl 4-{2-oxo-1H,3H-imidazo[4,5-b]pyridin-7-yl}piperidine-1- carboxylate
[0725] A solution of tert-butyl 4-(2,3-diaminopyridin-4-yl)piperidine-1-carboxylate (0.8 g, 2.736 mmol, 1.00 equiv) and CDI (0.89 g, 5.472 mmol, 2 equiv) in dimethylformamide (8 mL, 109.447 mmol, 40.00 equiv) was stirred for 16 h at rt under nitrogen atmosphere. The resulting mixture was diluted with 10 mL H2O and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl 4-{2- oxo-1H,3H-imidazo[4,5-b]pyridin-7-yl}piperidine-1-carboxylate (0.6 g, 68.88%) as a brown solid. Part II – Synthesis of 7-(Piperidin-4-yl)-1H,3H-imidazo[4,5-b]pyridin-2-one
[0726] A mixture of tert-butyl 4-{2-oxo-1H,3H-imidazo[4,5-b]pyridin-7-yl}piperidine-1- carboxylate (0.6 g, 1 equiv) in HCl (2 M in EA, 12 mL) was stirred overnight at rt. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep- HPLC with the following conditions (Column: XBridge Shield RP18 OBD Column, 19*150 mm, 5μm; Mobile Phase A: Water (0.05%NH3H2O), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 58% B in 8 min); Detector, UV220nm). This resulted in 7- (piperidin-4-yl)-1H,3H-imidazo[4,5-b]pyridin-2-one (400 mg) as a white solid. LC/MS: m/z 219.2 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 10.60 (s, 2H), 7.81 (d, J = 5.5 Hz, 1H), 6.83
(d, J = 5.5 Hz, 1H), 4.11 (s, 1H), 3.05 (s, 1H), 2.89 (s, 1H), 2.70 (s, 2H), 1.70 (d, J = 12.4 Hz, 2H), 1.56 (d, J = 12.8 Hz, 2H). Part III – Synthesis of 7-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)-1,3- dihydro-2H-imidazo[4,5-b]pyridin-2-one (II-3)
[0727] To a solution of 7-(piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 2HCl (80 mg, 90% Wt, 1.0 Eq, 0.25 mmol) in DMF (5 mL) was added DIPEA (251 mg, 0.338 mL, 7.8 Eq, 1.94 mmol), followed by 2-amino-4-(trifluoromethoxy)benzoic acid (66 mg, 1.2 Eq, 0.30 mmol) and HATU (95 mg, 1.01 Eq, 0.25 mmol). The solution was stirred at rt for 18 h. The reaction mixture was diluted with Water (25 mL) and transferred into a separating funnel. The layer was extracted with EtOAc (2 x 25 mL). The combined organic layers were collected, dried over So-dium sulfate, filtered and concentrated in vacuo.The crude product was purified by chromatog-raphy on RP Flash C18 (12 g cartridge, 0-100% MeCN/10 mM Ammonium Bicarbonate) to af-ford 7-(1-(2-amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)-1,3-dihydro- 2H-imidazo[4,5-b]pyridin-2-one (25 mg, 56 µmol, 23 %, 95% Purity) as a pale white solid. LCMS (ES, m/z): 422.2 (M+H)+.1H NMR in DMSO-d63262-043 was consistent with product structure at 96% purity.1H NMR (500 MHz, DMSO-d6) δ 11.25 (s, 1H), 11.02 (s, 1H), 7.81 (d, J = 5.4 Hz, 1H), 7.16 (d, J = 8.4Hz, 1H), 6.86 (d, J = 5.5 Hz, 1H), 6.64 (dd, J = 2.5, 1.2 Hz, 1H), 6.53 – 6.42 (m, 1H), 5.61 (s, 2H), 3.11– 2.82 (m, 3H), 1.87 – 1.59 (m, 4H). (2 protons not visible). EXAMPLE 9 – Synthesis of Additional 4-Piperidinyl-1,3-dihydro-2H-imidazo[4,5- b]pyridin-2-ones and Related Compounds [0728] The compounds listed in Table 8 below were prepared using experimental procedures described in the Examples and Detailed Description. Table 8 also lists each compound’s 1H
NMR characterization data and mass-to-charge ratio observed by LC/MS. Chemical structures are presented in Table 2 above. TABLE 8.
EXAMPLE 10 -- Synthesis of 4-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)- 5-fluoro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (III-1)
Part I – Synthesis of 4-chloro-1-(triisopropylsilyl) pyrrolo[2,3-b] pyridine
[0729] To a stirred solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine (450.0 g, 2949.0 mmol, 1.0 equiv) in THF (4,500 mL) was added NaH (106.2 g, 4424.0 mmol, 1.5 equiv) in portions at 0 ℃ under nitrogen atmosphere. The resulting mixture was stirred for 1h at 0 ℃ under nitrogen atmosphere. Then chlorotris(propan-2-yl)silane (853.0 g, 4424.0 mmol, 1.5 equiv) was added. The resulting mixture was stirred overnight at 75 ℃ under nitrogen atmosphere. The reaction was quenched by the addition of water/ice (5,000 mL) at room temperature. The
resulting mixture was extracted with EtOAc (3 x 2,000 mL). The combined organic layers were washed with brine (1x1000 mL) and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE to afford 4-chloro-1-(triisopropylsilyl) pyrrolo[2,3-b]pyridine (600 g, 65.85%) as a light yellow oil. Part II – Synthesis of 4-chloro-5-fluoro-1-(triisopropylsilyl) pyrrolo[2,3-b] pyridine
[0730] A solution of 4-chloro-1-(triisopropylsilyl) pyrrolo[2,3-b]pyridine (550 g, 1780.0 mmol, 1.0 equiv) in THF (8,000 mL) at -78 ℃ was treated with s-BuLi (1.3 M in n-hexane, 3 L, 3916.0 mmol, 2.2 equiv) for 1 h at -78 ℃ under nitrogen atmosphere followed by the addition of N-(benzenesulfonyl)-S-phenylfluoranesulfonamido (1122.8 g, 3560.0 mmol, 2.0 equiv) dropwise in THF (3,000 mL) at -70 °C. The resulting mixture was stirred for 1 h at -60 ℃ under nitrogen atmosphere. The reaction was quenched by the addition of sat. NH4Cl (aq.) (5,000 mL) at 0 ℃. The resulting mixture was extracted with EtOAc (3 x 3000 mL). The combined organic layers were washed with brine (1 x 5,000 mL) and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE to afford 4-chloro-5-fluoro-1-(triisopropylsilyl) pyrrolo[2,3-b] pyridine (400 g, 68.73%) as a yellow solid. Part III - Synthesis of 4-Chloro-5-fluoro-1H-pyrrolo[2,3-b]pyridine
[0731] A solution of 4-chloro-5-fluoro-1-(triisopropylsilyl) pyrrolo[2,3-b]pyridine (400 g, 1223.5 mmol, 1.0 equiv) and HCl (gas) in 1,4-dioxane (1,000 mL) and DCM (4,000 mL) was stirred for 2 h at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in water (3,000 mL). The mixture was basified to pH 10 with saturated Na2CO3 (aq.). The resulting mixture was extracted
with EtOAc (3 x 2,000 mL). The combined organic layers were washed with brine (1 x 2,000 mL) and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in 4-chloro-5-fluoro-1H-pyrrolo[2,3-b] pyridine (140 g, 67.08%) as a white solid. Rt 0.64 min (UPLC, Basic); m/z 202.4 (M+H)+ (ES+); 1H NMR (500 MHz, DMSO-d6) δ 11.54 (s, 1H), 8.12 (d, J = 4.9 Hz, 1H), 7.41 – 7.37 (m, 1H), 6.88 (d, J = 4.9 Hz, 1H), 6.57 – 6.52 (m, 1H), 4.09 (s, 1H), 3.08 – 2.95 (m, 3H), 2.69 – 2.62 (m, 2H), 1.77 – 1.62 (m, 4H). Part IV - Synthesis of tert-butyl 4-{5-fluoro-1H-pyrrolo[2,3-b] pyridin-4-yl}-3,6-dihydro- 2H-pyridine- 1-carboxylate
[0732] A solution of 4-chloro-5-fluoro-1H-pyrrolo[2,3-b]pyridine (100 g, 586.3 mmol, 1.0 equiv), tert-butyl 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1- carboxylate (181.3 g, 586.3 mmol, 1 equiv), K2CO3 (202.5 g, 1465.7 mmol, 2.5 equiv) and Pd(dppf)Cl2.CH2Cl2 (23.9 g, 29.3 mmol, 0.05 equiv) in dioxane (800 mL) and H2O (200 mL) was stirred for 2 h at 100 °C under nitrogen atmosphere. The reaction was quenched by the addition of water (4,000 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 2,000 mL). The combined organic layers were washed with brine (1 x 2,000 mL) and then dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (3:1) to afford tert-butyl 4-{5-fluoro-1H-pyrrolo[2,3-b] pyridin-4-yl}-3,6-dihydro-2H-pyridine- 1-carboxylate (100 g, 53.75%) as a yellow solid. Part V – Synthesis of tert-butyl 4-{3,3-dibromo-5-fluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4- yl}piperidine-1-carboxylate
[0733] To a stirred solution of tert-butyl 4-{5-fluoro-1H-pyrrolo[2,3-b]pyridin-4- yl}piperidine-1-carboxylate (300 mg, 0.939 mmol, 1.00 equiv) and NBS (652.02 mg, 3.662 mmol, 3.9 equiv) in t-BuOH (10 mL, 105.232 mmol, 112.03 equiv) was stirred for 2h at 30 degrees C. The resulting mixture was concentrated under reduced pressure.The resulting mixture was diluted with water (5 ml) and EA (5 ml).Then extracted with EA (2 x 5 ml). The combined organic layers were concentrated to used directly. Part VI – Synthesis of tert-butyl 4-{5-fluoro-2-oxo-1H,3H-pyrrolo[2,3-b]pyridin-4- yl}piperidine-1-carboxylate
[0734] A solution of tert-butyl 4-{3,3-dibromo-5-fluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4- yl}piperidine-1-carboxylate (300 mg, 0.608 mmol, 1.00 equiv) in THF (6 mL, 74.058 mmol, 121.74 equiv) and water (3 ml) was added zinc (198.86 mg, 3.040 mmol, 5 equiv) and NH4Cl (325.39 mg, 6.080 mmol, 10 equiv) and stirred for 1 h at 25 degrees C. The reaction was monitored by LCMS. The resulting mixture was filtered, the filter cake was washed with EA (3x3 ml). The filtrate was concentrated under reduced pressure. The resulting mixture was diluted with water (5 ml) and extracted with EA (3x3 ml). The combined organic layers were washed with con.NaCl, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to used directly.1H NMR (400 MHz, DMSO-d6) δ 11.20 – 10.86 (m, 2H), 7.97 (d, J = 3.5 Hz, 1H), 4.05 (dd, J = 14.3, 7.3 Hz, 2H), 3.70 (s, 2H), 3.00 – 2.66 (m, 3H), 1.71 (q, J = 5.7 Hz, 4H), 1.42 (s, 9H).
Part VII - Synthesis of 5-fluoro-4-(piperidin-4-yl)-1H,3H-pyrrolo[2,3-b]pyridin-2-one hydrochloride
[0735] Into a 2M HCl in EA (2 mL) were added tert-butyl 4-{5-fluoro-2-oxo-1H,3H- pyrrolo[2,3-b]pyridin-4-yl}piperidine-1-carboxylate (200 mg, 0.596 mmol, 1.00 equiv) at 25 degrees C and stirred for 2 h. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure to used directly. Part VIII - Synthesis of 4-(1-(2-Amino-4-(trifluoromethoxy)benzoyl)piperidin-4-yl)-5- fluoro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (III-1)
[0736] To a stirred solution of 5-fluoro-4-(piperidin-4-yl)-1H,3H-pyrrolo[2,3-b]pyridin-2-one hydrochloride (80 mg, 0.294 mmol, 1.00 equiv) in DMF (1 mL, 12.922 mmol, 43.89 equiv) were added 2-amino-4-(trifluoromethoxy)benzoic acid (78.13 mg, 0.353 mmol, 1.2 equiv), HATU (167.92 mg, 0.441 mmol, 1.5 equiv) and DIEA (114.16 mg, 0.882 mmol, 3.0 equiv) in portions at 25 degrees C. The resulting mixture was stirred for 2 h at 25 degrees C. The crude product was purified by Prep-HPLC to afford 4-{1-[2-amino-4-(trifluoromethoxy)benzoyl]piperidin-4-yl}-5- fluoro-1H,3H-pyrrolo[2,3-b]pyridin-2-one (27.8 mg, 21.54%) as a white solid. LCMS (ES, m/z): 439.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 7.98 (d, J = 3.4 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 5.60 (s, 2H), 4.80 – 3.80 (m, 2H), 3.74 (s, 2H), 3.13 – 2.85 (m, 3H), 3.02 (d, J = 13.4 Hz, 3H), 1.93 – 1.69 (m, 4H).
EXAMPLE 11 – Synthesis of Additional 4-Piperidinyl-1,3-dihydro-2H-pyrrolo[2,3- b]pyridin-2-ones and Related Compounds [0737] The compounds listed in Table 9 below were prepared using experimental procedures described in the Examples and Detailed Description. Table 9 also lists each compound’s 1H NMR characterization data and mass-to-charge ratio observed by LC/MS. Chemical structures are presented in Table 3 above. TABLE 9.
EXAMPLE 12 – Biological Assay for Inhibiting Isolated ERK5 [0738] Exemplary compounds were tested for ability to inhibit isolated ERK5 using the LANCE® Ultra time-resolved FRET assay. Assay procedures and results are described below. Part I – Procedures for Time-Resolved FRET Assay [0739] Recombinant human Erk5 catalytic domain (1-398 amino acids of accession number NP_002740.2) was purchased from Carna Biosciences (Product number 04-146, Lot 13CBS- 0805 C). The protein was expressed as an N-terminal GST-fusion protein (73 kDa) in E.coli. GST-Erk5 was purified using glutathione Sepharose chromatography and activated using His- tagged MAP2K5. The activated GST-Erk5 was then purified using Ni-NTA chromatography resulting in 53% purity. The protein was stored at 515 µg/mL (7.05 µM) in storage buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% v/v glycerol, pH 7.5), at -80°C. [0740] The substrate for the kinase was LANCE® Ultra Europium-anti-phospho-eIF4E- binding protein 1 (Thr37/46) peptide (Perkin Elmer TRF0216-D). The sequence motif for the peptide was ST(pT)PGGTLFST(pT)PG, with (pT) denoting the two potential phospo-theronines. The peptide was stored as a 5 µM stock solution in 50 mM Tris-HCl (pH7.4), 0.9% w/v NaCl, 0.1% w/v BSA and 0.05% w/v sodium azide, at -20°C. [0741] Test compounds were prepared as 30 mM stock solutions in DMSO, stored under dry nitrogen gas. Solutions were plated into Echo® Qualified 384-well low dead volume microplates
(Labcyte LP-0200). Compounds were then dosed into white, low-volume 384-well assay plates (Greiner Bio-One Ltd 784075) using the Labcyte Echo® 650 acoustic dosing platform. Test compounds were dosed in a 12-point, 2-fold dilution series at 100 µM top concentration then backfilled to 1% v/v DMSO. The top concentration was adjusted based on expected compound potency. A tool compound (BAY-885) was included in each assay plate as a standard. High controls (1% v/v DMSO) were included in rows A and O, with low controls (10 µM BAY-885) in rows B and P. Two identical sets of assay plates were prepared and tested in two independent experiments. [0742] At the beginning of the assay, 3 µL of 2-fold concentrated peptide buffer (100 nM ULight-eIF4E-binding protein 1 (Thr37/46) peptide, 300 µM ATP, 10 mM MgCl2, 1 mM EGTA, 50 mM HEPES, 1 mM DTT, 0.01% v/v Tween 20, pH 7.5) was added to each well using an electronic multichannel pipette. The reaction was initiated by adding 3 µL of 2-fold concentrated kinase buffer (15 nM Erk5, 10 mM MgCl2, 1 mM EGTA, 50 mM HEPES, 1 mM DTT, 0.01% v/v Tween 20, pH 7.5), using an electronic multichannel pipette and mixing the assay volume three times. The final reaction composition was 7.5 nM Erk5, 50 nM ULight-eIF4E-binding protein 1 (Thr37/46) peptide, 150 µM ATP, 10 mM MgCl2, 1 mM EGTA, 50 mM HEPES, 1 mM DTT, 0.01% v/v Tween 20, pH 7.5. As the protein purity was 53%, the true concentration of Erk5 was approximately 3.75 nM. [0743] The reaction was allowed to progress for 1 hour at 22°C sealed and protected from light. To terminate the reaction and detect substrate phosphorylation, 6 µL of 2-fold concentrated detection buffer (12mM EDTA and 4 nM Eu-anti-phosphoeIF4E-binding protein 1 (Thr37/46) antibody in LANCE® Detection Buffer (Perkin Elmer CR97-100)) was added to each well using an electronic multichannel pipette. The assay volume was mixed three times. [0744] The terminated reaction was allowed to incubate for 1 hour at 22°C sealed and protected from light. The level of resonance energy transfer was detected using an Envision Xcite plate reader (Perkin Elmer), with excitation at 350 nm and emission at 620 nm and 665 nm. The ratio of signal at 665 nm and 620 nm was taken as the level of phosphorylated substrate. The data was normalised to % inhibition by setting 0% as the signal from the high control and 100% as that from the low control. Values were plotted, and IC50 values were calculated using Dotmatics Studies (Dotmatics Knowledge Solutions).
Part II – Results [0745] Experimental results are provided in Table 10 and 10-A, below. The symbol “++++” indicates an IC50 less than or equal to 0.05 µM. The symbol “+++” indicates an IC50 in the range of 0.5 µM to greater than 0.05 µM. The symbol “++” indicates an IC50 in the range of 5 µM to greater than 0.5 µM. The symbol “+” indicates an IC50 in the range of 30 µM to greater than 5 µM. TABLE 10.
EXAMPLE 13 – Biological Assay for Inhibiting ERK5 in Cells [0746] Exemplary compounds were tested for ability to inhibit ERK5 activity in SN12C cells using a MEF2-responsive transcription element and two luciferase reporter genes. Assay procedures and results are described below. Part I – Procedures for Luciferase Reporter Gene Assay [0747] The polyclonal SN12C-MEF2-luc cell line was generated by stably transducing SN12C cells with aMEF2-responsive transcription element upstream of a firefly luciferase gene and a cytomegalovirus (CMV) promoter element upstream of a renilla luciferase gene. Generation of this cell line was carried out at Sygnature Discovery. This cell line was grown in RPMI 1640 media (Gibco #11530406) without phenol red supplemented with 10 % FBS, 1 % L- glutamine, 1 % penicillin/streptomycin, 250 µg/mL Hygromycin B gold and 1.25 µg/mL puromycin. Cells were grown at 37 °C in a humidified environment with 5 % CO2. [0748] On day 1 cells were seeded in 384-well black-walled plates (Greiner 781091) at a density of 10,000 cells per well in 20 µL of culture media. On day 2, using an ECHO 650, test compounds were added in serial dilutions and trametinib was added to all wells at a final concentration of 125 nM. Plates were then incubated for 24 hours at 37 °C. On day 3, 20 µL of Dual-glo luciferase reagent (Promega, E2940) was added to each well, and the plates were incubated at room temperature for 10 minutes. Luminescence signal was then read on an
EnVision Xcite multimode plate reader (Perkin-Elmer). Renilla luciferase substrate (Dual-glo stop & Glo Promega E2940) was added to all wells (20 µL per well), and the plates were incubated at room temperature for 10 minutes. Luminescence signal was then read on an EnVision Xcite multimode plate reader (Perkin-Elmer). [0749] The firefly signal was then normalised to the renilla signal, and IC50 values were calculated using Dotmatics Studies (Dotmatics Knowledge Solutions) or GraphPad Prism. Values for cells treated only with DMSO were defined as the minimum control. Values for cells treated only with trametinib (125 nM) were defined as the maximum control. Part II – Results [0750] Experimental results are provided in Table 11 and 11-A, below. The symbol “***” indicates an IC50 less than or equal to 0.05 µM. The symbol “**” indicates an IC50 in the range of 0.5 µM to greater than 0.05 µM. The symbol “*” indicates an IC50 greater than 0.5 µM. TABLE 11.
EXAMPLE 14 – Biological Assay for Inhibiting 3D Cancer Cell Cultures with Combination Therapy [0751] An exemplary compound from the prior published literature having ERK5 inhibitory activity was tested for ability to inhibit 3D cancer cell cultures of pancreatic cancer and lung cancer as part of a combination therapy with a MEK1/2 inhibitor. Assay procedures and results are described below. Part I – Procedures for 3D Cancer Cell Culture Assay [0752] Assays were conducted using KRAS mutant (NCI-H2122 and A549) and KRAS wild- type (NCI-H520) human lung cancer cell lines according to the procedures described in
Haagensen, E. J., et al. Eur. J. Cancer (2016) Vol.56, pp.69-76. Briefly, cells were seeded in soft agar in 96-well, low-attachment tissue-culture plates. After 24 hours, cells were treated with a concentration range of an ERK5 inhibitor alone, a MEK1/2 inhibitor alone, or a combination of the ERK5 inhibitor and MEK1/2 inhibitor. At the time of treatment, assay plates that did not receive treatment were collected and cell viability was measured using alamarBlue reagent to establish baseline cell viability. Treated plates were incubated for 7 days, and alamarBlue readout was then collected. [0753] Inhibition (%) was used as a measure of cell viability and was calculated using the equation I = 1 - T/U, where T is treated and U is untreated control. Single-agent response curve fitting, and the analysis of combination effects, were performed using CHALICE™ software from Horizon. The calculated synergy scores were based on the Loewe Additivity model and characterize the strength of synergistic interaction. A score greater than 1.5 represents synergistic activity between treatment agents. Part II – Results [0754] Experimental results are depicted in Figure 1, demonstrating in vitro synergy of ERK5 and MEK inhibition in KRAS-mutant cancer cells, but not wild-type cancer cells, in this 3D culture system. EXAMPLE 15 – Biological Assay for Inhibiting Mouse Xenograft Tumor Growth [0755] An exemplary compound from the prior published literature having ERK5 inhibitory activity was tested, alone or in combination with trametinib, for ability to inhibit tumor growth in patient-derived mouse xenograft models of pancreatic cancer and lung cancer. Assay procedures and results are described below. Part I – Procedures for Patient-Derived Mouse Xenograft (PDX) Tumor Growth Assay [0756] Balb/c mice (6-8 weeks old) were inoculated subcutaneously in the right flank with a primary human tumor xenograft model tumor fragment (2-3 mm3 in diameter) for tumor development. In one study, mice were inoculated with a human lung adenocarcinoma tumor model (MSCLC, ADC model LU6424) that harbors a BRAF mutation (LU6424); in a second study, mice were inoculated with a human pancreatic tumor model (adenosquamous carcinoma model PA6258) with a KRAS G12D mutation (PA6258). When mean tumor volume reached
approximately 150 -200 mm3, animals were randomly allocated to four treatment groups of 3 mice each. Mice were treated with one of the following: 1. Vehicle control, 2. Exemplary ERK5 inhibitor alone (60 mg/kg, dosed daily by intraperitoneal injection), 3. Trametinib alone (0.3 mg/kg, dosed daily orally), or 4. Combination of ERK5 inhibitor and trametinib (60 mg/kg, dosed daily by intraperitoneal injection, and 0.3 mg/kg, dosed daily orally, respectively). [0757] Tumors were measured twice per week using calipers. The exemplary ERK5 inhibitor used in this experiment is a potent and selective tool compound from the prior published literature having an IC50 in vitro of approximately 35 nM in each of the assays described in Examples 12 and 13, and with high selectivity for ERK5, but with a short half-life and short PD effect. Part II – Results [0758] Experimental results are depicted in Figures 2 and 3, demonstrating that the exemplary ERK5 inhibitor from the prior published literature reduces tumor growth in patient-derived mouse xenograft (PDX) models of pancreatic cancer (Figure 2) and lung cancer (Figure 3), and that tumor growth is further synergistically reduced when the ERK5 inhibitor is combined with trametinib (a MEK1/2 inhibitor). EXAMPLE 16 – Mouse Pharmacokinetic Studies [0759] Exemplary compounds were tested to determine their pharmacokinetic properties in mice using cassette dosing protocols. Assay procedures and results are described below. Part I – Procedures for Mouse Casette Pharmacokinetics Studies [0760] Pharmacokinetics studies were conducted using cassette dosing protocols, with five test compounds administered per mouse. Treatment groups were 3 mice per route of administration. Compounds were formulated in 5% DMSO and 95% PEG400 with final concentrations of 1 mg/mL for IV dosing and 0.5 mg/mL for PO dosing. Compounds were dosed at 2 mg/kg for IV dosing and 5 mg/kg for PO dosing. Blood samples were withdrawn at 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24 hours following IV dosing, and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24 hours following PO dosing. Blood samples were centrifuged at 4,000 g for
5 minutes at 4 °C to obtain plasma samples. Plasma samples were diluted with acetonitrile containing internal standard, vortexed for 30 seconds, then centrifuged at 4,000 rpm for 15 minutes at 4 °C. The supernatant was diluted with water, and compound concentration was determined by HPLC/MS/MS compared to calibration standards of 0.5-1,000 ng/mL. Part II – Results [0761] Experimental results are provided in Table 12, below. Where route is listed as “IV*”, the compound was dosed IV at 1 mg/kg. TABLE 12.
EXAMPLE 17 – Biological Assay for Inhibiting Cancer Cells with Combination Therapy [0762] Exemplary compounds are tested to determine their ability to inhibit cancer cell growth in combination with selected standard-of-care agents in cancer cell lines by CellTiter Glo Luminescent Cell Viability Assay. Assay procedures are described below. Part I – Procedures for Combination Therapy Assay for Inhibiting Cancer Cells [0763] Combinations to be examined with selected cell lines are listed in Table 13. Plates are prepared in matrix fashion, with one axis having a blank row and 8 serial dilutions (3-fold) of a second anti-cancer agent, and the other axis having a blank row and 6 serial dilutions (3-fold) of an exemplary ERK5 inhibitor compound. Final DMSO concentration in the cell cultures is 0.2%. Top concentration for most second anti-cancer agents is 3 µM. Top concentration for trametinib and cobimetinib is 1 µM. Top concentration for a TEAD inhibitor, MRTX1133, and a MEK-RAF inhibitor is 10 µM. Top concentration for an exemplary ERK5 inhibitor is 3 µM or 10 µM.
TABLE 13.
[0764] Cells are seeded according to the following procedure. 1. Prepare complete medium: Add FBS and appropriate additives according to the information sheet provided by the vendor. Mix gently. 2. Remove and discard culture medium using a vacuum pump. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.038% (w/v) EDTA solution to remove all traces of serum that contains trypsin inhibitor. 3. Add 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed. 4. Add 9.0 ml of complete growth medium and aspirate cells by gently pipetting. 5. Transfer the cell suspension to a centrifuge tube, and centrifuge at 1000 rpm for 4 minutes. 6. Discard the supernatant using a vacuum pump. 7. Add appropriate volume of complete medium. Suspend the cell pellet by gently pipetting. 8. Count the cell numbers with Vi-cell XR and adjust cells to appropriate density. 9. Add 200μL of cell suspension to 96-well opaque-walled clear bottom plates according to the planned plate layout, and place the plates in the CO2 incubator overnight. 10. Incubate the plate for 10 days at 5% CO2, 37°C.
[0765] Determination of cell viability following incubation using the CellTiter Glo Luminescent Cell Viability Assay is performed according to the following procedure. 1. Thaw the CellTiter-Glo buffer and equilibrate the lyophilized CellTiter-Glo substrate to room temperature prior to use. 2. Transfer the appropriate volume of CellTiter-Glo buffer into the bottle containing CellTiter-Glo substrate to reconstitute the lyophilized enzyme/substrate mixture. This forms the CellTiter-Glo reagent. 3. Mix by gently vortexing, swirling or by inverting the contents to obtain a homogeneous solution. The CellTiter-Glo substrate should go into solution easily in less than one minute. 4. Observe the cell morphology under an inverted microscope after corresponding treatment. 5. Equilibrate the plate and its contents to room temperature for approximately 30 minutes. 6. Add 100μL of CellTiter-Glo reagent to the assay plate. 7. Mix contents for 10 minutes on an orbital shaker to induce cell lysis. 8. Allow the plate to incubate at room temperature for 10 minutes to stabilize luminescent signal. 9. Paste the clear bottom with white back seal and record luminescence with Enspire plate reader, measurement time 0.1ms. INCORPORATION BY REFERENCE [0766] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes. EQUIVALENTS [0767] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing
description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims
Claims: 1. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, C1-4 hydroxyalkoxyl, -(C1-4 alkoxylene)-N(R4)(R5), halo, or -N(R4)(R5); or two occurrences of R1 attached to the same carbon atom are taken together with said carbon atom to form a cyclopropyl ring; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; or two occurrences of R1 attached to adjacent carbon atoms are taken together with said carbon atoms to form a carbon-carbon double bond; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, C3-6 cycloalkyl, C1-4 alkyl, C1-4 haloalkyl, or hydrogen; wherein said heterocyclyl and cycloalkyl is each substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo;
R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R4 and R5 each represent independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halo, cyano, -S-(C1-6 haloalkyl), -S-(C1-6 alkyl), -S(O)2-(C1-6 alkyl), - S(O)2N(R4)(R5), -C(O)N(R4)(R5), -N(R4)C(O)-(C1-6 aliphatic), -N(R4)C(O)-(C1-6 alkoxy), - N(R4)-(C1-6 hydroxyalkoxyl), -N(R4)S(O)2-(C1-6 alkyl), C3-6 cycloalkyl, phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered saturated or partially unsaturated monocyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, C1-4 haloalkyl, and oxo; X1 is -C(O)-, -S(O)-, or -S(O)2-; X2 is -C(R2B)=N-**, -C(O)-N(R2C)-**, or -C(O)-C(R2C)(R2C)-**; wherein ** indicates the point of attachment to the pyridine ring; A1 is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; n is 1 or 2; m and p are each independently 0, 1, 2, or 3; and q is 0, 1, or 2.
2. The compound of claim 1, wherein the compound is a compound of Formula I.
3. The compound of claim 1 or 2, wherein R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms.
4. The compound of any one of claims 1-3, wherein R3 is hydrogen or C1-4 alkyl.
5. The compound of any one of claims 1-4, wherein R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or - S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl.
6. The compound of any one of claims 1-5, wherein A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6.
7. The compound of any one of claims 1-6, wherein X1 is -C(O)-.
8. The compound of any one of claims 1-7, wherein n is 1.
9. The compound of any one of claims 1-8, wherein X2 is -C(O)-N(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring.
10. The compound of any one of claims 1-8, wherein X2 is -C(O)-C(R2C)(R2C)-**, wherein ** indicates the point of attachment to the pyridine ring.
11. The compound of any one of claims 1-8, wherein X2 is -C(R2B)=N-**, wherein ** indicates the point of attachment to the pyridine ring.
12. The compound of claim 1, wherein the compound is represented by Formula I-A:
(I-A) or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)- (C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo; and wherein said heteroaryl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, -N(R4)(R5), and halo; R3 is hydrogen or C1-4 alkyl; R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom;
R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2.
13. The compound of claim 12, wherein the compound is a compound of Formula I-A.
14. The compound of any one of claims 1-8 or 11-13, wherein R2B is a 4-7 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), oxo, hydroxyl, -N(R4)(R5), and halo.
15. The compound of any one of claims 1-8 or 11-13, wherein R2B is a 5-6 membered saturated monocyclic heterocyclyl having one or two heteroatoms independently selected from nitrogen and oxygen, wherein said heterocyclyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, oxo, and halo.
16. The compound of any one of claims 1-8 or 11-13, wherein R2B is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said heteroaryl is substituted with 0, 1, or 2 substituents
independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C3-5 cycloalkyl, -C(O)-(C1-4 alkyl), -C(O)-(C1-4 haloalkyl), -C(O)-(C3-5 cycloalkyl), hydroxyl, - N(R4)(R5), and halo.
17. The compound of claim 1, wherein the compound is represented by Formula I-B: (I-B
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2C is hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said
ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2.
18. The compound of claim 17, wherein the compound is a compound of Formula I-B.
19. The compound of claim 1, wherein the compound is represented by Formula I-C: (I-C
or a pharmaceutically acceptable salt thereof; wherein: R1 represents independently for each occurrence hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxyl, or C1-4 haloalkoxyl; or two occurrences of R1 attached to different carbon atoms are taken together to form a C1-3 alkylene group connecting said carbon atoms; R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, cyano, C1-4 hydroxyalkyl, C1-4 alkoxyl, C1-4 haloalkoxyl, or -N(R4)(R5); R2C represents independently for each occurrence hydrogen, C1-4 alkyl, or C3-5 cycloalkyl; R3 is hydrogen or C1-4 alkyl;
R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl; or R4 and R5 are taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated ring having one nitrogen atom; R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or -S-(C1-6 alkyl); or two occurrences of R6 are taken together with the intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of halo, C1-4 alkyl, and C1-4 haloalkyl; A1 is phenyl, a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6; m is 0, 1, 2, or 3; and p and q are each independently 0, 1, or 2.
20. The compound of claim 19, wherein the compound is a compound of Formula I-C.
21. The compound of any one of claims 1-10 or 17-20, wherein R2C represents independently for each occurrence hydrogen or C1-4 alkyl.
22. The compound of any one of claims 1-10 or 17-20, wherein R2C is hydrogen.
23. The compound of any one of claims 1-22, wherein R2A represents independently for each occurrence halo, C1-4 alkyl, C1-4 haloalkyl, or cyano.
24. The compound of any one of claims 1-22, wherein R2A is fluoro.
25. The compound of any one of claims 1-22, wherein q is 0.
26. The compound of any one of claims 1-24, wherein q is 1.
27. The compound of any one of claims 1-26, wherein R1 is hydroxyl.
28. The compound of any one of claims 1-26, wherein p is 0.
29. The compound of any one of claims 1-27, wherein p is 1.
30. The compound of any one of claims 1-29, wherein R3 is hydrogen.
31. The compound of any one of claims 1-30, wherein R4 and R5 each represent independently for each occurrence hydrogen or C1-4 alkyl.
32. The compound of any one of claims 1-31, wherein R6 represents independently for each occurrence C1-6 haloalkoxyl, C1-6 alkoxyl, -O-(C0–4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, halo, cyano, -S-(C1-6 haloalkyl), or - S-(C1-6 alkyl).
33. The compound of any one of claims 1-31, wherein R6 represents independently for each occurrence C1-6 haloalkoxyl, -O-(C0-4 alkylene)-(C3-6 cycloalkyl), -N(R4)(R5), C1-6 haloalkyl, or halo.
34. The compound of any one of claims 1-31, wherein R6 represents independently for each occurrence –OCF3, -O-(cyclopropyl), –NH2, –CF3, –F, or –Cl.
35. The compound of any one of claims 1-34, wherein A1 is phenyl substituted with m occurrences of R6.
36. The compound of any one of claims 1-34, wherein A1 is a 5-6 membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted with m occurrences of R6.
37. The compound of any one of claims 1-34, wherein A1 is a 5-6 membered monocyclic partially unsaturated oxo-heterocyclyl having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said oxo-heterocyclyl is substituted with m occurrences of R6.
40. The compound of any one of claims 1-37, wherein m is 1 or 2.
41. The compound of any one of claims 1-37, wherein m is 3.
42. A compound in Table 1, 1-A, 2, or 3 herein, or a pharmaceutically acceptable salt thereof.
43. A compound in Table 1, 2, or 3 herein, or a pharmaceutically acceptable salt thereof.
44. A pharmaceutical composition comprising a compound of any one of claims 1-43 and a pharmaceutically acceptable carrier.
45. A method of treating a disorder mediated by ERK5, comprising administering a therapeutically effective amount of a compound of any one of claims 1-43 to a subject in need thereof to treat the disorder.
46. The method of claim 45, wherein the disorder is cancer.
47. A method of treating cancer in a subject, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a compound of any one of claims 1-43 and (ii) a second anti-cancer agent, in order to treat the cancer.
48. The method of claim 47, wherein the second anti-cancer agent is a MEK inhibitor.
49. The method of any one of claims 45-47, wherein the cancer is a melanoma, carcinoma, or neuroblastoma.
50. The method of any one of claims 45-47, wherein the cancer is breast cancer, lung cancer, pancreas cancer, cervical cancer, colorectal cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, or nervous system cancer.
51. The method of any one of claims 45-47, wherein the cancer is breast adenocarcinoma, lung adenocarcinoma, pancreas adenocarcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, prostate adenocarcinoma, gastric adenocarcinoma, melanoma, lung squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, glioblastoma, or neuroblastoma.
52. The method of any one of claims 45-47, wherein the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, or colorectal cancer.
53. The method of any one of claims 45-52, wherein the subject is a human.
54. A method of inhibiting ERK5 activity, comprising contacting ERK5 with an effective amount of a compound of any one of claims 1-43 to inhibit ERK5 activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163156281P | 2021-03-03 | 2021-03-03 | |
US63/156,281 | 2021-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022187518A1 true WO2022187518A1 (en) | 2022-09-09 |
Family
ID=83154523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/018745 WO2022187518A1 (en) | 2021-03-03 | 2022-03-03 | Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022187518A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024017977A1 (en) | 2022-07-20 | 2024-01-25 | Sanofi | Imidazopyridine compounds, preparation thereof and therapeutic uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022561A1 (en) * | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
WO2019170543A1 (en) * | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
-
2022
- 2022-03-03 WO PCT/US2022/018745 patent/WO2022187518A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022561A1 (en) * | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
WO2019170543A1 (en) * | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
Non-Patent Citations (1)
Title |
---|
NGUYEN, D. ET AL.: "Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5", J. MED. CHEM., vol. 62, no. 2, 2019, pages 928 - 940, XP055913360, DOI: 10.1021/acs.jmedchem.8b01606 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024017977A1 (en) | 2022-07-20 | 2024-01-25 | Sanofi | Imidazopyridine compounds, preparation thereof and therapeutic uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109562106B (en) | CXCR4 inhibitors and uses thereof | |
KR20220034739A (en) | TEAD inhibitors and uses thereof | |
TW202108571A (en) | Tead inhibitors and uses thereof | |
WO2022051565A1 (en) | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions | |
WO2017223243A1 (en) | Cxcr4 inhibitors and uses thereof | |
WO2022051569A1 (en) | Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions | |
WO2022051568A1 (en) | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions | |
WO2022120355A1 (en) | Tead degraders and uses thereof | |
WO2022120354A1 (en) | Tead inhibitors and uses thereof | |
WO2022051567A1 (en) | Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions | |
EP4188374A1 (en) | Methods of treating mutant lymphomas | |
WO2021263203A1 (en) | Cxcr4 inhibitors and uses thereof | |
WO2022187518A1 (en) | Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions | |
KR20230172548A (en) | MEK inhibitors and uses thereof | |
WO2022187520A1 (en) | Substituted 3-piperidinyl-pyrazolo[3,4-b]pyridines and related compounds and their use in treating medical conditions | |
US11878958B2 (en) | MEK inhibitors and uses thereof | |
US20230233546A1 (en) | Methods of treating cancer | |
US20240092779A1 (en) | Usp1 inhibitors and uses thereof | |
WO2023173057A1 (en) | Mek inhibitors and uses thereof | |
WO2023173053A1 (en) | Mek inhibitors and uses thereof | |
EP3990456A1 (en) | Cxcr4 inhibitors and uses thereof | |
WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
WO2024081311A1 (en) | Cbl-b modulators and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22764074 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22764074 Country of ref document: EP Kind code of ref document: A1 |